Modeling Leigh syndrome using patient-specific induced pluripotent stem cells by Inak-Girrbach, Gizem
 









Modeling Leigh syndrome using patient-specific 







to obtain the academic degree 
Doctor rerum naturalium (Dr. rer. nat.) 
 
 
Submitted to the Department of Biology, Chemistry and Pharmacy  







































































The work was conducted from April 2015 until May 2019 under 
supervision of M.D. Dr. Alessandro Prigione  
at the Max Delbrück Center for Molecular Medicine  
in the Helmholtz-Association. 
 
I hereby confirm that I have written the thesis independently using solely 
the aids mentioned and without illicit assistance from third parties. 
 
 1. Reviewer: Prof. Dr. Erich Wanker 
 2. Reviewer: Prof. Dr. Helge Ewers 
 









































   
 
 Acknowledgment  
  First of all, I would like to thank Prof. Dr. Erich E. Wanker for allowing me to conduct 
this Doctoral Thesis at the Max-Delbrück-Center Berlin-Buch and also for his valuable feedbacks 
during the lab meetings as well as for reviewing this work.  Furthermore, I would like to express 
my gratitude to Prof. Dr. Helge Ewers from Freie Universität Berlin, who took an interest in my 
project and kindly agreed to review this doctoral thesis.  
 Special thanks are owed to my supervisor Dr. Alessandro Prigione, for giving me the 
opportunity to work on this interesting project and guiding me with excellent and patient care. 
He has always been available and given me valuable advice. His honest feedback certainly helped 
me to become an independent scientist. I greatly enjoyed our regular scientific discussions, 
which motivated me to stay focused on the project. I shall not be forgetting to thank Prof. Dr. 
Markus Schülke-Gerstenfeld for providing patient skin fibroblasts for the project, valuable 
advice throughout the project, as well as providing his lab space and equipment for the 
complementation of some critical experiments. 
 Furthermore, I am deeply grateful to our collaboration partners within this project. In 
particular, I would like to thank Dr. Agnieszka Rybak-Wolf for generating the 3D cerebral 
organoid models. Special thanks to Peter Glazar for his valuable contribution in analyzing the 
transcriptomics data and to Dr. Chris Secker for providing the lentivirus encoding SURF1.   
 Moreover, I would like to thank all my colleagues and lab mates in the Prigione Group, 
who made it possible to work in a supportive and harmonic environment. I would like to thank 
Dr. Barbara Mlody for her constant availability for answering all kind of questions and for making 
the lab days more entertaining with her humorous nature. Thanks to Annika Zink for her 
presence and support. Her constant motivation to keep an eye on the stocks of small molecules 
needed for differentiation protocols and giving me advice on critical time points was very 
helpful. Also, I would like to thank Carmen Lorenz, who walked me through cell culture and other 
important techniques when I started working in the lab. Special thanks to Dr. Pawel Lisowski; 
without his knowledge and help, generating an isogenic line would not have been possible in 
such a short time. Thank you to Celina Kassner for her technical assistant. There were several 
bachelor and master students who worked in our lab. In particular, I would like to thank Tobias 
Hahn for finding the right corrected clone after months of screening. I want to express special 
gratitude to Ummi Ciptasari who was a motivated, and dedicated student who helped me get 
through the last phase of my Ph.D. period. Also would like to thank Group Wanker members for 
their cooperation and for providing a pleasant working atmosphere. 
 
   
 
 I express my deepest appreciation to my husband Kai for his constant support and 
confidence at all times and walking me through the hard and good times hand in hand. In 
addition, I would like to thank my close circle of friends who were great listeners. Especially, I 
would like to thank Basak Arslan for her unlimited support. Lastly, I cannot thank my lovely 





























   
 
 Summary 
    Leigh syndrome (LS) is a severe early-onset neurodegenerative childhood disorder 
characterized by bilaterally symmetrical necrotic lesions in the basal ganglia region of the brain. 
It is a rare disease affecting 1/36,000 newborns, and affected ones display psychomotor 
regression and also lactic acidosis with peak mortality mostly before the age of three. It is a 
genetically and biochemically heterogeneous disorder caused by mutations of nuclear DNA 
(nDNA) or mitochondrial DNA (mtDNA) in more than 75 genes leading to disturbances in the 
mitochondrial respiratory chain. Mutations in the mitochondrial complex IV assembly factor, 
Surfeit locus protein 1 (SURF1), represent the most common cause and a severe form of LS. So 
far, SURF1-deficient animals have failed to recapitulate the neuronal pathology of human LS, 
hindering the understanding of the disease mechanisms. Thus, there is no effective therapy 
available. 
    To investigate the molecular mechanisms underlying the disease-specific neuronal cell 
death, I generated the first mechanistic human induced pluripotent stem cell (iPSC)-derived 
neuronal model of LS harboring SURF1 mutations. SURF1 iPSC-derived cultures showed aberrant 
bioenergetics already at the level of neural progenitors, disrupting their neurogenic potency. A 
biallelic correction of SURF1 via CRISPR/Cas9 restored the bioenergetics and enhanced neuronal 
sprouting as well as synaptogenesis in SURF1 iPSC-derived cultures. To study the manifestation 
of the spatial defects, cerebral organoids were generated. In contrast to corrected iPSC-derived 
organoids, SURF1 iPSC-derived organoids appeared smaller in size and displayed 
neurodevelopmental defects. Ultimately, analyzing the transcriptomics data of iPSC-derived 2D 
and 3D cultures, some novel hints for possible therapeutic strategies were revealed. Different 
treatment strategies were tested on iPSC-derived neural progenitor cells (NPCs) function to find 
a potential strategy and two candidates were shown to have beneficial effects on the 
phenotypes: Coactivator of PGC1-α receptor, Bezafibrate, was shown to rescue bioenergetic 
defects via PPAR signaling pathway and inhibition of TGF-β1 receptor via SB-431542 was shown 
to rescue neurite outgrowth defects in SURF1 iPSC-derived NPC cultures. 
     Altogether, this study is the first human iPSC-neuronal model for LS and gives insight 
into the role of SURF1 mutations in neuronal cells in the context of LS pathogenesis. SURF1 
mutation caused aberrant energy metabolism and prevented neuronal maturation.  With this 
study, NPCs were shown to be the first affected cell type in the neurodevelopmental cascade. 
Moreover, two candidate therapeutic targets have been suggested to improve the 
bioenergetics, and neuronal differentiation defects seen in patients derived neuronal cell model, 
which could be helpful for clinical disease research. 
 





































   
 
 Zusammenfassung  
 Leigh-Syndrom (LS) ist eine schwere neurodegenerative Erkrankung bei Kindern, die sich 
durch bilateral symmetrische nekrotische Läsionen in der Basalganglienregion des Gehirns 
auszeichnet. Es ist eine seltene Krankheit, die 1 von 36.000 Neugeborenen betrifft. Betroffene 
Personen zeigen eine psychomotorische Regression und auch eine Laktatazidose und haben die 
höchsten Sterblichkeitsrate meist vor dem dritten Lebensjahr. Es handelt sich um eine genetisch 
und biochemisch heterogene Störung, die durch Mutationen von Zellkern-DNA (nDNA) oder 
Mitochondrien-DNA (mtDNA) in mehr als 75 Genen verursacht wird und zu Defekten der 
Atmungskette in den Mitochondrien führt. Mutationen im mitochondrialen Komplex IV 
Assemblierungsfaktor SURF1 stellen die häufigste Ursache und eine schwere Form von LS dar. 
Bisher ist es nicht gelungen die neuronale Pathologie des menschlichen LS in SURF1-defizienten 
Tieren zu rekapitulieren, was das Verständnis der Krankheitsmechanismen erschwert. Daher ist 
bisher keine wirksame Therapie verfügbar.      
 Um die molekularen Mechanismen zu untersuchen, die dem krankheitsspezifischen 
neuronalen Zelltod und (auch der Gliazellenfunktionsstörung) zugrunde liegen, erstellte ich mittels 
humaner induzierter pluripotenter Stammzellen (iPSCs), das erste mechanistische Modell von LS 
welches SURF1-Mutationen enthält. Von SURF1-iPSCs abgeleitete Kulturen zeigten bereits auf der 
Ebene der neuronalen Vorläufer eine abweichende Bioenergetik, die ihre neurogene Potenz störte. 
Eine biallelische Korrektur von SURF1 über CRISPR / Cas9 stellte die Bioenergetik und das verstärkte 
Sprießen von Neuronen sowie die Synaptogenese in von SURF1-iPSCs abgeleiteten Kulturen wieder 
her. Um die Manifestation der räumlichen Defekte zu untersuchen, wurden zerebrale Organoide 
erzeugt. Im Gegensatz zu den von iPSC-abgeleiteten Organoiden der korrigierten Linie, schienen die 
von SURF1-iPSC abgeleiteten Organoide kleiner zu sein und zeigten neurologische 
Entwicklungsstörungen. Letztendlich wurden bei der Analyse der Omics-Daten von iPSC-
abgeleiteten neuronalen Kulturen einige neuartige Hinweise für mögliche Therapiestrategien 
aufgedeckt. An iPSC-abgeleiteten neuronalen Vorläuferzellen (NPCs) wurden verschiedene 
Behandlungsstrategien getestet und es wurde gezeigt, dass zwei Kandidaten vorteilhafte 
Auswirkungen auf die Phänotypen haben: Mit dem Coactivator von PGC1-α-Rezeptor Bezafibrate 
konnten bioenergetische Defekte durch Modifikation des PPAR Signalweg behoben werden. Es 
wurde gezeigt, dass die Hemmung des TGF-β1-Rezeptors durch SB-431542, 
Neuritenwachstumsdefekte in SURF1-iPSC-abgeleiteten NPC-Kulturen retten.  
 Zusammengenommen ist diese Studie das erste humane iPSC-neuronale Modell für LS 
und gibt einen Einblick in die Rolle von SURF1-Mutationen in neuronalen Zellen im Kontext der LS-
Pathogenese. Die SURF1-Mutation verursachte einen abnormen Energiestoffwechsel und 
 
   
 
verhinderte die neuronale Reifung. In dieser Studie wurde gezeigt, dass NPCs der erste betroffene 
Zelltyp in der neurologischen Entwicklungskaskade sind. Darüber hinaus wurden zwei mögliche 
therapeutische Ziele vorgeschlagen, um die Bioenergetik und neuronale Differenzierungsdefekte 
zu verbessern, die in einem vom Patienten abgeleiteten neuronalen Zellmodell auftreten und für 
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1. Introduction 
         More than a billion years ago, anaerobic bacteria were captured by primordial 
eukaryotic cells lacking the ability to use oxygen metabolically (Vafai et al., 2011). As this 
endosymbiotic relationship developed, the bacteria evolved into mitochondria and equipped 
host cells with aerobic metabolism, which is a much more efficient way of producing energy 
compared to anaerobic glycolysis. Although mitochondria are referred to as semi-autonomous 
organelles since they possess DNA, after years of evolution, they have become hard-wired with 
the host eukaryotic cell, and they are now under the dual control of nDNA and mtDNA 
(McFarland et al., 2010). 
     Mitochondrial diseases are described as a group of multisystem disorders caused by 
defects in components of the mitochondrial respiratory chain (RC), leading to the disruption of 
cellular energy processes. One of the significant challenges in mitochondrial diseases is their 
extreme clinical variability. Similar mitochondrial mutations associated with various distinct 
disorders and the same clinical condition may arise from several RC defects. For instance, 
ATPase6 mitochondrial mutation can lead to diseases such as Neuropathy, ataxia, and retinitis 
pigmentosa (NARP), maternally inherited Leigh syndrome (MILS), and familial bilateral striatal 
necrosis (FBSN), while the nuclear mutations SURF1, NDUSF4, and BCS1L can all lead to Leigh 
syndrome (DiMauro et al., 2003). Additionally, they exhibit phenotypic heterogeneity affecting 
various organs in the body, whereas they mostly manifest themselves in cell types with high 
energy demands, such as muscle cells and neurons (Wallace et al., 2005). Brain energy 
metabolism is complex and highly relies on oxidative phosphorylation (OXPHOS), which is the 
ATP synthesis by the oxygen-consuming RC. Thus, the role of mitochondrial respiratory chain 
deficiencies in the pathogenesis of a wide range of neurological disorders has been the focus of 
the scientific community recently and more intensively. There are also common 
neurodegenerative diseases that are secondary mitochondrial dysfunctional such as 
Alzheimer´s, Spinal muscular atrophy (SMA), or Friedrich Ataxia which are not caused by 
mitochondrial mutations but involve mitochondrial dysfunction in their disease pathology (Inak 
et al., 2017).   
     Currently, there is no effective therapy for primary mitochondrial disease Leigh 
Syndrome. Investigating the underlying pathological mechanism is essential to identify 
molecular targets for specific and compelling therapeutic intervention, which then also could be 
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1.1 Leigh syndrome  
1.1.1. Prevalence and clinical manifestations  
 LS (OMIM #256000), or subacute necrotizing encephalomyopathy, is a hereditary 
early-onset progressive neurodegenerative disorder. Neuropathologist Denis Leigh first 
described Leigh syndrome in 1951 (Leigh, 1951). It is considered a rare disorder, whereas it is 
relatively common as the incidence of 1 in 36,000 newborns (Darin et al., 2001). Higher 
incidences have also been reported in specific populations such as in the Faroe Islands (1:1700) 
and Saguenay Lac-Saint-Jean region of Quebec, Canada (1:2000) (Ostergaard et al., 2007; Morin 
et al., 1993). The clinical presentation of LS can be highly variable as the disease onset range 
starts from the neonatal period through adulthood. Mostly, the symptoms typically manifest 
during the first year of life, with congenital onset occurring in one-fourth of the cases. The 
disease is mostly leading to early death with a course that is variable but usually severe and has 
a peak of mortality before the age of three. Later onset and slower progression have also been 
reported (Rahman et al., 1996; Sofou et al., 2014; Rahman et al., 2017).  
     The first signs of LS seen in infancy are usually recurrent episodes of vomiting, difficulty 
in swallowing, which also leads to failure to thrive. Later on, during late infancy or early 
childhood, they exhibit severe muscle and movement problems as they may develop weak 
muscle tone (hypotonia), involuntary muscle contractions (dystonia), and problems with 
movement and balance (ataxia). These symptoms are mostly combined with the loss of 
sensation and weakness in the limbs (peripheral neuropathy). Additionally, incoordination of 
ocular movements is present in different forms. Individuals may develop weakness of the 
muscles moving the eyes (ophthalmoparesis) as well as rapid, involuntary eye movements 
(nystagmus), or degeneration of optic nerves (Lake et al., 2015; Lake et al., 2016). During the 
childhood period, they exhibit mental regression along with epileptic seizures. In most of the 
cases, patients undergo acute respiratory failure, and they may develop hypertrophic 
cardiomyopathy. Microcephaly cases have also been reported (Rahman et al., 2017). 
 
1.1.2.       Neuropathology and diagnostic methods  
         The pathology of the disease has relied on postmortem studies in the past, by the 
advent of computed tomography and magnetic resonance images (MRI), detection of the lesions 
have aided the diagnosis of the disease and the understating of its progression. The progressive 
encephalopathy is characterized pathologically by symmetric and focal necrotic lesions mainly 
in the basal ganglia which control movement. Its connected regions the cerebellum, which 
controls the ability to balance and coordinates movement; and the brainstem, which connects 
the brain to the spinal cord and controls functions as swallowing and breathing; also optic 
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nerves, which conveys visual information (Tiranti et al., 1998; Pecina et al., 2003; Rossi et al., 
2003) (Figure 1.1.2.). Lesions were characterized histologically, and they showed necrotic lesions 
with vacuoles accompanied by demyelination. Demyelination is associated with a loss of 
oligodendrocytes directing the myelination of axons, which suggests an impairment in the 
electric transmission between the cells. There was relative preservation of neurons, whereas 
the presence of degenerated neurons was also high, and they showed the swelling or shrinking 
of neuronal cell bodies. The glial cells looked swollen as an indication for gliosis, a hypertrophic 
state of astrocytes, probably as a response to damage or insult in the central nervous system 
(CNS). Additionally, capillary proliferation has also been observed in some of the cases (Lake et 









Figure 1.1.2: Magnetic resonance imaging of a LS patient 
a, Coronal T2-weighted image shows symmetric T2 prolongation involving the subthalamic nuclei (thin 
arrow). The substantia nigra (thick arrow), the posteroinferior portion of the putamina (arrowhead). b, 
T2 prolongation involves the medulla (thin arrow), inferior cerebellar peduncles (thick arrow), and dentate 
nuclei (arrowhead). c, Involvement of the interpeduncular nucleus (thin arrow) and central tegmental 




 The other hallmark of LS is high lactate levels in the blood, urine, and cerebrospinal 
fluid. These measurements are used for the diagnosis of LS in addition to MRI imaging. Recently, 
tests for mitochondrial dysfunction, more specifically defects in oxidative OXPHOS, were 
suggested to be included for the diagnostic criteria for LS (Pecina et al., 2003; Baertling et al., 
2014). Detailed family pedigree and the molecular genetic testing analysis should be conducted 
to understand if the cause is due to mitochondrial or nuclear mutations.  
 
1.1.3.     Disease genetics  
         The genetic cause of LS is exceptionally heterogeneous and can be inherited in 
different patterns. The genetic cause of the mitochondrial disease can reside in either mtDNA 
or nDNA and also can be X-linked (Gerards et al., 2016); NMIH). All of the affected genes are 
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directly or indirectly involved in the maintenance of mitochondrial OXPHOS, making LS one of 
the most prevalent mitochondrial disorders. Newly identified nuclear genetic causes are 
increasing, thanks to the use of next-generation and whole-exome sequencing and also 
attention to rare disease like LS has also been growing. 
     The inheritance pattern of mtDNA mutations is different from nDNA mutations since 
the traits do not segregate by Mendel´s law. It has a maternal inheritance pattern that mutations 
pass from an affected mother to the progeny. There are multiple mtDNA per mitochondrion and 
a few dozen mitochondria per cell, which leads to normal and abnormal mtDNA to be present 
in the same cell (Ruhoy et al., 2014). When mtDNA mutations can occur in a homoplasmic state, 
where all mtDNA molecules carry the same mutation, or in a heteroplasmic state, where only a 
proportion of mtDNA molecules carries the mutation (Darin et al., 2007; Inak et al., 2017). Both 
situations can give rise to LS. Also, cellular dysfunctions and clinical manifestations are believed 
to occur only after a certain threshold of mutation load has been exceeded. However, the 
mitochondrial threshold concept has been recently challenged as the same level of MT‐ATP6 
mutations have been shown to cause both mild and severe neurological syndromes (Childs et 
al., 2006). The mtDNA mutation load cannot entirely explain the phenotypic variability since the 
patient‐specific nuclear background attributes to the phenotype as well (Bénit et al., 2010; Inak 
et al., 2017). The single match between nDNA and mtDNA should, therefore, play an essential 
role in the disease pathogenesis of the mitochondrial disease.  
 nDNA mutations are, on the one hand, inherited in a Mendelian fashion, with 
autosomal recessive and X-linked inheritance as the etiology of LS. An autosomal recessive 
pattern of inheritance, where the cell has the two copies of the mutated allele, applies to most 
of Leigh syndrome-associated genes. For instance, recessive mutations in SURF1 occur in about 
one-third of all LS cases and represent the single most common cause of LS (Darin et al., 2001; 
Ruhoy et al., 2014; Gerards et al., 2016). On the other hand, a small number of affected 
individuals display X-linked recessive inheritance when the mutated gene is on the X-
chromosome, and one altered copy of the gene is sufficient to cause the disease. Thus males are 
affected by X-linked recessive disorders more frequently than females (NMIH). The most 
common form has been reported to be the X-linked pyruvate dehydrogenase (E1) alpha subunit 
gene (PDHA1) (Matthews et al., 1993). 
     Overall, whether of mtDNA or nDNA mutations, eventually all of these mutations 
exhibit their pathogenic effects on the mitochondrial respiratory chain where the primary source 
of energy production occurs. OXPHOS supplies the cell with energy in the form of ATP. 
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1.2. Cellular respiration in mitochondria 
     Mitochondria are about 0.5-1 µm in diameter and up to 7 µm long, whereas their 
shape and number per cell can vary on the particular tissue and their energy requirements 
(Krauss et al., 2001). They may appear in different shapes, but the general architecture is the 
same. They structurally have four compartments: the outer membrane, the inner membrane, 
the intermembrane space, and the matrix. They are all involved in various tasks that are pivotal 
for the cells. Cristae structures are formed by the enclosure of the inner membrane where they 
labyrinth into the mitochondrial matrix aiming to increase the surface of the inner membrane 
where OXPHOS takes place (Cogliati et al., 2016). Cristae are dynamic and undergo continuous 
remodeling according to mitochondria dynamics, which are biogenesis, fission, fusion, 
mitophagy, and motility. These mitochondrial dynamics also differ in different types of cells 
corresponding to changes in the energetic state requirements.  
     Mitochondria play a crucial role in cellular metabolism by producing the majority of 
cellular ATP via participating in several vital anabolic and catabolic pathways. Glucose, lipid fuels, 
and amino acids are the primary respiratory fuels, and mitochondria´ tasks can range from 
pyruvate oxidation to metabolism of fatty acids or amino acids to the generation of energy 
(DiMauro et al., 2003). Competition for respiration between substrates has always been 
indicated, whereas each organ has a unique metabolic profile, and they favor different use of 
fuels to meet their energy needs. For instance, under normal physiological conditions, glucose 
is considered as the sole fuel of the brain, while fatty acids are the heart´s primary source of fuel 
(Panov et al., 2014). The classical widely known cellular respiration via glucose could be divided 
into four main steps: glycolysis (where glucose is converted to pyruvate), pyruvate oxidation 
(where pyruvate enters mitochondrial matrix and produces Acetyl-CoA), citric acid cycle (Acetly-
CoA goes through a series of reaction and produces NADH, FADH2, and CO2) and OXPHOS (where 
ETC and ATP synthesis take place) (Fernie, et al., 2004). The significant pathways take place in 
the mitochondrial matrix, and only glycolysis takes place in the cytosol.  
     In the context of mitochondrial disorders, peculiarly LS, the main focus is narrowed 
down to the disorders caused by disturbances in the OXPHOS system where the final 
biochemical reaction produces the fuel of the cell as adenosine triphosphate (ATP).  
 
1.2.1.       OXPHOS 
     OXPHOS is embedded in the lipid bilayer of the inner mitochondrial membrane and 
composed of five multimeric protein complexes (I, II, III, IV, and V) where many sequential 
biochemical reactions are coordinated. First, the energy released by the oxidation conserved in 
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the reduced forms of electron carriers NADH and FADH2 is transported along with the complexes 
to molecular oxygen (with the aid of two electron carriers, ubiquinone (Q) and cytochrome c 
(cyt c) thereby reducing oxygen to water. Simultaneously, protons are pumped across the 
mitochondrial inner membrane from the matrix to the intermembrane space by complexes I, III, 
and IV. Lastly, ATP is generated by the influx of these protons back into the mitochondrial matrix 
through complex V. Cristae are also essential part of OXPHOS as 94% of complex III, and ATP 
synthase and approximately 85% of total cytochrome c are stored in this compartment 
(Scorrano, et al., 2002; Cogliati et al., 2016). It was reported that the number and density of 
cristae might reflect a cell´s demand for ATP. 
     This complex OXPHOS mechanism seems to be all handled in the inner membrane of 
mitochondria from a structural standpoint of view, whereas from a genetic point of view, 
OXPHOS is the teamwork of mtDNA and nDNA as it was mentioned before (Signes et al., 2018). 
Each of the complexes is assembled from multiple subunits, and these subunits could be 
encoded by both nDNA and mtDNA. Overall, 13 mtDNA-encoded structural proteins and 




Figure 1.2.1.: The mitochondrial respiratory chain complexes 
Multimeric five complexes are located in the inner mitochondrial membrane: reduced nicotinamide 
adenine dinucleotide (NADH) dehydrogenase–ubiquinone oxidoreductase (complex I, approximately 46 
subunits), succinate dehydrogenase–ubiquinone oxidoreductase (complex II, 4 subunits), ubiquinone–
cytochrome c oxidoreductase (complex III, 11 subunits), cytochrome c oxidase (complex IV, 13 subunits), 
and ATP synthase (complex V, approximately 16 subunits). The respiratory chain also requires two small 
electron carriers, ubiquinone (coenzyme Q10) and cytochrome c. The subunits encoded by mtDNA are 
highlighted in red, and the rest of the subunits are encoded by nDNA. Some encoded subunits by mtDNA 
or nDNA are indicated (Image was adapted from DiMauro et al., 2003). 
  
 Peculiarly, LS can be caused by mutations in more than 35 different genes of both 
nuclear and mitochondria origin and defects of the complexes impair OXPHOS, which leads to a 
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critically low level of cellular energy (Ruhoy et al., 2014). Every complex has a different 
composition, and the frequency of each mutation, causing a defect on a specific complex is 
different. Complex II, for instance, is the smallest complex of the respiratory chain, and all four 
subunits are nuclear-encoded. Mutations in complex II are relatively rare. While complex I is the 
first and largest enzyme of the respiratory chain with an abnormal respiratory chain enzyme 
activity under physiological conditions. Complex I mutations are also a common cause of LS 
(DiMauro et al., 2003; NMIH) and mutations in the NADH Dehydrogenase (Ubiquinone) Fe-Sulfur 
protein 4 (NDUFS4) subunit are reported to be the most frequent ones (Lake et al., 2016). 
 On the other hand, the mutations in the MT-ATP6 gene result in the most common 
form MILS by changing the function of the proton channel of complex V which results in a loss 
of ATP activity (Santorelli et al., 1996). Additionally, loss of ATP synthase dimers is reported to 
disrupt crista architecture in LS mitochondria (Siegmund et al., 2018). Defects in respiratory 
subunits can display themselves in different ways such as increased reactive oxygen species 
(ROS), decreased mitochondrial membrane potential, increased mitochondrial and cytoplasmic 
NADH, and increased cytoplasmic calcium addition to low levels of ATP (Herst et al., 2017). The 
most common cause of nuclear-encoded mutation in LS is defects of complex IV. 
     
1.2.2.    COX enzyme  
             Cytochrome C oxidase (COX, Complex IV, EC 1.9.3.1) is the terminal enzyme of the ETC 
catalyzing the oxidation of cytochrome c and the reduction of oxygen to water. The redox 
centers, two copper centers (CuA and CuB) and two heme A moieties (a and a3), are involved in 
transferring the electrons from cytochrome c to molecular oxygen. It assists proton 
translocation, setting up the electrochemical proton gradient that drives the synthesis of ATP 
from ADP and phosphate by ATP synthase (complex V). Since COX is the terminal enzyme, 
without is function, OXPHOS cannot be carried to completion, and no ATP can be generated 
from mitochondria. 
         Mammalian COX from the bovine heart was crystallized and shown to consist of 
thirteen subunits, ten of which (COX4, COX5a, COX5b, COX6a, COX6b, COX6c, COX7a, COX7b, 
COX7c, COX8) are encoded by nDNA. Very recently a fourteenth subunit candidate, NDUFA4, 
which was initially thought to be part of complex I and also encoded by nDNA, was proposed to 
be part of COX (Balsa et al., 2012). Out of fourteen subunits, three of which (COX1, COX2, and 
COX3) are encoded by the mitochondrial DNA (mtDNA) and very similar to those from bacterial 
COX (Figure 1.2.1.). These three mtDNA encoded subunits constitute the hydrophobic catalytic 
core that is assembled first during the formation of the complex. The three core subunits alone 
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are sufficient to produce a fully functional COX enzyme complex in bacteria (Kadenbach et al., 
2015). However, in mammalian COX, the catalytic core is surrounded by eleven nuclear-encoded 
structural subunits. COX biogenesis process is not fully known, but it first involves the 
maturation of the catalytic subunits COX1 and COX2, then the rest of the subunits are thought 
to be necessary for the stabilization of the catalytic core and its activity. Recently, it was shown 
that COX3 does not play a direct role in the catalytic core (Wirkström et al., 2018). Although the 
exact functions of these nuclear-coded subunits are not fully understood, they have been 
suggested to be a requirement for the stabilization and dimerization of the active holoenzyme 
complex. High catalytic capacity is highly dependent on the correct assembly of COX subunits, 
and it was shown to be the central rate-limiting control of mitochondrial respiration, and also 
mitochondrial membrane potential (Villani et al., 1998; Dalmonte et al., 2009).  
         There are also more than 30 known assembly factors involved in the integration of all 
the COX subunits and the maturation of the catalytic core, therefore the functionality of the 
enzyme. Most of the current knowledge of COX assembly is based on studies of mutant yeast 
strains with defective assembly (Barrientos et al., 2009) or human cell-line derived from patients 
with mutations in the structural subunits or assembly is assembly factors of COX (Williams et al., 
2004). The assembly process is well conserved between yeast and human, and many of the 
assembly factors identified in yeast have known homologs in mammals. Improper assembly of 
COX due to assembly factors leads to malfunction of this enzyme, and defects give fatal damage, 
especially to the cells with high energy demands. 
 
1.2.3.    COX defects 
         COX defects are mainly categorized as assembly defects, either due to mutations in 
the mtDNA genes encoding structural components of the COX or in nDNA genes encoding 
assembly factors (Leary et al., 2013). They also show heterogeneity in the clinical phenotype, 
whereas the most common form of the disease is LS. The pathogenic mutations causing LS 
identified so far originate from nDNA encoded genes and are summarized in Table 1.2.3. 
Subunits are thought to be necessary for the stabilization of the catalytic core and its activity. 
COX3 was shown recently that not be playing a direct role in the catalytic core (Wirkström et al., 
2018). High catalytic capacity is highly dependent on the correct assembly of COX subunits, and 
it was shown to be the central rate-limiting control of mitochondrial respiration, and also 
mitochondrial membrane potential (Villani et al., 1998; Dalmonte et al., 2009; Kadenbach et al., 
2015).           
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Table 1.2.3.: Complex IV genes are known to be associated with LS 
 
 The regulation of COX activity is quite exceptional as it is the only OXPHOS complex 
containing tissue-specific, and it has developmentally regulated isoforms (Kadenbach et al., 
2015; Kovářová et al., 2016). Therefore there are tissue-specific isoforms of COX that underlie 
the tissue-specific expression and the different degrees of severity seen in patients due to 
enzyme deficiency. For instance, mutations in the SURF1 primarily affect the brain, whereas the 
mutations in SCO2 or COX15 affect the heart and the brain primarily while the mutations in 
COX10 affect kidney and SCO1 liver tissues (Böhm et al., 2006). One explanation proposed for 
the requirement of a fine-tuned regulation stems from the fact that COX and cytochrome-c to 
be the rate limiting step of ETC in cells and tissues under physiological conditions (Sinkler et al., 
2017). Additionally, the free energy released in this reaction is much higher compared to the 
energy released from complexes I and III, which could make the target of regulation more 
important (Kennaway et al., 1990). Therefore the function of COX is tightly regulated and 
probably optimized according to the varying metabolic demands of the tissues.  
     Up to now, several pathogenic mutations causing LS in several assembly factors have 
been described, and the most common ones are shown to be in the SURF1 gene (Ruhoy et al., 
2011). The first identified and the most common form of the disease is due to defects of COX 
assembly factor SURF1 (Tiranti et al., 1998; Zhu et al., 1998; Péquignot et al., 2001; Pecina et al., 
2003). 
 
1.2.4.   SURF1 gene mutations 
 SURF1 gene of 4.7 kb is located on chromosome 9q34, the long arm of chromosome 9 
at position 34.1, encodes a highly-conserved protein SURF1. It contains 9 exons and codes for 
30 kDa protein of 300 amino acids. The domain structure of SURF1 protein is well conserved 
among eukaryotes and prokaryotes, which emphasizes its functional importance. It is located in 
the inner mitochondrial membrane and has been identified as a critical player in the early 
Gene Defect Location Reference 
COX10 Complex IV Nuclear Antonicka et al., 2003 
COX11 Complex IV Nuclear Böhm et al 
COX15 Complex IV Nuclear Bugiani et al., 2005 
LRPPRC Complex IV Nuclear Debray et al., 2011 
NDUAF4 Complex IV Nuclear Pitceacthly et al., 2013 
PET100 Complex IV Nuclear Lim et al.,2014 
SCO2 Complex IV Nuclear Joost et al., 2010 
SURF1 Complex IV Nuclear Rossi et al., 2003 
TACO1 Complex IV Nuclear Weraarpachai et al., 2009 
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assembly of COX (Hannappel et al., 2011), whereas its precise function remains unknown. 
However, the first results suggested that SURF1 may act in the formation of heme a3-CuB center 
(Yao et al., 1999) and later on, SURF1 has also been suggested to facilitate the insertion of heme 
a3 into the active site of COX (Khalimonchuk  et al., 2010; Smith et al., 2005). The maturation 
and stability of the binuclear heme a3-CuB center limit the association of COX2 with COX1 and 
thus could lead to defects in the assembly of COX.   
     Recessive mutations in SURF1 occur in about one-third of all LS cases and represent 
the single most common cause of LS (Zhu et al., 1998; Ruhoy et al., 2014). There have been 
approximately 80 mutations reported in the SURF1 so far, and almost 40 of them were shown 
to be pathogenic. The truncating mutations are a result of nonsense mutations, aberrant 
splicing, or frameshift deletions (Wedatilake et al., 2013; Ruhoy et al., 2014). They cause 
translation of incomplete forms of SURF1 protein that are rapidly degraded or instability of 
SURF1 mRNA. In both cases, it prevents the synthesis of the protein and leads to loss of function 
of SURF1 protein. Without SURF1 assembly factor, COX does not correctly assemble, which 
impairs the mitochondrial energy production. It has been shown that the absence of SURF1 or 
its yeast homolog Shy1 causes a severe deficiency of COX (Tiranti et al., 1998; Péquignot  et al., 
2001) and the experiments that done in cultures of LSSURF1 fibroblasts or muscle fibers displayed 
decreased COX activity, low oxygen affinity and impaired maintenance of mitochondrial 
membrane potential (Pecina et al., 2004).  
     The molecular mechanisms underlying the neurological impairment caused by SURF1 
defects in still needs to be elucidated, but the significant obstacle in our understanding of the 
disease pathogenesis has been the scarcity of adequate model systems. 
 
1.3. In vivo models of SURF1 gene mutations 
  SURF1 is a highly conserved protein, and the studies conducted on its yeast homolog 
SHY1 suggest a role for SURF1 in the formation of catalytic centers. Both SURF1 null-mutant 
human samples, as well as in yeast strains lacking Shy1, lead to functional alterations of the COX 
activity. However, SURF1 and Shy1 do not complement each other's defects, indicating 
functional divergence during evolution (Mashkevich et al., 1997; Nijtmans et al., 1998). There 
have been various SURF1-deficient in vivo models generated so far, ranging from invertebrates 
to mammals. In most cases, they have not mimicked the neuropathological symptoms seen in 
patients. 
      First in vivo models to study SURF1 defects came from Zeviani group. They have 
generated two KO mice in which they have targeted different parts of the exons of Surf1. In the 
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first model, they disrupted the gene by targeted insertion of a neomycin cassette and 
replacement of exons five to seven. This has led to embryonic lethality in the majority of the KO 
mice (Agostino  et al., 2003). The surviving ones showed different severity of COX deficiency 
among the tissues, mostly in muscle and liver, whereas not in the heart and brain. Defects in 
muscle tissues led to deficits in motor skills. However, Surf1 null mice did not display any 
apparent neuropathological abnormalities. In the second model, the exon seven in Surf1 was 
targeted. They again showed similar levels of COX defects like in the first mouse model, whereas 
the second model mice showed a prolonged lifespan. Once more, the new model also failed to 
show any neurodegenerative pathology (Dell'agnello et al., 2008). A prolonged lifespan 
phenotype was also observed in CNS specific Surf1 knock-down Drosophila model (Zordan et al., 
2006) and biochemical, and assembly COX defects were present. However, they also failed to 
show neuropathological symptoms and displayed a prolonged lifespan. This time, they tried to 
mimic the neurological phenotype by treating primary neurons of Surf1 KO mice with kainic acid 
(glutamate agonists that induce Ca2+ excitotoxicity) which is known to lead to massive Ca2+ influx 
through NMDA receptors and consequently induces neuronal death (Dell'agnello et al., 2007). 
Primary neurons taken from these mice showed significantly reduced the rise of cytosolic and 
mitochondrial Ca2+, and reduced mortality compared to controls. 
 Moreover, calcium-induced apoptosis was absent in KO mice, whereas it was 
prominent in control mice. This complete protection from Ca2+ dependent neurotoxicity induced 
might explain longevity phenotype seen in Surf1 KO mice. A surf1 knock-down zebrafish model, 
where they knocked down the gene expression with morpholine oligonucleotides, displayed 
reduced COX activity and developmental defects in endodermal tissue were observed (Baden et 
al., 2007). Interestingly, the development of secondary motor neurons was severely impaired 
(Baden et al., 2007). In the ubiquitous knock-down of Surf1 in Drosophila impaired larval 
development and lethality whereas the neuron-specific KD flies bypassed this lethality. They had 
abnormal photo behavior responses, whereas they did not show any sign of neurodegeneration 
(Zordan et al., 2006). Recently, there is another Drosophila model of LS based on the post-
transcriptional silencing of CG9943, the Drosophila homolog of SURF1. Silencing of Surf1 
expression in Drosophila S2R cells led to selective loss of COX activity associated with decreased 
oxygen consumption and respiratory reserve (Da-Re et al., 2014), which strongly suggest SURF1 
is essential for COX assembly and activity, hence mitochondrial function.  After the sequential 
failure of small animal models, particularly in rodents; SURF1 knock-out in piglets was generated 
very recently (Quadalti et al., 2018). SURF1−/− pig, the first swine model of mitochondrial 
disease, resulted in a severe lethal phenotype but the neurological defects were mild as there 
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was no overt neurodegeneration was detected in sections of entire CNS. However, they 
displayed a delay of CNS development with a significant reduction in the cortical thickness of 
the cerebrum along with cortical layering differences. Strikingly, a higher cellular density and a 
disorganized cortical structure with several immature neurons. There was no lactic acidosis and 
apparent COX deficiency. Moreover, SURF1−/− piglet revealed a different glial cell distribution 
pattern and microgliosis, whereas no demyelinating process.  
     Overall, in vivo models due to SURF1 mutations have not necessarily recapitulated the 
human neuropathological condition. Specifically, Surf1-knock-out rodents show extended 
lifespan and no neurological defects. The failure of Surf1 models probably arises from the fact 
that COX activity in humans is more dependent on SURF1 than other species (Kovarova et al., 
2016). Moreover, the fundamental interspecies differences make it challenging to model the 
disease precisely in general, and also it is difficult to test the efficacy and the toxicity of potential 
drugs from rodents to the human. Interspecies differences have led to the failures of many 
clinical trials of potential drugs for many neurological and mitochondrial diseases in recent years 
(Inak et al., 2017). In order to develop treatments, the mechanisms underlying human disease 
pathologies have to be clarified. Thus human iPSCs have emerged as an attractive platform for 
overcoming these current limitations of animal models for disease modeling and drug discovery 
(Takahashi & Yamanaka, 2006; Shi et al., 2016; Sayed et al., 2016) 
 
1.4. iPSCs for disease modeling 1 
         iPSC technology, the groundbreaking discovery by Shinya Yamanaka and Kazutoshi 
Takahashi in 2006, enables the reprogramming of somatic cells into embryonic stem cells (ESCs)-
like cells  by the ectopic expression of four exogenous factors: OCT3/4, SOX2, KLF4, and c-MYC 
(collectively called OSKM factors) (Takahashi & Yamanaka, 2006). iPSCs are very similar to ESCs 
in their morphology, proliferative capacity, and developmental potential despite their 
background, which makes them a perfect model for disease modeling. Recent work has shed 
new light on the gene expression profiles confirming that human iPSCs share a typical signature 
with human ESCs, and they exhibit highly comparable global gene expression and epigenetic 
profiles (Guenther et al., 2010; Zhao et al., 2017). However, the gene-delivery methods of 
reprogramming can affect the quality of resulting iPSCs, and non-integrating methods have been 
suggested to generate iPSCs closer to ESCs in their transcriptional profiles (Kang et al., 2015).  
                                                          
1 The text and figures in section 1.4 partially have been reused with modifications from the published version: 
 Inak, G.,. et al. Concise Review: Induced-pluripotent stem cell-based drug discovery for mitochondrial disease. Stem 
Cells. https://doi.org/10.1002/stem.2637 (2017). 
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      iPSCs have the capacity for self-renewal and differentiation, and can also be generated 
from the patients’ skin fibroblasts or other somatic cell sources like blood cells. Following the 
generation of iPSCs, they can be differentiated into several cell types that are known to be 
affected by the individual patient. There has been an enormous advancement in vitro 
differentiation protocols, which increases the robust generation of the affected cell types and 
decreases the cell-to-cell variability. In our review, it is also explained why patient iPSC-derived 
neurons appear as an ideal cell type for dissecting the pathogenetic mechanisms of 
mitochondrial neurological diseases. Since they represent the disease-affected cell type with the 
correct OXPHOS-dependent metabolism and carry the patient-specific nDNA and mtDNA match 
(Inak et al., 2017). On the other hand, iPSC-derived neural progenitor cells (NPCs) have also been 
suggested as a useful cellular model system for drug discovery of the mitochondrial disease 
previously and also in our lab. Mitochondria within NPCs derived from mouse iPSCs (Choi et al., 
2015) or human iPSCs (Beckervordersandforth et al., 2017; Lorenz et al., 2017) acquire an 
elongated morphology with defined cristae and dense matrices. This morphological change is 
accompanied by a metabolic shift toward OXPHOS metabolism that resembles that of 
differentiated iPSC-derived neurons.  
      Despite the advantages stated above, a significant challenge in the field of disease 
modeling using iPSCs is to discriminate the in vitro phenotype from the specific causative 
mutations and the individual´s genetic background. The field of precision medicine has become 
very important to overcome the heterogeneity of disease manifestations among patients. These 
days, gene editing of nuclear mutations in patient iPSCs has almost become a standard protocol. 
The most commonly used ones are TAL effector nucleases (TALENs) or the clustered regularly 
interspaced short palindromic repeats (CRISPR/ Cas9) system (Shi et al., 2017; Liu et al., 2018). 
These precise isogenic controls differ only at the genome-edited loci from the parental lines, 
which helps researchers to correlate the genetic mutations with the disease phenotypes without 
any other confounding influences from the genetic background.  
     The advantage of iPSC technology that iPSCs allow the development of innovative and 
effective cellular model systems in a personalized approach. Their use may significantly benefit 
the search for treatments against debilitating diseases. In the past, phenotype-based assays 
were limited by the lack of high throughput techniques, the weakness of disease-associated 
read-outs, and the limited access to biological material. This has now radically changed following 
the discovery of iPSCs. Patient-derived iPSCs can be differentiated into disease-relevant cell 
types, including those that are commonly not available, such as neurons and glia. Screenings 
conducted on such differentiated cells could be based on highly significant cellular phenotypes 
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that become apparent within patient-specific disease-relevant cellular contexts (Khurana et al., 
2015; Liu et al., 2018). Once the correct iPSC-derived neural cell model has been selected, 
several technological platforms may be applied for compound screenings. One of the most 
commonly used techniques is the cellular image-based high-content screening (HCS) analysis 
(Xia et al., 2012). Also, target-centered screenings can be performed in iPSC derivatives, where 
the effects of the target modulation can already be monitored within the correct cellular 
environment. All these approaches might enable the identification of drug candidates that have 
a higher chance of success rate and the potential to be applied in a personalized manner. 
Additional challenges of iPSC-based drug discovery are inherent to all in vitro cellular models, 
which may be dependent on the culture conditions and may not fully recapitulate the complex 
response of a whole organism. Cellular systems, e.g., neurons, cardiomyocytes, hepatocytes that 
are differentiated from the same iPSC lines can be tested for particular compounds. This 
“patient-in-a-dish” approach has the potential to predict the effect of a drug within different 















Figure 1.4.: iPSC disease modeling and drug discovery  
iPSCs can be differentiated into several cell types that are known to be affected by the individual patient. 
Using these cell types, it may be possible to identify disease phenotypes that are patient-specific and/or 
cellular-specific. One of the analyzed cell types can then be used as a model for carrying out HTS (high-
throughout screening). The obtained hit drug candidates can be applied on all the iPSC-derived cell types 
to analyze the efficacy and toxicity of the compounds within different patient-specific cellular systems. The 
integration of these responses may allow identifying with increased predictive power those drugs that 
have a higher chance to succeed once administered to the individual patient (Image from Inak et al., 2017). 
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 A more physiological approach would involve the use of three-dimensional (3D) 
organoids, which are complex brain region-specific structures containing both neuronal and glial 
cells (Keleva et al., 2016). Cerebral organoids can be derived from human PSCs through 
spontaneous differentiation and allow modeling of whole brain development. Also, it is possible 
to use patterning factors to derive brain region-specific organoids. These structures enable the 
investigation of individual brain regions and have been used to demonstrate a direct connection 
between the Zika virus and human microcephaly (Lancaster et al., 2013; Qian et al., 2017). 
Human PSC-derived cerebral organoids still do not show the signs of functional maturation of 
the post-natal and adult human brain. However, the use of miniaturized spinning bioreactors 
may significantly improve the future applications of cerebral organoids for HT screenings (Qian 
et al., 2017).  Finally, the reproducibility should be critically improved to reach a state in which 
the derived 3D structures consistently exhibit similar traits—shape, size, and cellular 
composition- under the same experimental conditions (McCauley et al., 2017). 
 Overall, the combination of iPSC, gene editing, and genome-wide technologies along 
with fast-growing knowledge of efficient differentiation protocols allow us to systematically and 
faithfully model human disease in relevant human cell types. This also appears as a robust model 
system which may allow conducting personalized drug discovery of disorders which may 
ultimately enable the identification of curative treatments against these debilitating conditions. 
Recent advancements in the development of human iPSC-derived three-dimensional (3D) 
models allowing mimicking in vivo tissues and organs eventually could aid to explore complex 
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2. Aim of the study 
 The main aim of this study was to develop a novel human iPSC-based model of Leigh 
syndrome carrying homozygous SURF1 mutations (LSSURF1) to investigate the molecular 
mechanisms underlying the neuronal pathology of predominantly basal ganglia region. 
Ultimately, this model may enable the development of novel treatment strategies against a 
debilitating and, so far, untreatable condition.  
 The objectives planned to fulfill the aim were:    
a) Generating isogenic iPSC pairs via using genome editing technologies  
b) Differentiating generated iPSCs into neuronal/astrocyte composite cultures  
c) Investigating the genotype and phenotype interplay in the obtained iPSC-derived 
composite cultures  
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3. Results 
3.1.  LS patient donors (LSSURF1) 
 The skin fibroblasts were obtained from three LSSURF1 patients from two distinct 
consanguineous families: SURF1 A (S1A) line carries the homozygous mutation c.530T>G 
(p.V177G), and SURF1 B (S1B) and SURF1 C (S1C) lines which were taken from siblings carry the 
same homozygous mutation c.769>A (p.G257R). All of the mutations are missense mutations 
which lead to a change from one amino acid to a different amino acid in a protein. The healthy 
control fibroblasts BJ and CON1 were previously characterized in our lab and used in our study 
(Lorenz et al., 2017). All of the fibroblast cell lines used in this study are summarized in Table 
6.1.1.A. with the background information. 
 
3.1.1.  Case reports  
 Prof. Schülke reported that the boy S1A (A.II.1) was the only child of healthy parents, 
who are first-degree cousins from Turkey (Figure 3.1.2. a). His disease manifested with a 
pronounced action tremor and prolonged episodes of hyperventilation at the age of 2 years. 
Due to progressive ataxia, he was only able to walk independently between 1-3 years of age. 
Severe dystonic episodes responded well to L-DOPA/Carbidopa (1.5 mg/kg BW) initially, but the 
effect wore off despite dosage increase to 12 mg/kg BW. From the age of 6 months, his growth 
fell below the third percentile. At 18 years of age, his height was 45 cm below and his head 
circumference 8 cm below the third percentile. Seizures were treated successfully with 
Levetiracetam. From the age of 15 years, frequent metabolic crises with respiratory insufficiency 
required intermittent mechanical ventilation at home through a tracheostoma. His clinical 
situation improved under therapy with the PPAR-agonist bezafibrate (8 mg/kg BW). In his later 
years, the patient was unable to speak, but he was very aware of things happening around him 
and able to understand spoken language. Due to his swallowing difficulties, he was fed through 
a percutaneous gastrostoma from the age of 15 years. The patient died at the age of 25 years 
from a bacterial infection and sepsis.  
 Another family´s both affected children, a girl S1B (B.II.1) and a boy S1C (B.II.2) were 
born to healthy consanguineous parents from Turkey (Figure 3.1.2. b). In the girl, parents 
observed psychomotor regression and ataxia from the age of 3 years with problems swallowing 
liquids, repeated cyanotic attacks, and ptosis. Seizures started at 4 years of age, and she died at 
the age of 8 years in a catabolic crisis with global respiratory failure. The boy was born with 
hypospadias grade II and was very hirsute from birth. By the age of 3.5 years, he lost muscle 
force and the ability to walk, sit, and speak. Triggered by a febrile Mycoplasma pneumoniae 
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infection, he developed choreiform movements of arms and legs with hyperventilation. The boy 
died from global respiratory and cardiac failure at the age of 5 years.  
 
3.1.2.  Molecular and functional characterization  
 Sequencing of SURF1 in S1A fibroblast line showed a homozygous variant (c.530T>G, 
NM_003172) in exon six that was heterozygous in both parents. Segregation of the mutation 
was verified by primer induced restriction analysis (PIRA). The PCR primer sequences and are 
listed in supplementary data. The PCR product of 141 bp was cut by Sma I into 23+118 bp in the 
presence of the mutation (Figure 3.1.2. a). The mutation causes the exchange of an evolutionary 
highly conserved valine for a glycine (p.V177G). The variant was absent in the ExAC database. 
On the other hand, the sequence analysis of SURF1 in S1B and S1C fibroblasts showed a 
homozygous c.769G>A variant in exon 8 causing the exchange of a highly conserved glycine for 
an arginine (p.G180R). The PCR product of 437 bp was cut by Ava II into 292 + 145 bp fragments 
only in the of the mutation (Figure 3.1.2. b). The PCR primer sequences are listed in Section 6.2.4. 
To understand if the protein SURF1 was expressed in the patient fibroblasts, Western blot 
analysis was conducted, and SURF1 protein was absent in all of the patient fibroblast lines (S1A, 

















Figure 3.1.2.: Molecular and functional characterization of LSSURF1 fibroblast lines  
a-b, Pedigrees of both families; segregation between the LS phenotype with homozygosity for the 
c.530T>G mutation in the families of S1A patient (A.II.1) and for the c.769G>A mutation in the family of 
S1B (B.II.1) and S1C patients (B.II.2). The mutations were assessed via PIRA using SmaI and AvaII, 
respectively. c-d, Immunoblot analysis showed that cultured skin fibroblasts from patient lines do not 
express SURF1 or  MT-CO2, probably due to the instability of the mutant protein. The mitochondrial protein 
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Porin (VDAC1) and ACTB were used a loading control, respectively. (Contributions are indicated in section 
8.3). 
 In the second Western blot analysis, an antibody against mitochondrial subunit MT-
CO2 (COX2) was used. Patient fibroblast lines S1A and S1C did not express MT-CO2 protein while 
healthy control fibroblasts expressed both SURF1 and MT-CO2 protein (Figure 3.1.2. d). (The role 
of COX2 in the assembly and functionality of COX enzyme was previously discussed in the section 
1.2.1.).  
 
3.1.3.  Clinical and neuropathological features 
 Cranial MRI uncovered bilateral basal ganglia necroses and T2-signal intensities in the 
brainstem in the Area postrema for patient S1A (Figure 3.1.3. a-c) and the characteristic basal 











Figure 3.1.3.: MRI images of LSSURF1 patients 
a-c, Cranial MRI images of S1A patient at 2.3 years and d-f, of S1C patient at 1.7 years of age. Open 
arrowheads depict T2-signal intense lesions in the basal ganglia as the pathological hallmark of LS. The 
closed arrowheads point at brainstem lesions compromising the formatio reticularis (a, b) and the 
substantia nigra (e) likely being associated with hyperventilation and dystonia. c and f, The lesions are 
accentuated further in the FLAIR sequences. (Contributions are indicated in section 8.3). 
 
 The other vital signatures of the disease are high lactate levels in the blood, urine or 
CSF samples, and the defects of COX activity in muscle biopsies. It was reported that CSF lactate 
was elevated to 4.3 mmol/l (N: <2) in patient S1A. Muscle biopsy at two years revealed a 
pronounced reduction of COX staining and an increase of neutral lipids. Low cytochrome C 
oxidase activity in the muscle (15 mU/mg NCP, N: 90-281) and the mitochondria-enriched 
fraction of cultured skin fibroblasts (130 mU/U CS, N: 680-1190) confirmed COX deficiency. 
Enzyme activities of the other respiratory chain complexes were normal. S1C patient had lactate 
levels at 4.5 mmol/l (N: <2). The biochemical investigation confirmed the COX deficiency in the 
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muscle (158 mU/U CS, N: 520-2080) and in cultured fibroblasts (100 mU/U CS, N: 342-627). The 
mitochondrial morphology appeared normal in the muscles of LSSURF1 patients in the EM images 
even though they had COX deficiency (Suppl. Figure 3.1.3.). Muscle biopsy of patient S1B also 
revealed a negative COX-staining.  Other OXPHOS complex activities were average.  
 
 
3.1.4.  The bioenergetic profile  
 SURF1 mutations impair the oxidative phosphorylation system of the mitochondria the 
first aim was to understand if SURF1 mutations have an exclusive effect on the bioenergetic 
profile of the skin fibroblasts. In order to dissect the functional consequences of SURF1 
mutations on cellular bioenergetics, the Seahorse XF Cell Mito Stress assay was conducted. The 
assay gives multiple parameters which give an insight into the mechanism of mitochondrial 
dysfunction in living cells.  (Detailed explanation of this assay is provided in section 7.1.8.). 
 Therefore fibroblasts of LSSURF1 patients (S1A and S1C) and healthy controls (BJ and 
CON1) were used. The mitochondrial respiration was assessed by measuring the oxygen 
consumption rate (OCR), ATP production-coupled respiration, and maximal respiration. All of 
the measurements were conducted under basal condition followed by sequential addition of 
oligomycin (1 µM), FCCP (1 µM), rotenone and antimycin (1 µM) as indicated in (Figure 3.1.4. a).  
There were no differences in mitochondrial between healthy controls and LSSURF1 patients at the 
level of skin fibroblasts (Figure 3.1.4. b). 
 
 


























Figure 3.1.4.: Bioenergetic profiling of fibroblast cultures of healthy controls and LS SURF1  
a, Oxygen consumption rate (OCR) profile in SURF1 fibroblasts (S1A and S1C) and healthy controls (BJ and 
CON1) (mean +/- s.e.m.; n=2 independent experiments). b-e, OCR, maximal respiration, and ATP 
production in fibroblasts cultures (mean +/- s.e.m.; n=2 independent experiments; Mann-Whitney U test; 
not significant).  
 
 
3.2. Generation of LSSURF1 iPSCs 
3.2.1. Non-integrative reprogramming method 
 The four ``Yamanaka factors´´ were delivered into skin fibroblasts S1A, S1B, and S1C using 
CytoTune-iPS 2.0 Sendai reprogramming kit which has been an efficient integration-free method of 
iPSC production available (Ban et al., 2011; Fusaki et al., 2009; Seki et al., 2010; Tokusumi et 
al., 2002). After delivering Sendai virus to patient skin fibroblasts; elongated cell morphology has 
been slowly changed, and round shape morphologies began to form after 14 days of post-
transduction (Figure 3.2.1.). As the PSC-like colonies got more prominent, they were picked and 
used for pluripotency characterization (Figure 3.2.1. b). There were no colony formations observed 
in S1B fibroblast culture. Only two patient fibroblasts were reprogrammed into iPSCs in this study, 
and I labeled them as SVS1A and SVS1C (Figure 3.2.1. b).  The pluripotent stem cell lines used in this 
study were summarized in Table 6.1.1.B. with the background information. 
 











Figure 3.2.1.: Generation of LSSURF1 iPSCs from skin fibroblasts 
a, A diagram representing the reprogramming of fibroblasts using Sendai virus (SeV). Skin fibroblasts from 
SURF1 (S1A and S1C) were transduced with the CytoTune-iPS 2.0 Reprogramming kit forming SURF1 iPSCs 
SVS1A and SVS1C. b, Bright field images of fibroblasts show the morphological changes of the cells (from 
elongated shape towards round shape ) around day 14. Bright field image showing mature iPSC colony 
morphologies after 20 days of transduction. Scale bars: 50 µm. 
 
 
3.2.2.  Molecular and functional characterization  
 The cultured iPSC colonies can be detected under the microscope by their morphology, 
whereas detailed characterization of iPSCs is required for the registration of stem cell lines.   
 
3.2.2.1.  Mutation analysis 
 Next aim was to confirm the genetic identity of generated iPSC lines, genomic DNA from 
the respected lines was isolated, and it was used as a template for PCR amplification of the SURF1 
sequence after checking the purity on Nanodrop. The primers for each patient lines were designed 
separately and are listed in section 6.2.4. Amplification of a nuclear DNA region containing the 
c.530T>G for SVS1A line and c.769>A for SVS1C line was carried out along with a control line. The 
PCR protocol is listed in section 7.2.5. PCR products of the expected size were identified by agarose 
gel electrophoresis (Suppl. Figure 3.2.2.1.). Next, the PCR products were sent for Sanger sequencing 
after the gel-extraction procedure, and the sequencing results conducted by forward and reverse 
primers confirmed the mutations on the specific locations retain (Figure 3.2.2.1.). This confirms that 
Sendai virus reprogramming did not cause any alterations on the mutation site for both lines SVS1A 
and SVS1C.                   
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Figure 3.2.2.1.: Molecular characterization of iPSCs of LSSURF1  
a-b, Electropherograms showing both forward and reverse wild-type sequences of SURF1 labeled as control 
and the nucleotide changes in patient iPSCs SVS1A (left), and in SVS1C (right). Stars in pink represent the 
nucleotide substitutions, c.530 T>G (SVS1A) and c.769 G>A (SVS1C). Stars in black represent the wild-type 
condition of the mutation site. 
 
3.2.2.2.  Pluripotent identity analysis 
 In order to show the pluripotent identity of the generated iPSCs, first 
immunohistochemistry analysis was conducted. Both lines expressed endogenous protein markers 
associated with pluripotency, including NANOG, TRA-1-60, and LIN28 (Figure 3.2.2.2. a).   Next, the 
pluripotency-associated transcription factors were evaluated by quantitative real-time polymerase 
chain reaction (qPCR), and human embryonic stem cell (hESC) line H1 was used as a positive control. 
SVS1A and SVS1C expressed pluripotency-associated genes, including OCT4, NANOG, SOX2, GDF3, 
DPPA4, and DNMT3B in a similar fashion as the hESC line H1 (Figure 3.2.2.2. b). Only SVS1A showed 
fewer expression levels for NANOG and SOX2 compared to the control line. Lastly, to check the in 
vitro differentiation potential of reprogrammed cell lines was checked. iPSCs were kept in 
suspension culture, they formed embryoid bodies and differentiated into different germ layers 
expressing markers of ectoderm (PAX6), mesoderm (SMA), and endoderm (SOX17) (Figure 3.2.2.2. 
c).  
 
























Figure 3.2.2.2.: Functional characterization of iPSCs of LS SURF1  
a, Representative images of immunofluorescence analysis showing pluripotency-associated marker 
proteins such as NANOG, TRA-1-60, and LIN28 in SVS1A and SVS1C. Scale bar: 50 µm. b, Quantitative real-
time RT-PCR of pluripotency-associated markers in CTRL ES (H1) and SURF1 iPSC (SVS1A and SVS1C). Data 
were normalized to ACTB (mean +/- s.d.; n=2 independent experiments). c, Embryoid body based in vitro 
differentiation analyses of SVS1A and SVS1C showing their ability to differentiate into three germ layers 
and demonstrated here by positive markers for endoderm (SOX17), mesoderm (SMA), and ectoderm 
(PAX6). Nuclei were counterstained with Hoechst. Scale bar: 50 µm. 
 
 
3.2.2.3.  Characterization of genome rearrangements  
 Reprogramming of fibroblasts to iPSCs, routine in vitro maintenance of iPSCs, and genetic 
manipulation of iPSCs could cause genomic instability. Therefore, frequent evaluation of the 
genomic integrity of stem cells is required. There are different methods to detect genomic 
aberrations or mutations on a genome-wide scale. In order to reach a higher resolution, the method 
of choice in this study is array-based technology, which allows us to investigate copy number 
variations (CNVs) across the whole genome at kb resolution (Le Scouarnec et al., 2011). A single 
nucleotide polymorphism (SNP) array method, shows a variation at a single site in DNA. The virtual 
karyotyping analysis showed no abnormalities, which means there is no gain or loss of variations in 
a deleterious way.  The genomic integrity between fibroblasts and iPSCs was maintained (Figure 
3.2.2.3.).  
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 In order to have a complete profile of chromosomal DNA sequence as well as the 
information of the mitochondrial DNA of the generated lines, we have provided DNA samples 
for whole genome sequencing (WGS). The analysis is ongoing.  
 
 
Figure 3.2.2.3.: Virtual karyotyping analysis to evaluate the genomic integrity of LSSURF1 iPSCs 
a-b, SNP array analysis confirmed that SVS1A and SVS1C carried a normal karyotype and were derived 
from the original fibroblast cells S1A (top) and S1C (bottom), respectively.  Virtual karyotyping is digital 
information reflecting a karyotype to evaluate genomic integrity, and it can detect genomic copy number 
variations at a higher resolution level. (Contributions are indicated in section 8.3). 
 
 
3.3. Generation of isogenic pairs via genome editing technology 
 The next step was to employ gene editing techniques on generated lines to create isogenic 
pairs which can provide the best experimental design for accurate disease modeling. The strategy 
was to have isogenic pairs for patient iPSC lines SVS1A and SVS1C by correcting the mutations on 
the SURF1 gene. The isogenic line pairs would come from the same origin; match in genetic 
background, epigenetics, differentiation capacity, derivation, and adaptation to culture.  
 
3.3.1.  TALEN-based isogenic pair for SVS1A line 
 After generating clinically feasible SVS1A iPSCs, the aim was to employ TALENs system for 
precise correction of 530T>A on SURF1 gene in SVS1A iPSCs and to introduce the mutation 530T>A 
on both alleles in SURF1 gene in control TFBJ iPSC line. The strategy of generating TALEN-based 
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isogenic pair for SVS1A is schematized in Figure 3.3.1. There are different kits provided for TALEN 
technology, and the method of choice was Musunuru/Cowan Lab TALEN kit. Instructions were 
provided on the Addgene website for engineering transcription activator-like effectors (TALs) to 
bind to the desired DNA sequence. Each codon has a specific position on the well plate provided by 
the kit, and the designed sequences are listed in section 6.2.4.  
 After the target sequence was identified, string pairs (TALE 1 & 2) were designed to 
correct the mutation 530T>A on SURF1 gene in SVS1A iPSC line. Also, another pair of strings 
(TALE 1 & 3) was designed to introduce the same mutation 530T>A on SURF1 gene on both 
alleles in control iPSC in parallel line (Figure 3.3.1. b-c). The strings with specific restriction sites 













Figure 3.3.1.: The strategy of generating TALEN-based isogenic iPSC pair for SVS1A  
a, Scheme of the SURF1 gene and where the mutation c. 530 T>G resides. b, To correct the mutation on 
SVS1A iPSCs, TALE 1 and TALE2 strings will be used. c, To introduce the mutation on the control iPSC TFBJ 
line, TALE1 and TALE3 strings will be used.  Both strings will be integrated into the HR vector by the 
designed restrictions sites, respectively. 
 
 
3.3.1.1.   Screening for the corrected clones in SVS1A iPSC culture 
 Once the TALEN constructs were assembled (section 7.2.1.), the focus was given to correct 
the mutation first. The target cells were transfected with the plasmids, followed by puromycin 
selection, and the clones were picked. Once the clones grew (assuming derived from single cells), 
PIRA PCR was done to screen for the corrected clones in SVS1A culture. The BsaJI enzyme cuts the 
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WT and SVS1A sequences at different sites. WT band would give two bands (15 + 56 bp) while SVS1A 
band would give three bands (92+23+56 bp) (Figure 3.3.1.1.). In PCR gel, it is recognizable from 
upper bands if the patient line is corrected or not. This is only the case for clone 2, whereas it is 
probably heterozygous or mixed (Figure 3.3.1.1.). On the other hand, clone 1 is not corrected as 
there is only a lower band. However, attempts have failed to find the pure and corrected clone, and 













Figure 3.3.1.1.: PIRA PCR to screen for the right clones including HR + TALE1 + TALE 2  
To confirm the presence of the mutation, we used primer induced restriction analysis (PIRA). BsaJ cut the 
PCR product of 550 bp into 92 + 23 + 56 bp fragments only in the presence of the mutation c.530 T>G or 
was cut into 115 + 56 bp in the presence of correct base pair. SVS1A+ HR and Clone 12 (red underlined) 
seem to have both upper bands 115 and 92 bp, which indicates the heterozygous situation. 
 
   
3.3.2.  CRISPR/Cas9-based isogenic pair for SVS1C line 
 After generating clinically feasible SVS1C iPSCs, the aim was to employ the clustered 
regularly interspaced short palindromic repeats (CRISPR/Cas9) system for precise correction of 
769G>A on SURF1 gene in SVS1C iPSCs.  
 
3.3.2.1.  CRISPR/Cas9 vector construction and design  
 In order to correct the mutation c.769G>A on both alleles in SVS1C iPSCs, the cells were 
transfected with a pU6 vector coding for a specially designed gRNA and the endonuclease high 
fidelity eCas9. A specific pU6 vector, including a specially designed gRNA, is prepared and amplified 
in MACH1 bacteria cells. iPSCs harboring the 769G>A mutation (SVS1C) were transfected by 
Lipofectamine 3000 and with the vector. An ss HDR repair template carrying the knock-in sequence 
was also delivered at the same time. Two silent mutations were introduced to help to trace the 
SVS1C.C clones and confirm the accurate correction of the mutation in the HDR template. The 
sequence of the template is listed in section 6.2.4.  In order to increase the success rate of targeted 
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correction, plasmids expressing RAD52 and dominant-negative p53-binding protein 1 (dn53BP1) 
were delivered to promote homologous direct repair (HDR) and inhibit non-homologous end joining 



























Figure 3.3.2.1.: The strategy of generating CRISPR/Cas9-based isogenic line pair for SVS1C  
a, Schematics of the CRISPR/Cas9 knock-in strategy showing the plasmids and (HDR) template. Plasmid #1  
is a pU6(BbsI)-CAG-eCas9-venus-bpA(#1) 10,146bp vector (coding for a specific designed gRNA and for the 
endonuclease Cas9).Plasmid #2 is a 614.pCAG-hRad52-EF1BFP  8,207 bp coding for RAD 52. Plasmid #3 is 
a 602.pCAG-i53-EF1BFP 7,175bp vector coding for dn53BP1. b, Detailed schematics of the gRNA and the 
HDR template carrying the knock-in sequence for repairing the mutation c.769G>A on both alleles in 
SVS1C. Underline represents Silent mutations; pink stars and black stars represent the mutations and the 
corrections, respectively. (Contributions are indicated in section 8.3.). 
 
3.3.2.2.    Screening for the corrected clones  
 Plasmid RAD52 has a Venus reporter (positive-green), and plasmid including dn53BP1, has 
a BFP reporter (positive-blue). As the vector codes a Venus reporter, three days after transfection, 
the cells were sorted by FACS (Suppl. Figure 3.3.2.2.). The confluence of the cells was low; therefore, 
only 8.76 % of double positive cells were sorted. They were plated on MEFs plates to support single 
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cells growing. Following the transfection and fluorescent sorting, the picked and grown clones were 
screened using restriction PIRA PCR. The PCR product of 550 bp was cut by BbSI into 221+324 bp 
fragments only in the presence of the mutation c.769G>A (Figure 3.3.2.2.). Since clones 3p, 3bb, 
and 3c show one band visible indicates the corrected clones, whereas the PCR product of 3k after 








Figure 3.3.2.2.: A primer‐introduced restriction (PIRA) PCR analysis to screen for corrected clones 
The PCR product of 550 bp was cut by BbsI into 221 + 324 bp fragments only in the presence of the mutation 
c.769 G>A. Clones 3p, 3b, and 3c have the same band sizes as the CTRL, indicating a successful homozygous 
correction. (Contributions are indicated in section 8.3.). 
 
 
3.3.2.3. Molecular and functional characterization  
3.3.2.3.1. Mutation Analysis 
 PIRA PCR gave the first evidence that three clones (3p, 3bb, and 3c) were corrected (Figure 
3.3.2.2.). To confirm the genetic identity of corrected mutation c.769G>A in iPSC clones, desired 
fragments of intact DNA of the clones were extracted from an agarose gel and sent for Sanger 
sequencing which confirmed the homozygous correction of the mutation (Figure 3.3.2.3.1.). 
Additionally, two silent mutations in the HDR template were also visible in the sequence of newly 
formed clones which confirms the successful correction of the mutation. The background 
























Figure 3.3.2.3.1.: Molecular characterization of CRISPR-Cas9-based corrected iPSCs (SVS1C.C) 
a-b, Electropherograms showing both forward and reverse sequences of patient line SVS1C and genetically 
corrected clones of SVS1C.C line (clones 3p, 3bb, 3c). Stars in black represent the corrected base pair of the 
mutation c.769 G>A. The corrected clones have the same sequence as the repair template; underlines 




3.3.2.3.2. Pluripotent identity analysis 
 Characterization of the generated iPSCs was done to prove their pluripotent identity. 
Immunohistochemistry analysis was conducted. All lines expressed endogenous markers associated 
with pluripotency, including OCT3, SOX2, NANOG, and TRA-1-60. The corrected lines retain features 










Figure 3.3.2.3.2.: Functional characterization of CRISPR-Cas9-based corrected iPSCs (SVS1C.C)  
Corrected iPSC lines (3p, 3bb, 3c) retained pluripotent identity. Representative images of 
immunofluorescence analysis showing pluripotency-associated marker proteins such as OCT4, SOX2, 
NANOG, and TRA-1-60. Nuclei were counterstained with Hoechst.  Scale bar: 50 µm. 
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3.3.2.3.3. Characterization of genome rearrangements  
 SNP array was done at the Berlin Institute of Health (BIH) Stem Cell Core facility to look 
at the genomic integrity. The virtual karyotyping analysis showed no abnormalities, which means 
there is no gain or loss of variations in a deleterious way.  The corrected clones of SVS1C.C iPSCs 
had normal karyotypes (Figure 3.3.3.3.2.).  
 
 
Figure 3.3.3.3.2.: Molecular characterization of CRISPR-Cas9-based corrected iPSCs (SVS1C.C) 
Karyotype analysis confirmed that SVS1C.C clones (3p, 3bb, 3c) carried a normal karyotype and were 




3.3.2.4.  The bioenergetic profile  
 The second aim was to understand if SURF1 mutations have an exclusive effect on the 
bioenergetic profile of the iPSCs (Detailed explanation of this assay is provided in section 7.1.8.). 
Skin fibroblasts, which were reprogrammed to iPSCs, should have become more glycolytic. Thus 
they would not be necessarily affected by the disturbances of OXPHOS due to SURF1 mutations. In 
fact, there were no differences in the oxygen consumption rate or in any other other mitochondrial 
respiration parameters between SVS1C and SVS1C.C iPSC lines (Figure 3.3.2.4.). However, 


































Figure 3.3.2.4.: Bioenergetic profiling in iPSC cultures of SVS1C isogenic line pair 
a, Oxygen consumption rate (OCR) profile in iPSCs derived from SVS1C and SVS1C.C (mean +/- s.e.m.; n=2 
independent experiments). b-e, OCR, maximal respiration, ATP production, and extracellular acidification 
rate (ECAR)  in iPSC cultures (mean +/- s.e.m.; n=2 independent experiments).  
 
 
3.4. Differentiation of iPSCs into dopaminergic neuron enriched composite 
cultures  
 Degeneration of dopaminergic (DA) neurons is the predominant basal ganglia 
pathology seen in LS patients. Thus next step was to differentiate healthy control, patient and 
genetically corrected iPSCs into functional dopaminergic neurons through the first generation 
of neural progenitor cells using small molecules (smNPCs). I adopted a small molecule-based 
protocol was to generate NPCs and DA-enriched composite cultures from iPSCs (Reinhardt et 
al., 2013; Choi et al., 2015). It takes around ten days to get NPCs from iPSCs and 4 or 8 weeks to 
retrieve dopaminergic neurons at different maturation stages. During the first stage of retrieving 
NPCs from iPSCS, the cells go through different states and form different cell types such as 
neurospheres and neural epithelial cell cells (Figure 3.4. b). Once they grow as a uniform 
monolayer on Matrigel-coated plates, they are directed towards DA neuronal identity by 
neuronal maturation media. The phase contrast images of the cell types display the 
morphological changes of the cells undergoing as they acquire a neuronal identity. For instance, 
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while there are more round spheres in neurosphere cultures, and there are more elongated 












Figure 3.4.: Derivation of neural progenitor cells (NPCs) and dopaminergic (DA)-enriched composite 
cultures  
a, Summary graph of the progression of PSCs to fully differentiated NPC-derived neurons. b, PSCs were 
differentiated to NPCs via the first generation of embryoid bodies (EBs). EBs were plated on Matrigel-
coated plates and induced to differentiate to neural epithelial cells. The microscopic images of the 
transformation of the cells from EBs to DAs. Scale bar: 20 µm, 50 µm, 50 µm, 50 µm. 
 
 
3.4.1.  Characterization of iPSC-derived NPCs 
3.4.1.1.  NPC identity analysis 
    Characterization of iPSC-derived NPCs was done to prove they are neural progenitor cells 
via immunohistochemistry analysis. All lines expressed endogenous protein markers associated 
with neural progenitor cells such as NESTIN, PAX6, SOX2, and HES5, as well as neuronal cells such 







Figure 3.4.1.1.: Characterization of NPCs cultures of LSSURF1 Differentiated neural epithelial cells were 
stained for neuronal progenitor markers NESTIN, PAX6, and HES5. TUJ1 and MAP2 mature neural markers 
were also present to indicate they have a premature neuronal character. Nuclei were counterstained with 
Hoechst. Scale bar: 50 µm. 
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3.4.1.2.   The functional characterization of COX  
 SURF1 protein is a key assemble factor of COX and helps the core subunits (COX1, 
COX2, and COX3) to assemble in the right way so the enzyme can function adequately (The role 
of COX2 in the assembly and functionality of COX enzyme was previously discussed in the section 
1.2.1.). Here the aim was to understand if there is any detectable MT-CO2 protein in NPC 
cultures of LSSURF1. Western blot analysis showed that MT-CO2 protein was almost undetectable 
in NPCs derived from patient lines (SVS1A and SVS1C) while NPCs from healthy controls and 
corrected lines all expressed MT-CO2 (Figure 3.4.1.2. a). SURF1 is most likely involved in an early 
assembly of COX through MT-CO2.  
 The transmission electron microscopy (TEM) images of the mitochondria in patient-
NPCs were taken to understand if the mitochondria have any structural abnormalities due to 
SURF1 defects. Mitochondria in NPCs from all lines displayed healthy mitochondrial structure 
(Figure 3.4.1.2. b). They also showed a fused ultrastructural morphology with well-developed 
cristae, which was an indication of OXPHOS dependence of NPCs. Then the functional analysis 
of complex II and IV activity were done; NPCs derived from healthy controls and corrected lines 
gave a brown indamine polymer product upon providing 3,3'-diaminobenzidine (DAB) substrate. 
In contrast, there was no brown color seen in NPCs derived from patient lines since DAB product 
was not saturated due to dysfunction of COX (Figure 3.4.1.2. c). The activity of complex II 
succinate dehydrogenase (SDH) remained similar in all NPCs, which was confirmed by a blue 
formazan end product upon reduction of nitroblue tetrazolium (NBT).  
 These confirmed that the defects in SURF1-mutant cells were specific for complex IV 
and that they have a functional defect rather than structural. Overall, the findings demonstrated 



































Figure 3.4.1.2.: The functional defects of COX in NPC culture of LSSURF1  
a, Representative immunoblot analysis of MT-CO2 in iPSC-derived NPCs from CTRL ES (H1), CTRL iPSC 
(XM001 and TFBJ), SURF1 iPSC (SVS1A and SVS1C), and genetically corrected SVS1C.C (clones 3p and 3bb). 
Protein levels were normalized to ACTB. MT-CO2 protein was absent in patient lines. Similar results were 
obtained in n=2 independent experiments. b. Transmission electron microscopy (TEM) of mitochondria 
showing normal structure in all NPC lines. Scale bar: 500 nm. c. Mitochondrial enzyme activity in NPCs 
derived from all lines is presented. The activity of complex IV cytochrome c oxidase (COX) was not 
detectable in patient lines (SVS1A and SVS1C), while the activity of complex II succinate dehydrogenase 
(SDH) was present in all cell lines. Similar results were obtained in n=2 independent experiments. Scale bar: 
500 nm. (Contributions are indicated in section 8.3.). 
 
 
3.4.1.3.  The bioenergetic profile  
  Patient-derived NPC cultures displayed defects in COX activity (Figure 3.4.1.2.). Thus in 
order to dissect the bioenergetics consequences of the NPC cultures of LSSURF1, the Seahorse XF Cell 
Mito Stress assay was conducted. The mitochondrial respiration analysis was done by measuring 
the OCR, ATP production-coupled respiration, and maximal respiration. Additionally, glycolytic 
 
  36 
 
capacity analysis was done by measuring ECAR (Figure 3.4.1.3.A. a). NPCs derived from patient lines 
exhibited significantly reduced mitochondrial respiration parameters (Figure 3.4.1.3.A. b-d), and 
the mitochondrial bioenergetics was restored upon mutation correction in SVS1C.C-derived NPCs 
(Figure 3.4.1.3.B b-d). NPCs should have become a bit more OXPHOS dependent as they are 
differentiated from iPSCs. This is the first evidence that SURF1 mutations lead to bioenergetic 
defects. On the contrary, NPCs derived from patient lines displayed high ECAR levels compared to 
NPCs derived from healthy controls and corrected lines (Figure 3.4.1.3.A e, Figure 3.4.1.3.B e). 

























Figure 3.4.1.3.A.: Impaired bioenergetics in NPC cultures of LSSURF1  
a, Oxygen consumption rate (OCR) profile in iPSC-derived NPCs from CTRL ES (H1) from CTRL iPSC (TFBJ 
and XM001) and SURF1 patients (SVS1A and SVS1C). b-e, OCR, maximal respiration, ATP production and 
extracellular acidification rate (ECAR) in NPC cultures (mean +/- s.e.m.; n=5 independent experiments; *** 































Figure 3.4.1.3.B : Restored bioenergetics upon mutation correction in NPC cultures of SVS1C.C 
a, Oxygen consumption rate (OCR) profile in iPSC-derived NPCs from SVS1C and SVS1C.C (mean +/- s.e.m.; 
n=5 independent experiments). b-e, OCR, maximal respiration, ATP production and extracellular 
acidification rate (ECAR) in NPC cultures (mean +/- s.e.m.; n=5 independent experiments; *** p<0.001; 
Mann-Whitney U test).  
 
 
3.4.1.4. Enzymatic assessment of lactate production  
  NPCs derived from patient lines exhibited lower levels of OCR and high levels of ECAR. 
Through glycolysis, glucose is converted into pyruvate and transported into the mitochondria 
for aerobic respiration, or converted into lactate for anaerobic respiration.  
  The supernatants collected from the NPC cultures were used for enzymatic lactate 
assay. NPCs derived from patient lines tend to have higher lactate levels compared to NPCs from 
healthy controls (Figure 3.4.1.4. a), which were also detected in the liquor and serum of most LS 
patients. High lactate levels were reduced upon mutation correction (Figure 3.4.1.4. b). An 
increase in lactate production over time might suggest increased glycolysis to generate ATP as a 
compensation mechanism to OXPHOS defects. Additionally, NPCs from patient lines might have 
more progenitor cell character than neuronal character. Neural stem cells/progenitor cells 
usually rely on more glycolytic activity, and as they differentiate to neuronal cells, metabolic 
switch from glycolysis towards OXPHOS occur. If they are more neuronal progenitor cells, it 
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suggests them to be more proliferative and cellular proliferation assay done in NPC cultures of 
isogenic line pair showed that patient NPCs proliferate more compared to the corrected line  
(Suppl. Figure 3.4.1.4.) (Candelario et al., 2013; Mlody et al., 2016). Less proliferative capacity of  
NPCs from healthy controls and corrected lines might be because they might have more 












     Figure 3.4.1.4.: Quantification of extracellular lactate in NPC cultures of all lines 
a, Quantification of extracellular lactate in the supernatant of iPSC-derived NPCs from CTRL ES (H1), CTRL 
iPS (TFBJ and XM001) and  SURF1 iPS (SVS1A and SVS1C)  (mean +/- s.e.m.; n=4 independent experiments; 
one-way ANOVA followed by Bonferroni multiple comparison tests, not significant). b, Quantification of 
extracellular lactate in the supernatant of NPC cultures from isogenic lines SVS1C and SVS1C.C (mean +/- 
s.e.m.; n=4 independent experiments; *** p<0.001; Mann-Whitney U test). 
 
 
3.4.1.5.  Neuronal profiling  
 NPC identity and bioenergetic characterization of NPCs showed that within the NPC 
cultures, there are already immature neuronal cells that express neuronal protein markers such 
as TUJ1 and MAP2 addition to NPC markers (Figure 3.4.1.1.). Accordingly, mitochondria in NPCs 
already exhibit cristae structures similar to those of mature neurons (Figure 3.4.1.2 b) (Lorenz 
et al., 2017).  
 Patient-derived NPC cultures showed higher glycolytic activity and were more 
proliferative. The next aim was to quantify the number of cells expressing TUJ1 protein marker, 
neurite outgrowth capacity, and branching capacity in NPC cultures. High-content (HCA)-based 
automated fluorescent imaging-based analysis of neuronal morphology was done in NPC 
cultures of isogenic iPSC lines in multi-well format (Figure 3.4.1.5. a). There was no difference in 
the number of NPCs expressing TUJ1 protein markers between the isogenic lines, whereas the 
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neurite length per neuron and branch points per neuron were significantly lower in NPC cultures 
















Figure 3.4.1.5.: Restored neuronal branching upon mutation correction in NPC cultures of SVS1C.C 
a, Representative images of the high content analysis (HCA) mask for neuronal profiling showing shorter 
neurites (in green and red), fewer branch points (in pink) in iPSC-derived NPCs from SVS1C. Scale bar: 25 
µm. b, HCA-based quantification of neuronal profiling based on TUJ1-expressing neurons in NPC cultures 
of SVS1C and SVS1C.C (mean +/- s.e.m.; n=5 independent experiments; *** p<0.001; Mann-Whitney U 
test).  
 
Neuronal profiling analysis of iPSC-derived NPCs showed that SURF1 defects disrupt 
neuronal branching capacity already at the level of NPC state. The mutation repair in SVS1C.C 
restored the neurite outgrowth capacity and branching capacity of the NPCs. It would be a 
necessity to confirm this phenotype in DA enriched composite cultures to understand if this 
phenotype is real. 
 
3.4.2.  Characterization of iPSC-derived DA-enriched composite cultures 
3.4.2.1.  Dopaminergic neuron identity analysis 
  After the initial generation of NPCs, patient lines were differentiated further into DA 
enriched cultures and were let in cultures for 4, 6, and 8 weeks for different stages of maturity. 
In order to characterize the DA cultures in more detail, there were several experiments 
conducted: 
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   First, extensive immunohistochemical analysis was performed, and large 
populations of TUJ1 and MAP2 expressing neuronal cells were found. They also expressed the 
synaptic markers SYP and VAMP2, the DA markers NURR1, FOXA2, and TH at 8 weeks (Figure 
3.4.2.1.A. a, 3.4.2.2.B. a). After they were proven to express neuronal and DA-related markers, 
HCA-based quantification of TUJ1 analysis was conducted to compare the number of neurons 
expressing TUJ1 markers between the lines. DA cultures derived from patient lines at 4w and 8w 
showed significantly fewer cells expressing TUJ1 protein markers compared to DA cultures 
derived from healthy controls (Figure 3.4.2.1.A b). Mutation correction increased the neuronal 
percentage in DA cultures of SVS1C.C at 8w, suggesting a restored neurogenic potential of the 
patient-derived DA cells (Figure 3.4.2.1.B b). There was no significant difference observed at 4w 
DA cultures between the isogenic lines.  
  
Figure 3.4.2.1.A.: Impaired neuronal generation in DA-enriched composite cultures of LSSURF1  
a, iPSC-derived Dopaminergic (DA)-enriched composite cultures from CTRL ES (H1), CTRL iPSC (TFBJ and 
XM001), SURF1 iPSC (SVS1A and SVS1C) expressed the neuronal markers TUJ1 and MAP2, the synaptic 
markers SYP and VAMP2, the DA markers NURR1, FOXA2, and TH. (Scale bar: 50 µm). b, High content analysis 
(HCA)-based quantification of TUJ1-expressing neurons in iPSC-derived 4w  and 8w dopaminergic (DA)-
enriched neuronal cultures from CTRL ES (H1), CTRL iPSC (TFBJ and XM001), SURF1 iPSC (SVS1A and SVS1C) 
((mean +/- s.e.m.; n=3 independent experiments; ** p<0.01; *** p<0.001; Mann-Whitney U test; one-way 
ANOVA followed by Bonferroni multiple comparison test, *** p<0,001). c, Representative Magnetic-Activated 
Cell sorting (MACS)-based histogram plots of NCAM-positive cell population in 4w DA and 8w DA cultures in 
comparison to negative sorted cells (in grey). Fluorescence intensity (x-axis) was plotted against the relative 
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Additionally, magnetic-activated cell sorting (MACS) analysis was conducted to quantify the cells 
with the cell surface marker of neural cell adhesion molecule (PSA-NCAM), which is a distinctive 
marker of immature neuronal-restricted progenitors. They play a role during neurogenesis, 
which entails the migration, survival, and process of outgrowth of newly generated neurons. DA 
cultures from patient lines (SVS1A and SVS1C) showed a reduced amount of NCAM-positive 
neuron-restricted progenitors compared to cultures from healthy controls, which suggests 
impaired neurogenesis (Figure 3.4.2.1.A c). Altogether, the mutation correction restored the 
neuronal generation (Figure 3.4.2.1.B.). 
 
   
Figure 3.4.2.1.B.: Restored neuronal generation upon mutation correction in DA-enriched composite 
cultures of SVS1C.C 
a, iPSC-derived DA-enriched composite cultures from SVS1C and SVS1C.C at 8 weeks expressed the 
neuronal markers TUJ1 and MAP2, the synaptic markers SYP and VAMP2, the DA markers NURR1, FOXA2, 
and TH. (Scale bar: 50 µm). b, High content analysis (HCA)-based quantification of TUJ1-expressing 
neurons in iPSC-derived 4w  and 8w dopaminergic (DA)-enriched neuronal cultures from CTRL ES (H1), CTRL 
iPSC (TFBJ and XM001), SURF1 iPSC (SVS1A and SVS1C) ((mean +/- s.e.m.; n=2 independent experiments; 
*** p<0.001; Mann-Whitney U test). 
 
 
3.4.2.1.1.Transcriptomic profile of DA neuronal identity 
 In order to understand the disease-associated disrupted neuronal profile better and 
characterize DA-enriched composite cultures in a more obvious way, RNA sequencing was 
performed on 4w and 8w cultures from CTRL ES (H1), CTRL iPSC (XM001), and SURF1 iPSC (SVS1A 
and SVS1C). Principle component analysis (PCA) showed a clear separation between the 
transcriptomic profile of the patient and control lines (Figure 3.4.2.1.1.A a). Transcriptome 
analysis was also performed on 4w and 8w DA cultures from isogenic lines (SVS1C and SVS1C.C) 
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using ribo-zero total RNA-seq to analyze the potential differences in a more precise way. PCA 
analysis also showed a clear separation between the transcriptomic profiles of DA cultures of 















Figure 3.4.2.1.1.A.: PCA plot of DA-enriched composite cultures of all lines 
a, Principal component analysis (PCA) of the mRNA-based transcriptome (polyA) of 4w and 8w DA cultures 
derived from SURF1 iPSC (SVS1A and SVS1C) vs. CTRLS (H1 and XM001) (n=3 independent experiments). x and 
y-axis represent the principal component 1 and 2 explaining 78.8% and 7.8% of the variance, respectively (n=3 
independent experiments). b, PCA of ribo-zero total RNA-seq based transcriptome of 4w and 8w DA cultures 
derived from isogenic lines. x and y-axis represent the principal component 1 and 2 explaining 62.2% and 
15.8% of the variance, respectively (n=3 independent experiments). (Contributions are indicated in section 
8.3.). 
 
 After the first characterization of DA-enriched composite cultures and finding defects 
in the neuronal generation, the transcriptomic data was used to give more depth to the findings. 
Interestingly, patient-derived cultures at 4w and 8w exhibited upregulation of genes associated 
with embryonic development and pluripotency such as LIN28A, POU5F1, USP44, DPPA3, and 
DPPA4 (Figure 3.4.2.1.1.B. a). Moreover, SURF1-mutant cultures displayed downregulation of 
genes involved in neuronal differentiation such as NCAM1, PHOX2B, FOXA2, or interneurons like 
REEL, which is also known to control neuronal migration. This downregulation was even more 
evident in the cultures of 8w. Additionally, there was a downregulation in FOXA1 and FOXA2 
genes, which are known to regulate DA neurogenesis (Figure 3.4.2.1.1.B. c). Moreover, a set of 
DA genes were also analyzed, and patient-derived DA cultures exhibited different gene 
expression profile at both weeks. Overall, data suggest that SURF1 mutations caused a 
transcriptional reconfiguration suggestive of suppression of neuronal differentiation and fate 
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Figure 3.4.2.1.1.B.: Differentially regulated neuron-specific genes in composite cultures of LSSURF1 
a-b, Log fold changes (LFC) of genes regulating pluripotency, neuronal differentiation, and DA specification 
in iPSC-derived 4w (empty bars) and 8w (dotted bars) DA cultures from SURF1 iPSC (SVS1A and SVS1C) vs. 
CTRL (H1 and XM001) (* p<0.05, ´´ p<0.01, o p<0.001, • p<0.0001).  
 
  Transcriptome dataset of isogenic line pair highlighted the defects in neuronal 
differentiation and DA neuronal fate specification more distinctively as SVS1C was compared to 
genetically corrected SVS1C.C line. Usually, each cell has the same developmental potential at 
the beginning, whereas as they mature, they choose different paths due to their fate 
specification. In SURF1 patient-derived DA neuronal cultures, the data suggest cell culture to 
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entail more premature neuronal cells, or more progenitor cell types as all of the pluripotent 
genes were significantly upregulated (Figure 3.4.1.1.1.C. a), neuronal differentiation (Figure 
3.4.1.1.1.C. b) and DA specific genes very significantly downregulated (Figure 3.4.1.1.1.C. c). For 
instance, LMX1B is known to be involved in the differentiation of mDA progenitors and 
maturation of post-mitotic DA neurons along with NURR1. There was also a significant 
downregulation of MAOB at both weeks, which suggests a defective metabolism of dopamine 






























Figure 3.4.2.1.1.C.: Differentially regulated neuron-specific genes in composite cultures of SVS1C 
isogenic line pair 
a-c, Log fold changes (LFC) of genes regulating pluripotency, neuronal differentiation, and mDA neuron 
specification in iPSC-derived and 4w (empty bars) and 8w (dotted bars) DA cultures  from SVS1C and 
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3.4.2.2.  Glial cell identity analysis  
  After doing neuronal characterization in NPC-derived DA-enriched composite cultures, 
the focus was then given to understand if there were any glial cell types in the culture. First, 
immunohistochemical analysis was performed on 4w and 8w DA cultures from CTRL ES (H1), 
CTRL iPSC (XM001), and SURF1 iPSC (SVS1A and SVS1C), and isogenic lines (SVS1C and SVS1C.C). 
All cell lines expressed mature glial cell marker S100ß and the astrocyte marker GFAP (Figure 
3.4.2.2. a). Each line showed variability in GFAP and S100ß expression and, in some cases, there 
was no co-localization of the markers. The morphologies of the glial cells also varied from each 
other in each experiment. In order to quantify the glial cells and to understand if they exhibit 
any differences in number, magnetic-activated cell sorting (MACS) analysis was performed with 
the glial progenitor marker (A2B5) and mature astrocyte marker (GLAST). The number of A2B5-
positive glial-restricted progenitors and the number of GLAST-positive mature astrocytes 

























Figure 3.4.2.2.: Glial cell profile in DA-enriched composite cultures of all lines 
a, Astrocyte markers S100ß and GFAP markers are present in iPSC-derived 8w dopaminergic (DA)-enriched 
neuronal cultures from CTRL ES (H1)  from CTRL iPSC (TFBJ and XM001), SURF1 iPSC (SVS1A and SVS1C), 
and isogenic pair line (SVS1C and SVS1C.C) (Scale bar: 50 µm).  b, Representative Magnetic-Activated Cell 
sorting (MACS)-based histogram plots of A2B5-positive cell population in 4w and 8w DA  composite 
cultures in comparison to negative sorted cells (in grey). Fluorescence intensity (x-axis) was plotted against 
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the relative Cell number (y-axis). Percentage values refer to the number of positive cells over the total 
number of cells (n=3 independent experiments). d, MACS-based quantification of glial surface markers: 
CD11b for microglia and O4 for oligodendrocytes, and GLAST for mature glial cells in CTRL ES (H1)  from 
CTRL iPSC (TFBJ and XM001), SURF1 iPSC (SVS1A and SVS1C) derived 8w DA cultures (n=3 independent 
experiments).  
 
Additionally, MACS analysis was performed to understand if there are any other glial cell types 
present in the differentiated cultures derived from NPCs. CD11B was chosen to identify the 
microglial cells and O4 for oligodendrocyte population. There was no CD11B and O4 positive 
cells detected in DA cultures derived from NPCs in any of the lines.  (Figure 3.4.2.2. d). 
 
 
3.4.2.2.1. Transcriptomic profile of glial identity 
     First initial experiments did not show any significant differences in glial cell number 
between composite cultures derived from healthy controls and patient iPSCs. RNA-seq analysis 
showed upregulation of most of the glial genes such as GFAP, S100B, and AQP4 in SURF1-iPSC-
derived cultures in both weeks (Figure 3.4.2.2.1 a), whereas the differences were not significant. 
On the contrary, all of the glial genes were significantly downregulated in the patient line when 
it was compared to SVS1C.C (Figure 3.4.2.2.1 b).  
 
Figure 3.4.2.2.1.: Differentially regulated glial genes in DA-enriched composite cultures of all lines 
a, Log fold changes (LFC) of genes regulating astrocyte identity in iPSC-derived 4w (empty bars) and 8w 
(dotted bars) DA cultures from SURF1 iPSC (SVS1A and SVS1C) vs. CTRL (H1 and XM001). b, Log fold 
changes (LFC) of genes regulating astrocyte identity in iPSC-derived 4w (empty bars) and 8w (dotted bars) 




3.4.2.2.2. Assessing the functionality of glial cells  
   The presence of glial cells in DA-enriched composite cultures can mimic the 
physiological condition seen in the CNS. There were variabilities in the transcriptomic analysis 
of glial cell profile among the groups. It is known that astrocytes tend to respond to damage or 
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insults by proliferating and undergoing hypertrophy. In order to understand if the glial cells 
present in differentiated DA-enriched composite cultures are resting or reactive, V-PLEX 
mesoscale inflammatory (panel I) was performed on the collected supernatants to look at their 
cytokine profile. It measured ten cytokines, which play a role in inflammation response. 
Supernatants from DA cultures at 4w and 8w were analyzed for each line separately and then 
were compared to understand if they show any differences. The cytokines were present in non-
stimulated composite cultures, and the highly present ones were highlighted in red (Suppl. Table 
3.4.2.2.2.). Only DA cultures derived from hESC line H1 also show the presence of TNF-α. The 
cytokines IL-13, IL-6, and IL-8 were present in all the samples but were not significantly altered 
in LSSURF1 cultures. There was no clear outcome from the glial profile analysis of the lines as they 
behaved differently. Cytokine panel analysis indicated that the glial cells are active in culture, 
whereas there were no differences in the reactivity profile between patient lines and healthy 
























Figure 3.4.2.2.2.: Cytokine profiling in composite cultures of all lines  
Cytokines measured using Mesoscale Inflammatory Panel I. Astrocyte-derived cytokines expression over 
time in mature in iPSC-derived 4w and 8w dopaminergic (DA)-enriched neuronal cultures from a, CTRL iPSC 
(XM001); b, CTRL iPSC (TFBJ); c-d, SURF1 iPS (SVS1A and SVS1C). The significant differences between 4w 
(light color) and 8w (dark color) DA cultures are underlined with red.   
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3.4.2.3. The bioenergetic profile  
    In order to understand if SURF1 mutations have an exclusive effect on the bioenergetic 
profile of the DA-enriched composite cultures, the Seahorse XF Cell Mito Stress assay was 
conducted. DA-enriched composite cultures derived from patient lines exhibited significantly 
reduced mitochondrial respiration (basal OCR, maximal respiration, and ATP production) (Figure 
3.4.2.3.A c-f) and the mitochondrial bioenergetics was restored upon mutation correction in 
SVS1C.C-derived cultures for both 4 and 8 weeks (Figure 3.4.2.3.B c-f). Bioenergetic defects 
became biochemically apparent already at the level of NPCs, shown previously (Figure 3.4.1.2. 
c, 3.4.1.3.A. b-d). (Detailed explanation of this assay is provided in section 7.1.8.). 
   
 
Figure 3.4.2.3.A.: Impaired bioenergetics in DA-enriched composite cultures of LSSURF1  
a-b, Oxygen consumption rate (OCR) profile in iPSC-derived 4w  and 8w dopaminergic (DA)-enriched 
neuronal cultures from CTRL ES (H1), CTRL iPSC (XM001) and  SURF1 patients (SVS1A and SVS1C). c-f, OCR, 
maximal respiration, ATP production, and extracellular acidification rate (ECAR) in 4w and 8w DA cultures 
(mean +/- s.e.m.; n=5 independent experiments; * p<0.05; ** p<0.001; *** p<0.001; Mann-Whitney U test; 
one-way ANOVA followed by Bonferroni multiple comparison test, *** p<0,001).  
 
  
 Moreover, patient-derived composite cultures exhibited higher ECAR levels at 4 weeks 
compared to composite cultures of healthy controls. On the contrary, patient-derived composite 
cultures displayed reduced ECAR levels at 8th weeks compared to composite cultures derived 
from healthy control lines. At this very mature stage, DA-enriched composite cultures of the 
patient lines seem to stop compensating energy demand via glycolysis. All parameters related 
to mitochondrial respiration and glycolysis were significantly lower in composite cultures of 
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patient lines compared to healthy controls and corrected lines at 8w. (Figure 3.4.2.3.A. f, Figure 




















Figure 3.4.2.3.B.: Restored bioenergetics upon mutation correction in DA-enriched composite cultures 
of SVS1C.C 
a-b, Oxygen consumption rate (OCR) profile in iPSC-derived 4w and 8w dopaminergic (DA)-enriched 
neuronal cultures from SVS1C and genetically corrected SVS1C.C. c-f, OCR, maximal respiration, ATP 
production, extracellular acidification rate (ECAR) in 4w and 8w DA cultures (mean +/- s.e.m.; n=3 
independent experiments; * p<0.05; *** p<0.001). 
 
 Altogether SURF1 mutations impair mitochondrial respiration in DA-enriched 
composite cultures at both 4 and 8th weeks, which was initially observed biochemically and 
bioenergetically at the NPC level. Additionally, the compensation mechanism of the 
differentiated culture of the patient lines via glycolytic respiration seems not to be sufficient 
anymore at 8th weeks, and this is where the severity of the phenotype becomes apparent.   
 
3.4.2.3.1. Enzymatic assessment of lactate production 
   The supernatants collected from the DA-enriched composite cultures were used for 
enzymatic lactate assay, and cultures derived from patient lines tend to have higher lactate levels 
compared to cultures from healthy controls (Figure 3.4.2.3.1.). DA-enriched composite cultures of 
SVS1C produced an increased amount of glycolysis-derived lactate compared to the corrected line. 
The tendency in high lactate levels could be a result of the presence of immature cell types or 
astrocytes which are primarily glycolytic. 
 











Figure 3.4.2.3.1.: Quantification of extracellular lactate in composite cultures of all lines  
a, Quantification of extracellular lactate in the supernatant of  iPSC-derived 4w  and 8w dopaminergic 
(DA)-enriched neuronal cultures from CTRL ES (H1), CTRL iPSC (TFBJ and XM001) and  SURF1 patients 
(SVS1A and SVS1C)  b, Quantification of extracellular lactate in the supernatant of iPSC-derived 4w  and 
8w dopaminergic (DA)-enriched neuronal cultures from isogenic lines SVS1C and SVS1C.C (mean +/- s.e.m.; 
n=4 independent experiments; *** p<0.001; Mann-Whitney U test). 
 
 
3.4.2.3.2. Transcriptomic profile of bioenergetics 
 In order to understand the disease-associated disrupted bioenergetic profile better 
and characterize DA-enriched composite cultures in a more evident way, transcriptome analysis 
was performed on 4w and 8w DA cultures from CTRL ES (H1), CTRL iPSC (XM001), and SURF1 
iPSC (SVS1A and SVS1C) (Figure 3.4.2.3.2. a) using polyA mRNA-sequencing and of 4w and 8w 
DA cultures from SVS1C and SVS1C.C using ribo-zero total RNA-seq (Figure 3.4.2.3.2. b).  
 8w neuronal cultures from SURF1 iPSC downregulated PPRGC1A (PGC1A), a master 
activator of mitochondrial biogenesis and OXPHOS metabolism that is important for neuronal 
maturation. SURF1 iPSC 8w DA cultures also downregulated PDK3 and PDK4, negative regulators 
of glucose oxidation and crucial for maintaining energy homeostasis. At the same time, 4w and 
8w cultures from SURF1 iPSC showed increased expression of glycolysis-promoting lactate 
dehydrogenase enzymes LDHA and LDHD. Interestingly, the genes that were shown for the 
bioenergetic profile indicated an upregulation of mtDNA-encoded genes (such as MT-CO1). At 
the beginning of differentiation, neuronal cells have increased energy demands and may thus 
attempt to compensate their COX deficiency through an augmented expression of components 
of the catalytic core of COX enzyme. However, upon prolonged differentiation, this 
compensatory mechanism may be shut down as it becomes insufficient. Taken together, 
maturing neuronal cultures carrying SURF1 mutations might fail to activate mitochondrial 
metabolism over time and therefore retain features of glycolytic metabolism. Additionally, 
patient-derived composite cultures showed downregulation of SNPH and KIF5C which were 
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shown to mediate the activity-dependent immobilization of axonal mitochondria in time-lapsing 





















Figure 3.4.2.3.2.: Differentially regulated bioenergetics genes composite cultures of all lines 
a-b, Log fold changes (LFC) of genes regulating mitochondrial bioenergetics and dynamics in iPSC- in 4w 
(empty bars) and 8w (dotted bars) DA-enriched composite cultures from SURF1 iPSC (SVS1A and SVS1C) 
vs. CTRL (H1 and XM001) and in 4w (empty bars) and 8w (dotted bars) DA cultures from SVS1C and SVS1C.C 
(mean +/- s.d.; * p<0.05, ´´ p<0.01, o p<0.001, • p<0.0001).  
 
 
3.4.2.3.3.The functional consequences of bioenergetic defects 
 The mitochondrial dynamics and bioenergetics reciprocally influence each other, so 
the next aim was to assess the consequences of the bioenergetic defects in differentiated 
neurons through quantification of mitochondrial movement. iPSC-derived 4w and 8w DA 
cultures from healthy controls (H1 and XM001), patient lines (SVS1A and SVS1C), and corrected 
line (SVS1C.C) were live-stained with MitoTrackerRed and imaged with a spinning disk 
microscope for almost five minutes. All experiments were done in triplicates and stored. Only 
isogenic lines were analyzed due to time restrictions. The analysis showed that SVS1C-derived 
DA composite cultures showed a significant increase in mitochondrial motility in comparison to 
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Figure 3.4.2.3.3.: Restored number of stationary mitochondria upon mutation correction in composite 
cultures of SVS1C isogenic line pair 
a, Representative images of iPSC-derived 8w DA cultures live-stained with MitoTrackerRed and imaged 
with a spinning disk microscope. Culture of SVS1C has 76 total mitochondria, 26 moving mitochondria (in 
pink) and the culture of SVS1C.C has 87 total mitochondria and 45 moving mitochondria. Scale bar: 10 µm. 
b, Quantification of stationary mitochondria in 4w and 8w DA cultures from SVS1C and genetically 
corrected SVS1C.C (median +/- 95% confidence interval; *** p<0.001, one way ANOVA followed by Tukey 
Honestly Significant Differences). (Contributions are indicated in section 8.3.). 
 
 The uncoupler FCCP was given to culture to test the newly established system and 
analysis method, FCCP is known to reduce the motility of mitochondria by causing rapid 
dissipation of the membrane potential, which further reduces the mitochondrial calcium uptake, 
and therefore ATP levels fall below the levels needed for movement (Miller et al., 2004). Indeed 
after treating 4w and 8w DA cultures with FCCP, the percentage of moving mitochondria 
reduced significantly (Suppl. Figure 3.4.2.3.3.). Since neurons have sophisticated structural 
features and ATP has a limited diffusion capacity in the long axonal process (Hubley et al., 1996); 
neurons anchor ATP mitochondria in the regions where metabolism capacity is in high demand 
at distal ends. By anchoring mitochondria at the places, mitochondria serve as stationary power 
plants for stable ATP supply necessary to maintain the synaptic homeostasis (Courchet et al., 
2013; Sheng, 2017). Hence, the disruption of mitochondrial bioenergetics and motility in SURF1-
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3.4.2.4.  Neuronal profiling  
    Neurons undergo a variety of complex morphological arrangements to assemble into 
neuronal circuits and propagate signals. As NPCs start to mature, they undergo axonal 
differentiation such as forming new branching and new dendritic formation. They become more 
elongated so that they can form synapses to communicate with each other. This whole 
mechanism indeed is not free for costs. Axonal growth required a considerable amount of 
energy for building material as well as for intracellular transport. Considering the defects seen 
in mitochondrial respiration defects, then next aim was to address the capacity of neurons to 
generate branches using high-content analysis (HCA)-based quantification of neurite length per 
neuron and branching points per neuron in 4w and 8w DA neuronal cultures in multi-well 
format.  
 The main regions within a neuron are the nucleus, cell body, neurites, and branch 
points. Processed images show nuclei was circled in red, cell bodies in cyan, neurites in green, 
and branch points in yellow color. This is illustrated in the following figure with their color 
annotations (Figure 3.4.2.4. a). When the neurons reach the maturity of 4 and 8 weeks, they 
were seeded on the assay plates and analyzed four days later. Therefore this is an assessment 
of outgrowth capacity of the neurons. Results showed that the neurite outgrowth capacity was 
significantly disrupted in neurons from SURF1 iPSC compared to neurons from healthy controls 
(Figure 3.4.2.4. b-c). They had shorter neurite length and also fewer branch points. The branch 
points are where the elongated neurites split to output information. The difference in outgrowth 
capacity became particularly more evident at 8 weeks. Correction of SURF1 mutation in SVS1C.C 
neurons restored the neuronal complexity in neurites and as it restored the energy capacity of 
the patient cells (Figure 3.4.2.4.  d-e). This data also shows that energy capacity is critical for 
axonal outgrowth. Of course, there are also other essential factors for the formation of a healthy 
growth cone of an axon. Besides the intrinsic factors, extrinsic factors such as wisely known 














































Figure 3.4.2.4.: Aberrant neuronal branching in neurons of DA-enriched composite cultures of LSSURF1  
a, Representative images of the HCA mask for neuronal profiling showing shorter neurites (in green), fewer 
branch points (in yellow) in iPSC-derived 8w DA-enriched composite cultures from SVS1A and SVS1C. Scale 
bar: 50 µm. b-c, High content analysis (HCA)-based quantification of neuronal profiling based on TUJ1-
expressing neurons in iPSC-derived DA cultures from CTRL ES (H1), CTRL iPSC (XM001) and  SURF1 patients 
(SVS1A and SVS1C). d-e, High content analysis (HCA)-based quantification of neuronal profiling based on 
TUJ1-expressing neurons in iPSC-derived DA cultures from SVS1C and genetically corrected SVS1C.C (mean 
+/- s.e.m.; n=3 independent experiments; *** p<0.001; one way ANOVA followed by Bonferroni multiple 
comparison tests).  
 
 
3.4.2.4.1.Transcriptome analysis of axonal guidance  
 Addition to the energy capacity of the cells, axonal guidance cues help healthy growth 
cone to find the right target cells to form synapses. Axons express guidance receptors on their 
elongating tip and navigate to their targets by using the guidance cues which could be attractive 
or repulsive that can act over long distances or locally.  Extrinsic cues implicated in axonal 
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branching vary a lot, and some of the important ones such as NTN1, semaphoring receptor 
NRP1, and SLIT3 were downregulated in patient-derived DA neuronal cultures. Some studies 
showed that the absence of these proteins caused defects in axon guidance and target 
recognition, thus defects in synapse formation (Figure 3.4.2.4.1.) (Dominici et al., 2017). There 
was also a significant downregulation in intrinsic guidance molecules. For instance, a member 
of the ARP2/3 complex, ARX, which is known to help the formation of axon branches (Spillane 
et al., 2011; Wegner et al., 2008) was downregulated. The transcription factor GATA3 also 
showed differential expression, which is known to be a downstream effector of Hoxb1 that 









Figure 3.4.2.4.1. Differentially regulated axonal guidance genes in composite cultures of all lines 
a-b, Log fold changes (LFC) of genes essential for axonal guidance in iPSC- in 4w (empty bars) and 8w 
(dotted bars) DA cultures from SURF1 iPS (SVS1A and SVS1C) vs. CTRL (H1 and XM001) and in 4w (empty 
bars) and 8w (dotted bars) DA cultures from SVS1C and SVS1C.C (mean +/- s.d.; * p<0.05, ´´ p<0.01, o 
p<0.001, • p<0.0001).  
 
 
3.4.2.5.  Passive and active membrane properties of the neurons 
 Altogether, SURF1 mutations led to defects in bioenergetics, mitochondrial trafficking, 
and branching capacity, which are giving hints for possible defects in neurotransmission. 
Functional synapses require mitochondria to supply ATP and especially in high demand areas 
such as synapses. For instance, in the brain, synapses are the primary sites of ATP consumption 
and mitochondria supply most of the ATP (almost 90 %), while glycolysis contributes to the little 
part of the ATP (around 10 %) (Harris et al., 2012). In order to understand if there are any defects 
in the functionality of maturing neurons, patch-clamp electrophysiology recordings were done 
to assess passive membrane properties, to measure of neuronal function over time, potential 
firing properties, and synaptic activity at different maturation stages which are 4w, 6w and 8w. 
 Patch-clamp analysis demonstrated that differentiating neurons from healthy controls, 
patients, and corrected lines matured over time, as indicated by their passive membrane 
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properties showing time-dependent increase in cell capacitance (as neurons increase in size) 
(Suppl. Figure 3.4.2.5. a-b) and decrease in input resistance (as neurons acquire more ion 
channels in their plasma membrane) (Suppl. Figure 3.4.2.5. c-d). Although passive membrane 
properties were indicating the neurons were healthy, the active membrane properties of 
neurons (i.e., electrical potentials across the plasma membrane activated by voltage) differed 
between patients and controls. There was a significant increase in sodium and potassium 
currents at 8w compared to 4w neurons derived from healthy controls (Figure 3.4.2.5.A. a-b). 
On the contrary, this increase from 4w to 8w in neurons from patients was less pronounced for 
K currents and none for Na currents (Figure 3.4.2.5.A. c). The mutation correction significantly 






Figure 3.4.2.5.A.: Defects in sodium and potassium currents in neurons of DA-enriched composite 
cultures LSSURF1 
a-c, Sodium and potassium currents in iPSC-derived 4w and 8w DA cultures from CTRL ES (H1) (left), CTRL 
iPS (TFBJ and XM001) (middle), and SURF1  iPS (SVS1A and SVS1C) (right). (mean +/- s.d.; n= at least 2 
independent experiments; * p<0.05, ** p<0.01, *** p<0.0001; two-way ANOVA). d,e Comparison of 
sodium and potassium currents in iPSC-derived 4w, 8w DA cultures from SVS1C and SVS1C.C. (mean +/- 
s.d.; n= at least 2 independent experiments; * p<0.05, ** p<0.01, *** p<0.0001; two-way ANOVA). 
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  The number of spikes was counted for each recording to understand the spiking 
patterns of neurons, and they were classified as none (no spike), single spike (one spike), and 
multiple spikes (at least two spikes). Neurons communicate by sequences of short pulses, so-
called action potentials, or spikes. Neurons in composite cultures from patient lines had a higher 
number of non-spikers, and fewer single-spikers compared to cultures from healthy controls and 
corrected lines (Figure 3.4.2.5.B. a, c). There were not any differences at multiple spiking profile 
between the lines at 4th weeks old. On the other hand, at 8th weeks, cultures from healthy control 
and corrected lines had much higher multiple-spikers compared to patient-derived neuronal 















Figure 3.4.2.5.B.: Spiking profile of neurons in DA-enriched composite cultures of all lines 
a-b, Percentage of neurons (mean) that are not spiking, single spiking, or multiple spiking in iPSC-derived 
4w (left) and 8w (right) DA cultures from CTRL ES (H1), CTRL iPS (TFBJ and XM001), and SURF1 iPS (SVS1A 
and SVS1C). c-d, Percentage of neurons (mean) that are not spiking, single spiking, or multiple spiking in 
iPSC-derived 4w (left) and 8w (right) DA cultures from SVS1C and SVS1C.C. DA neuronal cultures from 
control and corrected lines show an increased number of multiple spikes while neurons from patient lines 
show a decreased percentage in multiple spikes and an increase in the number of single spikes. 
 
 In the next experiment, multiple spiking profile is analyzed in a more detailed way. 
There were a much higher number of spikes derived from the CTRL ES (H1) than any other lines 
(Figure 3.4.5.2.C. a). Neurons from CTRL iPSC tend to have a higher number of spikes compared 
to patient lines, whereas it was not significant. Neuronal cultures from CTRL ES and SVS1C.C 
exhibited post-synaptic currents indicative of synaptic activity, which was not observed in SVS1C 
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neuronal culture (Figure 3.4.5.2.C. b-c). There were no synaptic currents in the neuronal cultures 
from healthy controls, which highlights the importance of having an isogenic line in this study 




Figure 3.4.5.2.C.: Synaptic activity of neurons in DA-enriched composite cultures of all lines 
a, Number of spikes increases as injected current (pA) increases. iPSC-derived 8w DA cultures from CTRL 
ES (H1), CTRL iPS (TFBJ and XM001) and genetically corrected (SVS1C.C) tend to have a higher number of 
spikes (mean +/- s.d.; n= at least 2 independent experiments). b, Representative electrophysiology traces 
showing iPSC-derived 8w DA cultures from SVS1A and SVS1C showing less multiple spiking activity 
compared to CTRL ES (H1) and CTRL iPS (TFBJ and XM001) and genetically corrected (SVS1C.C). c, iPSC-
derived 8w DA cultures from CTRL ES (H1) and genetically corrected line (SVS1C.C) showing postsynaptic 
currents. (Contributions are indicated in section 8.3.). 
 
 
3.4.2.5.1. Transcriptome analysis of neuronal activity profile  
 HCA-based neuronal profiling and patch-clamp recordings showed that SURF1 
mutations cause less branching complexity as well as impair the functionality of maturing 
neurons which disrupts their firing properties and their ability to establish synaptic connections.  
 In the transcriptomic analysis of DA-enriched composite cultures, SURF1-mutant 4w 
and 8w DA cultures showed downregulation of synaptic genes (SYP, SYT13, and SNAP25), 
potassium and sodium channel genes (SCN2A, SCN9A, KCNC2, KCN3A), as well as NMDA and 




























Figure 3.4.2.5.1.: Differentially regulated synaptogenesis genes in composite cultures of all lines 
a-e, Log fold changes (LFC) of genes regulating synaptogenesis in iPSC-derived 4w (empty bars) and 8w 
(dotted bars) DA cultures from CTRL ES (H1), CTRL iPS (TFBJ and XM001) and SURF1 patients (SVS1A and 
SVS1C)  and isogenic lines (SVS1C and SVS1C.C) (mean +/- s.d.; * p<0.05, ´´ p<0.01, o p<0.001, • p<0.0001).  
 
 
3.5. Derivation of three-dimensional (3D) cerebral organoids from iPSC cultures  
 Since monolayer cultures do not allow studying the manifestation of spatial 
developmental defects, and currently there is not adequate in vivo model of LS, a three-
dimensional (3D) model of neuronal development was employed to explore the consequences 
of SURF1 mutations on organogenesis which would help to understand the disease etiology 
(Suppl. Figure 3.5.A.).  
 The first goal was to understand if there are any differences in the size of the organoids 
between the groups. Patient-derived organoids appeared smaller in many independent 
experiments during derivation of cerebral organoids in culture. The initial cell number seeded 
were the same, whereas it was already observable that at day ten, the size of organoids was 
differing from each other and remained different at day 40 (Figure 3.5.A. a). Cross-sectional 
analyses by ImageJ confirmed that cerebral organoids derived from SVS1C were significantly 
smaller in size than organoids derived from the isogenic controls SVS1C.C (clones 3p and 3bb) 
(Figure 3.5.A. b-c). The reduced size of the organoids mimics the neurodevelopmental disorder, 
microcephaly, which has been reported in some cases of LS patients as well.  
 
















Figure 3.5.A.: Smaller cerebral organoids derived from iPSC cultures of LSSURF1  
a, Representative images of cerebral organoids derived from SVS1C and SVS1C.C at several days of 
differentiation starting from the day embedded into Matrigel (day 0). Scale bars: d0: 500 µm, d10: 200 
µm, d40: 200 µm. b, Representative images of brain organoids from isogenic lines at day 40 were done 
doing cross-sectional area analysis by Image J. Scale bar: 100 µm, (circled in red line). c, Quantification of 
the size cerebral organoids demonstrated that the two clones of SVS1C.C had a comparable size compared 
to organoids from SVS1C  (pink dotted line) (median +/- 95% confidence interval; n=2 independent 
experiments). (Contributions are indicated in section 8.3.). 
 
 Brain development in vivo exhibits a high degree of heterogeneity and regionalization. 
Immunohistochemical analysis of SVS1C organoids exhibited a dramatic disruption of the 
neuroepithelial layer surrounding fluid-filled cavities that are reminiscent of embryonic 
ventricles. Hoechst stainings taken at different magnifications showed very severe defects in the 
compartmentalization of cerebral organoids derived from patients (Figure 3.5.B. a). Next, 
quantitative real-time PCR analysis of cerebral organoids from isogenic lines was done to look 
at the gene expression profile with the appropriate primers, which were significantly different 
in 2D neuronal cultures. Staining the sections of cerebral organoids derived from patient lines 
with NPC markers SOX2 and neuronal marker TUJ1 showed the aberrant distribution of SOX2 
and TUJ1, suggesting defects in neuronal compartmentalization (Figure 3.5.B. c-d).  
 In agreement with previous findings in 2D DA cultures, SVS1C organoids showed 
downregulated expression of genes involved in neurogenesis like DCX, NKX2.2, LHX2, and of 
genes associated with neuronal firing and synaptic activity like SYP, SYT3, KCNQ2, and SCN7A, 
and of genes regulating axon guidance like ARX, SPON1, NTN1, and GATA3.  (Figure 3.5.B. b). 
SVS1C organoids also showed reduced expression of genes regulating mitochondrial 
metabolisms like PGC1A and PDK4, while the expression of genes associated with glycolysis such 
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Figure 3.5.B.: Spatial defects in iPSC-derived cerebral organoids of LSSURF1  
a, Summary of the workflow with day information and done experiments. b, Representative images of 
cerebral organoids derived from iPS CTRL (XM001), isogenic line pair (SVS1C and SVS1C.C) showing the 
disruption of the epithelial layers in SVS1C. Nuclei were counterstained with Hoechst.  Scale bars: 500 µm 
(above), 1000 µm (below). c. Quantitative real-time PCR in cerebral organoids derived from SVS1C and 
SVS1C.C. Data were normalized to GAPDH (mean +/- s.d.). d-e, Representative images of cerebral 
organoids derived from SVS1C and SVS1C.C showing the reduced presence of SOX2-positive progenitors 
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(in green) and TUJ1-positive neurons (in red) at day 40 and 90 respectively. Nuclei were counterstained 
with Hoechst. Scale bar: 100 µm. (Contributions are indicated in section 8.3.). 
 
 
3.5.1.  Transcriptome analysis of neurodevelopmental genes 
 Since DAPI staining suggested defects in compartmentalization in patient-derived 
organoids; human cerebral organoids might similarly display heterogeneous brain regions. The 
pluripotent and neural identity gene expression profiles were analyzed (Figure 3.5.1.A.). 
Important transcription factor FOXG1, a key player in neurodevelopment process whose 
downregulation is a sign for structural brain abnormalities, was significantly downregulated.  
Another developmental marker SIX3 was also significantly down; it is known to be essential for 
early eye development, which might form the basis of the visual problems seen in LS patients. 
Usually, pluripotency markers OCT4 (also known as POU5F1) and NANOG would diminish during 
organoid differentiation, whereas patient-derived organoids maintained the upregulation of 
pluripotent markers compared to the organoids derived from the corrected line. Meanwhile, it 
is expected to see neural identity markers SOX1 and PAX6 to be upregulated, indicating 
successful neural induction. SOX1, known as maintenance of neural progenitors, was 
upregulated. PAX6, a regulator in the coordination and pattern formation required for 
differentiation and proliferation, was downregulated. Dorsal cortical marker EMX1 was also 
significantly downregulated, and it is known to be necessary for specification of positional 
identity as well as differentiation of specific neuronal phenotypes.  TBR1, which is a critical 
neuron-specific factor for forebrain and have been implicated in neurodevelopmental disorders 
such as autism spectrum disorder, is downregulated in SVS1C-derived cerebral organoids. TBR1 
is usually used as a marker of the pre-plate of the brain where reelin (RELN)-containing zone 
helps pyramidal neurons to migrate, which helps the formation of brain structures. RELN is also 
significantly downregulated, which could explain the defects seen in the cytoskeleton of the 
organoids. Another critical neurodevelopmental transcription factor CTIP2 (BCL11B) and SATB2 
known to help projection identities, were also significantly differentially regulated. Overall, all 
these differentially regulated genes suggest that LS can be considered as a neurodevelopmental 
disorder. Additional detailed transcriptomic data were provided to show deregulation of cell 
fate specification, as well as midbrain dopaminergic neuron specification in detail. (Supp. Figure 















Figure 3.5.1.A.: Differentially regulated neurodevelopmental genes in cerebral organoids of LSSURF1 
Log fold changes (LFC) of genes regulating neurodevelopment in iPSC-derived cerebral organoid cultures 
from SVS1C compared to genetically edited line SVS1C.C (´´ p<0.01, • p<0.0001).  
 
  
 3.6.  Overlap of differentially regulated genes in iPSC-derived 2D and 3D cultures 
 There is an overlap in genes differentially expressed in both 8w DA cultures (2D) and 
cerebral organoids (3D) of isogenic lines. The transcriptomic analysis highlighted defects in 
bioenergetics, neurogenesis and neuron projection, and morphogens for LS disease mechanism. 
Genes related to proliferation-pluripotency were highlighted in orange; morphogens in blue; 







































Figure 3.6.: Commonly differentially regulated genes in iPSC-derived 2D and 3D models 
a, MA plot showing log fold changes (LFC) of commonly differentially expressed genes in 8w DA cultures 
from SVS1C vs. SVS1C.C. b, MA plot showing fold (LFC) of commonly differentially expressed genes in 
cerebral organoids from SVS1C vs. SVS1C.C. (Highlighted genes in orange: proliferation-pluripotency, blue: 
morphogenes, purple: bioenergetics, and green: neurogenesis and neuronal wiring).  
  
 Conclusively, the 3D model recapitulated the defects observed in the 2D monolayer 
neuronal cultures and confirmed that SURF1 mutations impair the neural progenitor state, 
thereby disrupting the process of neurogenesis in terms of failing to generate functional 
neurons, which are the consequences of the defects in mitochondrial respiration of 
mitochondria.  Additionally, the genes involved in general developmental pathways such as 
anatomical structural morphogenesis, regionalization, and system development stood out, 
indicating the defects in early neurodevelopmental processes.  
 
 
3.7.  Targeting NPC function to screen for potential therapeutic strategies   
 The generation of neuronal and cerebral organoid cultures from patient iPSCs gave a 
unique opportunity to identify LS-specific neuronal phenotypes. In addition to that, transcriptome 
analysis done on the cultures provided enormous data to support the findings as well as gave novel 
hints for possible therapeutic targets. While the neuronal and cerebral organoid models of SURF1-
associated LS exhibit apparent disease phenotypes in neuronal profiling and bioenergetics, the 
dataset also showed that the defects start in early neurodevelopmental processes. Therefore, 
targeting NPC function and trying to prevent disease pathology as early as possible would be a good 
strategy for LS.  
  iPSC-derived NPC cultures encompass pre-mature neurons, and those derived from 
patient lines exhibited significantly smaller neurites and significantly reduced oxygen consumption 
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(Figure 3.4.1.4., 3.4.1.5.). These two phenotypes seen in pre-mature neurons were also in 
agreement with the phenotypes seen in mature DA neuronal cultures at both 4w and 8w (Figure 
3.4.1.3.A, Figure 3.4.1.5). Therefore, the chosen therapeutic interventions were tested on those 
well-defined readouts, which would possibly give the first truthful hints for the maturing neurons.  
 
 
3.7.1.  SURF1 gene augmentation  
 In this study, gene correction on the SURF1 gene restored the COX activity, 
bioenergetics defects, promoted the neuronal generation, and maturation, which showed those 
phenotypes to be SURF1 specific. Next, our goal was to understand if SURF1 overexpression 
would also be sufficient to rescue the defects in cellular bioenergetics and neuronal branching 
complexity seen in patient-derived NPCs.  
  NPCs from SVS1C were transduced with a lentiviral vector encoding wild-type SURF1 
to assess the potential rescuing effect of SURF1 overexpression (SURF1-OE) and also with 
lentiviruses encoding only the GFP derivative mCitrine (GFP) as a control.  SURF1-OE showed 
significantly improved mitochondrial respiration (OCR, maximal respiration, and ATP 
production) (Figure 3.7.1.A. a-c). Glycolytic capcaity was also analyzed, and SURF1 OE 
significantly decreased the ECAR levels almost to the levels of corrected line, whereas it was not 
reduced compared to GFP OE NPCs which is the real control for this experiment (Figure 3.7.1.A. 
d). Therefore, ECAR measurement was not a very clear readout, as shown previously.  
Additionally, the collected supernatants from the NPC cultures were used for enzymatic lactate 
assay, which led to a significant reduction of lactate production (Figure 3.7.1.A. e). Moreover, 
SURF1-OE improved the mitochondrial respiration and lowered the high lactate levels, indicating 
SURF1´s critical role in energy metabolism. Additionally, disrupted bioenergetics in DA 8w 





















Figure 3.7.1.A.: Bioenergetic profiling in NPC cultures of SVS1C line upon stably expressing wild-type 
SURF1 
a-e, Oxygen consumption rate (OCR), maximal respiration, ATP production, extracellular acidification rate 
(ECAR) and extracellular lactate in NPC cultures from SVS1C lines stably expressing GFP derivative mCitrine 
(GFP) or wild-type SURF1 (SURF1-OE). Yellow line is the value for genetically corrected SVS1C.C line (mean 
+/- s.e.m.; n=2 independent experiments; * p<0.05, ** p<0.01, *** p<0.001; Mann-Whitney U test).  
 
 
 The effect of SURF1 OE on branch complexity was assessed with HCA-based 
quantification. Unexpectedly, SURF1 OE did not promote axonal growth compared to GFP OE 
NPCs nor SVS1C NPCs itself; in fact, overexpression caused a further decrease in neurite length 
per neuron and branch point counts (Figure 3.7.1.B.). Overall, SURF1 overexpression does not 
ameliorate neurite outgrowth in NPCs, whereas SURF1 OE restored defects in neuronal 














Figure 3.7.1.B.: Neuronal profiling in NPC cultures of SVS1C upon stably expressing wild-type SURF1 
High content analysis (HCA)-based quantification of neuronal profiling such as neurite length per neuron 
(a) and branch point total count (b) based on TUJ1-expressing neurons in NPC cultures of SVS1C lines stably 
expressing GFP derivative mCitrine (GFP) or wild-type SURF1 (SURF1-OE). Yellow line is the value for 
genetically corrected SVS1C.C line (mean +/- s.e.m.; n=2 independent experiments; * p<0.05, ** p<0.01, 
*** p<0.001; Mann-Whitney U test).  
 
 
3.7.2.  Metabolic conditioning  
 In the next step, previously suggested metabolic conditioning strategies such as 
hypoxia, glucose, and pyruvate supplementation were tested to see if they improve the cellular 
bioenergetics and neural branching in patient-derived NPC cultures. 
 Hypoxic conditions were previously shown to be beneficial in animal models of LS 
harboring a mutation in complex I (Jain et al., 2016; Ferrari et al., 2017). The rationale behind is 
that hypoxia activates adaptive program allowing cells to cope with limited oxygen levels. Low 
oxygen levels shift the reliance from mitochondrial oxidative mechanism towards glycolysis. 
Secondly, glucose supplementation is suggested for LS patients during acute metabolic 
decompensation (Parikh, et al., 2001). Thirdly, pyruvate supplementation was suggested to 
restore the glycolysis pathway through decreasing the NADH/NAD(+) ratio which was initially 
increased due to OXPHOS defects also has been proposed as a treatment for LS caused by COX 
defects through decreasing the lactate-pyruvate ratio (Komaki et al., 2010). 
 Overnight culture under hypoxia (5% oxygen) significantly improved mitochondrial 
respiration in SURF1-NPCs. At the same time, however, hypoxia caused an undesired further 
significant increase in ECAR as well as lactate in SVS1C-NPCs (Figure 3.7.2.A. a, Suppl. Figure 
3.7.2.). Moreover, glucose and pyruvate supplementation did not improve mitochondrial 
respiration in patient-derived NPCs, whereas they showed a possible beneficial effect in 
decreasing the ECAR levels.  
 
 
















Figure 3.7.2.A.: Bioenergetic profiling in NPC cultures of SVS1C upon metabolic conditioning 
a-c, Oxygen consumption rate (OCR) (left) and extracellular acidification rate (ECAR) (right) in NPC cultures 
from SVS1C that were cultured overnight under hypoxia, different concentrations of glucose and pyruvate 
concentrations. Yellow line is the value for genetically corrected SVS1C.C line (mean +/- s.e.m.; n=2 
independent experiments; * p<0.05, ** p<0.01, *** p<0.001; Mann-Whitney U test).  
 
 
 Furthermore, the branching complexity was assessed with HCA-based quantification. 
Overnight culture under hypoxia (5% oxygen) had an adverse effect on neuronal profiling in 
NPCs derived from patient lines. It significantly reduced the neurite length per neuron and also 
the number of branch total count per neuron (Figure 3.7.2.B. a). On the other hand, overnight 
glucose and pyruvate supplementation did not show any beneficial effect on neurite length per 
neuron and branching total count in a dose-dependent manner in a consistent way (Figure 
3.7.2.B. b-c).  
 
 

















Figure 3.7.2.B.: Neuronal profiling in NPC cultures of SVS1C upon metabolic conditioning 
a-c, High content analysis (HCA)-based quantification of neuronal profiling such as neurite length per 
neuron (left) and branch point total count (right) based on TUJ1-expressing neurons in NPC cultures of 
SVS1C that SVS1C that were cultured overnight under hypoxia, different concentrations of glucose and 
pyruvate concentrations. Yellow line is the value for genetically corrected SVS1C.C line (mean +/- s.e.m.; 
n=2 independent experiments; * p<0.05, ** p<0.01, *** p<0.001; Mann-Whitney U test). (Contributions 
are indicated in section 8.3.). 
 
 Overall, hypoxia partially rescues bioenergetics defects but harms neurite outgrowth. 
Pyruvate and glucose did not rescue mitochondrial respiration defects, whereas it was beneficial 
in decreasing ECAR levels; whereas did not ameliorate neurite outgrowth. 
 
 
3.7.3.  Dietary supplements: antioxidants 
 Another approach to manage the symptoms of patients with mitochondrial diseases 
has been by providing them vitamins or dietary supplements. Here the focus was given to the 
most commonly used supplementary ingredients acting as an antioxidant (N-acetyl cysteine, 
vitamin C, vitamin E, and alpha-lipoic acid), and as a compound that can be used as an alternative 
energy source such as Carnitine (Karaa et al., 2016).  
 Reduced levels of glutathione (GSH) is one of the signs for the dysfunction of 
mitochondrial respiration. NAC is one of the antioxidants used to prevent glutathione depletion 
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in the brain by systemically increasing cysteine levels, and it is beneficial for models of complex 
I disease (Wright et al., 2015; Polyak et al., 2018). Ascorbic acid (AA) is also known to increase 
intracellular GSH levels, which are also known to increase the rate of ATP synthesis. Also, vitamin 
E has a reducing effect of GSH, and its analog name is α-Tocotrienol (AT3). An in vivo-derived 
metabolite EPI-743 (2-electron redox cycling agent) is currently in clinical phase 2 trials (Matinelli 
et al., 2012; Pastore et al., 2013). Another critical antioxidant commonly used is lipoic acid which 
is an essential cofactor for mitochondrial metabolism which participates in catalysis of multiple 
enzyme complexes such as pyruvate dehydrogenase and is currently being used in studies and 
clinical trials to see their effect in RC-deficient patients (Patel et al., 2012). Lastly, L-Carnitine is 
used as an agent to increase substrate supply to the respiratory chain and is involved in B-
oxidation of fatty acids and results in the generation of ATP via OXPHOS.  
 NPC cultures of SVS1C were cultured overnight with different concentrations of 
antioxidants NAC, AA, DHLA, L-Carnitine, and AT3 and seahorse analysis was performed to assess 
their bioenergetics profile for any improvement. None of the supplements improved the OCR 
levels, whereas all of them besides NAC decreased the ECAR levels significantly to the levels of 

















































Figure 3.7.3.A.: Bioenergetic profiling in NPC cultures of SVS1C upon antioxidant treatments 
a-e, Oxygen consumption rate (OCR) (left), and extracellular acidification rate (ECAR) (right) in NPC 
cultures from SVS1C that were cultured overnight with different concentrations of antioxidants N-Acetyl 
L-Cysteine (NAC), ascorbic acid (AA), Dihydrolipoic acid (DHLA), L-Carnitine, and a-Tocotrienol (AT3). 
Yellow line is the value for genetically corrected SVS1C.C line (mean +/- s.e.m.; n=2 independent 




Branch complexity was assessed with HCA-based quantification. Overnight treatment 
with antioxidants did not improve the defects in neurite length per neuron and branch total 
count in a dose-dependent manner. NAC and L-Carnitine had a slight effect of suggesting that 
they might be beneficial. More experiments might be needed to clarify the effect (Figure 
3.7.3.B.).  
 













Figure 3.7.3.B.: Neuronal profiling in NPC cultures of SVS1C upon antioxidant treatments:  
a-e, High content analysis (HCA)-based quantification of neuronal profiling such as neurite length per 
neuron (a) and branch point total count (b) based on TUJ1-expressing neurons in NPC cultures of SVS1C 
that were cultured overnight with different concentrations of antioxidants N-Acetyl L-Cysteine (NAC), 
ascorbic acid (AA), Dihydrolipoic acid (DHLA), L-Carnitine, and a-Tocotrienol (AT3). Yellow line is the value 
for genetically corrected SVS1C.C line (mean +/- s.e.m.; n=2 independent experiments; * p<0.05, ** p<0.01, 
*** p<0.001; Mann-Whitney U test). (Contributions are indicated in section 8.3.). 
 
 
3.7.4.  Small-molecules targeted pathways 
 A set of small molecule screenings were tested to identify potential treatment 
strategies for LSSURF1 patients. These small molecules were chosen for this study either have been 
previously identified to be advantageous for LS patients with other mutations or transcriptome 
dataset have shown differential regulation.  The small molecules or drug treatments on NPCs 
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were done overnight and followed by either assessment of the cells bioenergetic and neuronal 
profiling.  
 RT-PCR, as well as transcriptome dataset of the patient-derived DA composite, and 
cerebral organoid cultures showed a very significant reduction in the expression of PGC1-α 
(Figure 3.4.2.3.2.b., Figure 3.5.c., Figure 3.6.) which is known to have neuroprotective effects by 
increasing mitochondrial biogenesis and its functioning (Lehmann et al., 2018; Kovářová, et al., 
2012). Therefore, a pan-PPAR agonist, bezafibrate was chosen to be tested on SURF1-mutated 
NPC cultures. Bezafibrate was also shown previously to improve COX activity and mimic the 
effect of PGC1-α overexpression (Yatsuga et al., 2012). Another strategy was to deliver FGF21, 
which regulates glucose metabolism and promotes PGC1-α expression in human DA neurons 
(Kharitonenkov et al., 2014). Transcriptome analysis also showed a very significant upregulation 
of transforming growth factor beta (TGF-β) receptor (TGFßR1), which is known to regulate 
neuronal morphogenesis (Nakashima et al., 2018). Therefore, SB431542 (TGFβR1 inhibitor) was 
decided to be given as a treatment which is included in the neural induction media to induce 
differentiation of NPCs into DA-enriched composite cultures.  Another tested small molecule 
was SAG (smoothened agonist), which is known to promote motor neuronal differentiation and 
health via sonic hedgehog (SHH) pathway which was significantly downregulated in the dataset 
of patient-derived neuronal cultures. Another exciting outcome of the transcriptomic dataset 
was the downregulation of brain-derived growth factor (BDNF), which is already in the 
differentiation media. Higher concentrations of BDNF were also tested. Also, retinoic acid (RA) 
was given to stimulate RA pathway, which is also known to be essential for motor neuronal 
health (Wada et al., 2009) and was also dysregulated in the dataset of patient cultures. 
Additionally, positive results have been reported on several mouse models using compounds 
increasing NAD+ concentration, such as the NAD+ precursor NR (Cerutti et al., 2014; Schönford 
et al., 2018). Additionally, PDE5 inhibitor Avanafil has been suggested effective in partially 
rescuing the diseased phenotype induced by the MT-ATP6 mutation (Lorenz et al., 2017). Thus 
different concentrations were also tested.  
 NPC cultures of SVS1C were cultured overnight with different concentrations of small 
molecules, and seahorse analysis was performed to assess their bioenergetics profile (Figure 
3.7.4.A.). Bezafibrate improved bioenergetics profile by increasing OCR levels significantly in a 
dose-dependent manner. Also, Bezafibrate increased the maximum respiration and ATP 
production significantly, and in a dose-dependent manner (Suppl. Figure 3.7.4.). On the other 
hand, SB, as well as NR, led to a consistent decrease in ECAR levels in a dose-dependent manner. 
FGF21, SAG, RA, and Avanafil did not have any consistent effect on bioenergetics profile.  
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Figure 3.7.4.A.: Bioenergetic profiling in NPC cultures of SVS1C upon drug treatments 
a-h, Oxygen consumption rate (OCR) (left), and extracellular acidification rate (ECAR) (right) in NPC 
cultures from SVS1C that were cultured overnight with different concentrations of drugs of Bezafibrate, 
Fibroblast growth factor 21 (FGF21), SB-431542 (SB), smoothened agonist (SAG), brain-derived 
neurotrophic factor (BDNF), retinoic acid (RA), nicotinamide riboside (NR), and Avanafil. Yellow line is the 
value for genetically corrected SVS1C.C line (mean +/- s.e.m.; n=2 independent experiments; * p<0.05, ** 
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 Branch complexity was assessed with HCA-based quantification following an overnight 
treatment with small molecules.  
 
Figure 3.7.4.B.: Neuronal profiling in NPC cultures of SVS1C upon small molecule treatments 
a-h, High content analysis (HCA)-based quantification of neuronal profiling such as neurite length per 
neuron (left) and branch point total count (right) based on TUJ1-expressing neurons in NPC cultures of 
SVS1C that were cultured overnight with different of drugs of Bezafibrate, Fibroblast growth factor 21 
(FGF21), SB-431542 (SB), smoothened agonist (SAG), brain-derived neurotrophic factor (BDNF), retinoic 
acid (RA), nicotinamide riboside (NR), and Avanafil. Yellow line is the value for genetically corrected 
SVS1C.C line (mean +/- s.e.m.; n=2 independent experiments; * p<0.05, ** p<0.01, *** p<0.001; Mann-
Whitney U test).  
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Results indicated that Bezafibrate and SB, which had a beneficial effect on bioenergetics, also 
increased the neurite length per neuron and branch total count in a dose-dependent manner 
significantly. FGF21 showed a dose-dependent increase, whereas it was not significant. SAG and 
Avanafil seem to have a slight beneficial effect, whereas more experiments need to be 
performed to understand if the effect is real. BDNF, RA, and NR did not have any effect on 
neuronal profiling (Figure 3.7.4.B.) 
  Overall, Bezafibrate as PGC1-α agonist rescues bioenergetics profile and SB-431542 as 




























  77 
 
4. Discussion 
 Leigh syndrome has been considered as an early-onset neurodegenerative disease. 
However, the mechanistic and pathophysiological understanding of LSSURF1 is hindered by the lack 
of effective model systems (Dell'agnello et al., 2007; Lin et al., 2013; Da-Re et al., 2014; Baden et 
al., 2007). SURF1 knock-out has been carried out in several animals (flies, mice, zebrafish, and 
piglets), but all these efforts failed to recapitulate the neurological phenotypes of human LSSURF1 
fully.  
 In this study, a human mechanistic model of LSSURF1 based on patient-derived 2D neural 
cultures and 3D brain organoids was generated. Using these models, I found that SURF1 
mutations impair the function and neurogenic potency of NPCs, ultimately leading to neurons 
with reduced complexity and activity. Data are in agreement with the clinical features of LS, 
which generally include developmental delay and cognitive impairment. Microcephaly has often 
been reported in LS patients (Sofou et al., 2014). SURF1 knock-out piglets, while not fully 
recapitulating the clinical phenotype of LSSURF1, also exhibited developmental alterations and 
reduced cortical thickness (Quadalti et al., 2018). Hence, it is possible that neurogenesis defects 
might contribute to the pathology seen in LS patients, which commonly involves severe 
neurodevelopmental manifestations and would explain why the onset of the disease displays 
itself in infancy and childhood. 
 Neurogenesis encompasses a series of complex cell fate transitions culminating in the 
terminal differentiation of NPCs into neurons. This process is accompanied by a metabolic shift 
from glycolysis to mitochondrial-based oxidative metabolism (Khacho et al., 2019; Lorenz et al., 
2017). NPCs may represent the first cell type during this course to depend on the mitochondrial 
oxidative function. Moreover, in our lab, we previously demonstrated that human iPSC-derived 
NPCs activate the OXPHOS machinery and that they are equipped with functionally mature 
mitochondria. Should mitochondrial bioenergetics be impaired during brain development, NPCs 
might thus be the first cell population to be negatively affected. The dysfunction of bioenergetics 
occurred already at the level of NPCs and led to defects in neuronal generation and maturation, 
disrupting the branching capacity and firing activity of neurons. NPCs might be still compensating 
the defects through glycolysis until they are pushed towards neurons do not solely depend on 
OXPHOS mechanism. This shift is probably the time point where the phenotype becomes 
apparent and eventually severe.  Classically, once the bulk of neurogenesis has occurred, NPCs 
can become glial cells at the end of the differentiation phase. The patient-derived glial cell profile 
varied among the lines without an apparent phenotype suggesting they might not be the 
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primarily affected. The reason why glial cells did not show an extreme phenotype might be 
because glial cells mainly rely on glycolytic metabolism.  
 LSSURF1 causes bioenergetics defects and failure in the development of mature neurons, 
and these phenotypes were reverted upon biallelic correction of SURF1 mutation via 
CRISPR/Cas9 genome editing. However, SURF1 OE was not sufficient to rescue both phenotypes 
and failed to improve neurogenesis upon delivery of a lentiviral vector encoding wild-type SURF1. 
Currently, other suggested treatment strategies aim at providing energy support through 
hypoxia, glucose, and pyruvate conditioning which were also tested and also failed to rescue 
neurogenesis phenotype seen in LSSURF1 NPCs despite partially rescued bioenergetic profile. 
Other current experimental treatment schemes of LS have been centered around antioxidants 
to prevent the build-up of damaging free radicals (Baertling et al., 2014; Garone et al., 2018). 
However, blocking oxidative damage was not sufficient in restoring neurogenesis nor 
bioenergetics. Antioxidant regiments may also dampen the physiological effect of radicals 
signaling, thereby blunting compensatory responses (Dogan et al., 2018). Findings of this study 
may open the way to new therapeutic avenues for LS, focusing on improving neurogenesis rather 
than solely providing energy support or preventing the degeneration of fully functionally 
neurons. 
 Moreover, transcriptomics data of patient-derived 2D neural cultures and 3D brain 
organoids revealed enormous data of differentially expressed genes and pathways regulating 
neurogenesis, nervous system development, axonal guidance, synaptic function as well as 
mitochondrial biogenesis and OXPHOS metabolism. Among the several tested small molecules 
targeting one of those pathways stated above, two candidates reverted the phenotypes in LSSURF1 
NPCs. Firstly, induction of PGC1α, the master regulator of mitochondrial biogenesis, restored the 
bioenergetics defects significantly and had a beneficial effect in neuronal profile in a dose-
dependent manner. Secondly, inhibition of TGFß1 receptor restored neurogenesis defects 
significantly. In this study, a novel combination therapy approach may hold promise to enhance 
responses further.  
 
4.1.  iPSC technology: A versatile tool for modeling LS 
 The choice of a model organism to study human disease mechanisms has always been 
an important step. So far, many powerful experimental models such as mouse and fruits flies 
have been generated and used to understand neurological and mitochondrial disorders. 
However, use the animal models for diseases have recently come under scrutiny because of 
repeated failure of data and were not be able to translate to humans. Given that drug discovery 
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is a lengthy and costly process, pursuing the most efficient strategy is, therefore of utmost 
importance. iPSC modeling has been a powerful tool for studying LS for several reasons.  
 Specifically, a substantial obstacle in understanding the mechanisms of LS is the lack of 
effective modeling systems. In the case for LS due to mutations in the gene SURF1, where Surf1‐
knock‐out animals show extended lifespan and no neurological defects. It is because COX 
assembly is species- and tissue-specific, and all data generated so far suggest COX assembly is 
much more dependent on SURF1 in humans than rodents. iPSCs sidestep the limitations and thus 
provide a powerful and versatile tool for disease modeling, especially for LS due to SURF1 
mutations. Skin fibroblasts from LS patients were reprogrammed to iPSCs, therefore avoiding the 
concerns of interspecies differences as associated with using animal models. 
 Furthermore, iPSC modeling does not involve the usage of human embryos as in the 
human ESC research; thus, it prevents all of the ethical and religious concerns that were raised 
in the past. However, with the induction of pluripotency, the cells need to undergo 
reprogramming phase where they need to overcome developmentally imposed epigenetic 
barriers. Thus the critical question raised in iPSC research was whether the iPSCs are as robust 
as the ESC and whether their genomes have similar pluripotent states. In this study, I have also 
used ESC line, and ESC-derived differentiated cell types in all experiments as a positive control 
and iPSC controls have behaved similarly to ESC control lines in most of the experiments. 
However, there were differences in spiking and cytokine profile of ESC compared to iPSCs, as ES-
derived neurons showed synaptic activity, and they secreted much more cytokines (Figure 
3.4.2.2.2., Figure 3.5.1.B.). 
 In order to investigate the link between genotype and phenotype,  gene editing 
technology was applied to iPSCs in this study. The precise correction of the mutation in the same 
genetic background allowed a more accurate way of disease modeling. In this study,  control 
lines were compared to the patient lines as well as one patient lines, were compared to its 
corrected isogenic pair. Most of the results have been in line. However isogenic line pair has 
given a more distinctive and clear signature of the phenotype, and this eventually allowed to 
identify the molecular mechanisms better. Also, I have observed that the S1A patient line was 
doing slightly better than S1C lines in every experiment; thus lacking an isogenic corrected line 
of S1A was disadvantageous.  The initial aim was to correct the mutation on both patient iPSCs, 
whereas TALENs gene editing on S1A lines failed as there were no drive single cell-derived clones 
from the transfected lines found. Also, the clones screened so far always gave mixed sequencing 
results on the mutation site. The other problem was that the transfected and picked clones were 
differentiating as they were seeded on the plate and did not manage to maintain the pluripotent 
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state. However, it was still very advantageous to have S1C patient isogenic line to conclude the 
experiments. 
 Furthermore, there have been challenges in understanding and treating diseases by 
the absence of in vitro models because culturing primary cells affected by the disease was not 
possible. As LS has been considered as an early-onset neurodegenerative disease implying 
progressive loss of neurons by time, and, given that, the neuropathology represents itself 
mainly in basal ganglia region, the focus was given on differentiation protocol enriched with 
dopaminergic neuronal cells to understand the pathology a bit better.  The DA cultures were 
maintained for 4 and 8 weeks to monitor the disease pathology and progression at specific time 
points. There was a reduction in the number of neurons in patient-derived DA-enriched 
composite cultures specifically at 8th weeks, whereas there was no morphological features of 
cell death and no progressive neuronal loss observed in the cultures. The neurons were 
checked regularly under the microscope every third day, and patient-derived DA cultures also 
preserved the right amount of neurons at both weeks. Patient-derived neuronal cultures 
appeared not healthy, but they also required media every third day and sometimes even more 
than control DA-enriched composite cultures. The first clue on the state of patient-derived 
neurons came with the help of patch-clamp recordings. Neurons of patient lines showed a time-
dependent increase in cell capacitance and a decrease in input resistance, which indeed 
supports the neurons were preserved. However, the active membrane properties of neurons 
differed between patients and controls, suggesting defects in the maturation of neurons and 
synaptic activity. The premature profile of the patient neurons was also confirmed by the 
defective branching complexity of patient-derived neurons by using high-content analysis 
based quantification.  
 On the other hand, another diseases-associated cell type, I was able to analyze in 
culture was glial cells.  Leigh syndrome patients have gliosis and glial dysfunction in disease 
pathology. Thanks to the iPSC-derived composite cultures entailing astrocytes, I was able to 
have an insight into the glial mechanism, and I have called differentiated cultures as DA-
enriched composite cultures. They mimic or model the disease pathology better than expected 
thanks to entailing both primary brain cells types of CNS in vitro. Typically, in the CNS, in case 
of neurotrauma, damaged central axons do not generally regenerate or become remyelinated. 
Astrocytes aim to promote and protect nerve growth by undergoing morphological and 
functional changes, and reactive glial cells become proliferative. It has always been a debate 
whether the role of reactive astrocytes at the injury site is beneficial or detrimental or maybe 
both. In vitro glial cells tend to appear as reactive, thus assessing glial cells in disease pathology 
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is not easy. Media collected from both composite cultures were used for cytokine detection 
assay, and there were no differences present. However, all of the cytokines were detected in 
the culture, which shows that glial cells were active and functional. The other possibility to 
analyze glial function is through assessing the bioenergetic profile of the composite culture.  
 iPSC-derived composite cultures were grown on the seahorse assay plates allowed 
assessment of mitochondrial and non-mitochondrial respirations lively. It is known that brain 
energy metabolism is highly dependent on the oxidation of glucose, glycolysis, and mostly 
followed by OXPHOS. The ratio of used oxygen to glucose consumption is ~6:1, and OXPHOS 
converts the molecules into ATP, which provides ~87 % of the ATP generated (Kety, 1957; 
Sokoloff 1960). However, when brain activity is increased, brain cells tend to back themselves 
up through glycolysis even though the net production of ATP is little. This requirement was 
shown with a regional stimulation electron tomography studies showed local blood flow 
increases by ~50%, and there is an increase in glucose consumption; whereas the increase in 
oxygen utilization was much less suggesting glucose to be metabolized through non-oxidative, 
probably through glycolysis (Madsen, 1999). This was also supported by the findings of elevated 
lactate levels upon stimulation of brain cells (Yellen et al., 2018; Mazuel et al., 2017). This 
outcome could also be thanks to the help from astrocytes as neurons regulate the energy supply 
by turning on glycolysis in astrocytes as well. When active neurons release glutamate, it is taken 
up by astrocytes and converted to glutamine, thus producing lactate to be exported back to 
neurons as a substrate for OXPHOS. However, astrocyte-neuron lactate shuttle theory has also 
been challenged. Lately, it has been suggested that this alternative mechanism is not very much 
needed, although its role in supporting neurons is desirable (Diaz-Garcia et al., 2018).  It has also 
been argued that neurons might also be doing glycolysis on their own in response to stimulation 
and they might be exporting lactate rather than importing. Patient DA-enriched composite 
cultures showed higher ECAR and lactate levels compared to healthy composite cultures. The 
first explanation could be that patient-derived composite cultures compensate their defects in 
mitochondrial respiration by increasing the non-mitochondrial respiration. Another reason 
could be the presence of premature neuronal cells in the culture as transcriptome analysis 
indicated that patient-derived composite cultures upregulated pluripotent genes and 
downregulated the neuronal-specific genes. These cell types rely on the glycolytic mechanism 
rather than OXPHOS. The other explanation for high ECAR levels could be the activity of the glial 
cells as they also rely on glycolytic metabolism. Considering there were no differences in glial 
cell profile in number and cytokine profile that might not be the leading cause. ECAR and lactate 
levels were not consistent among the lines. Given that, transcriptomics data showed an 
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upregulation of pluripotent genes in patient-derived composite cultures; lactate may be a result 
of progenitor cells or immature neurons since they rely on glycolysis.  
 On the contrary, bioenergetics profiling experiments showed that patient-derived 
composite cultures exhibited significantly reduced mitochondrial respiration due to SURF1 
mutations. SURF1´s exact mechanism in COX assembly is still not known. As western blot results 
showed, patient neuronal cells do not express MT-CO2 protein; this overall might be another 
evidence for SURF1´s crucial role in the COX  assembly through catalytic core subunits of COXII. 
 After bioenergetic profiling, the focus was given to mitochondria itself, which are 
highly specialized and dynamic organelles that modulate their function through biogenesis, 
fusion, and fission events. Mitochondria trafficking along the axons or docking of mitochondria 
at the synapse areas are very crucial for synaptic hemostasis. Additionally, mitochondrial 
biogenesis assists in maintaining healthy mitochondria in axons and dendrites and would have 
the potential to respond rapidly to local changes in case of stimulation or an insult. Each cell 
type has a different structure of mitochondria. During reprogramming of somatic cells into iPSCs, 
cellular metabolic demands change, and mitochondria need to undergo extensive alterations, 
and they increase their mitochondria number (St John, 2015; Zhang et al., 2011). For instance, 
mitochondria in PSCs are small and have globular morphology while neurons have elongated, 
cristae-rich mitochondria since they are highly dependent on OXPHOS and cannot compensate 
through glycolysis which is the primary energy source for PSCs (Cho et al., 2006; Prigione & 
Adjeye, 2010). Therefore, defects in mitochondria have different levels of severity in different 
cell types. It could be that the nastiest and cruel mutations are in the nuclear genes encoding 
respiratory chain subunits tend to present early in infancy and childhood and are usually fatal 
ones as it presents themselves as Leigh syndrome. By applying old mitochondria tracking 
methods from the primary neurons of the animal models (Zhang et al., 2011), I was able to stain 
mitochondria in iPSC-derived composite cultures. Patient-derived composite cultures showed 
an abnormal increase in mitochondrial motility, which means less stationary mitochondria. 
Stationary mitochondria are crucial for axonal branching and synaptic hemostasis. Given that 
iPSC-derived composite cultures entail astrocytes, it would be necessary to use a neuronal 
marker to differentiate the cell types and mask them with image processor aiming to analyze 
mitochondria movement only in neurons. In this study, the defective mitochondrial movement 
in a broad view was the outcome. However, the transcriptome analysis showed downregulation 
of SNPH in patient-derived composite cultures, and SNPH is neuronal specific and known to be 
the ´static-anchor´ specific for axonal mitochondria (Chen & Sheng, 2013).  
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 Recently, there have also been technological advances allowing iPSCs to be cultured in 
three dimensions, to produce organoids representing various human tissues such as the brain. 
iPSC-derived cerebral organoids allow us to look at the developmental features in detail. Patient-
derived cerebral organoids led to disrupted neuronal layering and reduced cortical thickness. 
Since DAPI staining suggested defects in compartmentalization in patient-derived organoids; 
human cerebral organoids might similarly display different brain regions. The pluripotent and 
neural identity gene expression was analyzed from the transcriptomics data (Figure 3.6). 
Important transcription factor FOXG1, an essential key player in neurodevelopment process 
whose downregulation is a sign for structural brain abnormalities, was significantly 
downregulated. Classically, neurogenesis starts with precursor cell proliferation in 
neurodevelopmental biology and continues as their capacity to generate new cell types, and if 
they survive, they will get functionally integrated. Radial glial cell types have different fate 
choices as they can differentiate into neurons, or they could also give rise to glial cells. This 
balance is tightly maintained, regulating the neurogenic capacity of the stem cell pool.  Patient-
derived organoids show upregulation in genes for proliferating responsible for precursor cell 
types (Figure 3.6). Then there is a downregulation of genes responsible for neurogenesis and 
postmitotic maturation cell types.  Patient-derived cerebral organoids showed repression of 
astrogenesis genes compared to the edited line as all of the genes were downregulated (Figure 
3.5.1.A.) (Sloan et al., 2018) Overall, patient-derived cerebral organoids suggested dysfunctional 
neurogenesis in the pathogenesis of LSSURF1 and added another meaningful angle to defects seen 
in 2D cultures at NPC levels.  
 Additionally, patient‐derived iPSCs were differentiated into disease‐relevant cell types, 
and comprehensive transcriptome analysis of the composite cultures provide hints for targets, 
in this study. Some of them were tested in the high content platform. Screenings conducted on 
such differentiated cells were based on highly significant cellular phenotypes that become 
apparent within patient‐specific disease‐relevant cellular contexts. For instance, I have used 
high-content screening for neuronal profiling to look at the branching complexity as well as 
seahorse platform for bioenergetics assessments with several determined small molecules in a 
multi-well format. Two candidates were proven to improve the phenotypes, and the 
combinatory delivery of these two molecules may hold a potential to improve both phenotypes 
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4.2.  COX activity as a biomarker of neuronal activity  
 COX is the only complex among the respiratory chain that has alternative isoforms, 
which suggest additional levels of regulation of COX activity due to its importance. Several 
theories were explaining why additional regulation exists for COX, such as high free energy 
released in enzymatic reactions and irreversibility of the COX reactions. The identity of the cell 
is associated with mitochondrial function as well. For instance, PSCs are glycolytic, and they have 
low mitochondria in number and fewer cristae structures. When they are pushed to differentiate 
into neurons, they increase their mitochondrial content and activity (Cho et al., 2009). Overall, 
it has been stated more clearly very recently that the COX genes are involved in the 
transcriptional networks of the neurons that COX activity can be considered as a biomarker of 
neurons and likely crucial for differentiation as well (Chicherin et al., 2019).  
 In previous studies, it has been shown that by altering the activity of neurons as with 
tetrodotoxin (TTX)-induced impulse blockade or with KCl-mediated depolarizing stimulation, the 
levels of cytochrome c oxidase in affected neurons were also altered. Such alterations were not 
only observed in the activity of the enzyme, but also its protein and mRNA amount, and at a 
transcriptional level (Wong-Riley, 1989; Wong-Riley, 2012). Additionally, every assembly factor 
of COX has tissue specificity. For instance, in LSSURF1, muscle cells do not usually show the same 
level of impairment as neuronal cells. Conversely, mutations in the gene encoding SCO2, which 
is a different assembly factor of COX, more strongly impair cardiac bioenergetics leading to 
cardiomyopathy rather than LS. In this study, patient-derived DA-enriched composite cultures 
with COX defects due to SURF1 mutations exhibited impairment in neuronal differentiation, 
maturation, and activity thus it supports the crucial role of COX activity in neuronal development 
and SURF1´s neuronal specificity.  
 Moreover, specificity factor 4 (Sp4) has been suggested to regulate all of COX subunits 
in primary neurons by regulating the transcription factors (TFAM, TFAMb, and TFB2M) and 
SURF1. Correctly, SURF1 has been shown to regulate the expression of NMDA receptor subunits 
GRIN1, GRIN2A, and GRIN2B (Johar et al., 2013; Priya et al., 2013). Indeed, transcriptomics data 
of patient-derived composite cultures showed significant downregulation of all of the NMDA 
receptors (Figure 3.4.2.5.1.) which are the critical mediators of excitatory neurotransmission, 
and glutamate is the primary excitatory neurotransmitter which binds to NMDA, AMPA, and 
kainate receptors. In this study, patient-derived neurons were lacking synaptic activity, and 
genetic correction of SURF1 reconstituted the full neuronal activity as they exhibited post-
synaptic currents. Given the importance of NMDA receptors in energy metabolism and neurons, 
mutations related to NMDA receptors lead to severe diseases. GRIN2B gene was shown to play 
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a crucial role in neuronal development and mutations on this gene were shown to impair 
neuronal differentiation in human neurons (Bell et al., 2018), as well as mutations of this gene, 
were implicated in several neurodevelopmental disorders such as autism spectrum disorder 
(ASD) or attention deficit hyperactivity disorder (ADHD) (Hu et al., 2016). 
 
4.3. Using NPC function for therapeutic screening 
 The generation of neuronal and cerebral organoid cultures from patient iPSCs gave a 
unique opportunity to identify LS-specific neuronal phenotypes and 2D and 3D models of SURF1-
associated LS exhibit apparent disease-associated defects starting in early neurodevelopmental 
processes. Therefore, targeting NPC function and trying to fix the problem as early as possible 
would be a good strategy for LS. 
 2D and 3D cultures hold few disadvantages and are an unsuitable model to screen for 
therapeutic strategies in this study. Differentiation protocol and derivation of cerebral organoids 
are long lasting; there was a necessity to use another compatible cell type like NPCs that can fasten 
the screening process for potential therapeutics. iPSC-derived NPCs have two essential properties 
that make them useful model in this study. The first one is that they are capable of robust, immortal 
expansion, which makes it easier to handle in culture. The second one is that they already undergo 
a neuronal-like metabolic switch towards OXPHOS which is useful for us to foresee the possible 
phenotypes of mature neuronal cells derived from patient iPSCs in our assays (explained in section 
1.3.). Additionally, the severity of the mitochondrial defect leads to the fragile neuronal population 
in patient-derived cultures, making them difficult to handle, especially for large-scale screenings. 
Also, both the neurons and organoid model system are non-expandable and takes a substantial 
amount of time to be generated. iPSC-derived NPCs have been previously employed for identifying 
treatment interventions in the context of mitochondrial diseases in our lab (Lorenz et al., 2017).  
Moreover, a mutation in the mtDNA gene MT-ATP6 that is associated with LS also caused abnormal 
NPC functionality. Hence, it is possible that neurogenesis defects might contribute to other forms 
of LS and other mitochondrial disorders, which commonly involve severe neurodevelopmental 
manifestations (Falk et al., 2010). 
 
4.3.1.  Gene augmentation therapy (GAT) as a potential strategy 
 In this study, a lentivector wild-type SURF1 was delivered to patient NPC cultures to 
assess the potential rescuing effect of SURF1 overexpression. Results showed that SURF1 
rescued the bioenergetics defects significantly, but did not promote neurogenesis ar NPC level. 
Moreover, SURF1 overexpression by lentivirus delivery promoted neurogenesis as it increased 
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the percentage of neuronal cells, neurite length per neurons, and branch total count in patient-
derived neuronal cultures at 8w (Figure 3.7.1.). There are ongoing clinical trials on GAT for CNS 
disorders (Anguela et al., 2019). GAT also ameliorated the LS-like phenotypes in the complex I 
gene Ndusf4 knock-out mice (Di Meo et al., 2017). Given the proposed impairment of 
neurogenesis, GAT in LSSURF1 should be carried out as early as possible to enable the formation 
of functional neurons and neuronal networks in the patients. Further studies are needed to 
investigate in details the potential adverse reactions of SURF1- GAT in live animals and to identify 
the most effective strategy concerning viral vector types, timing, and sites of delivery. 
  
4.3.2.  Bezafibrate: Coactivator of PGC1-α receptor 
 Upregulation of mitochondrial biogenesis pathways has emerged as one of the most 
commonly suggested mitochondrial therapies. While the strategy does not solve the underlying 
cause of the disorders, it may help to increase OXPHOS through the added number and mass of 
mitochondria. PGC-1α is known as the master regulator of mitochondrial biogenesis and cellular 
energy metabolism.  It is expressed at high levels in mitochondria-rich cells with high energy 
demands such as neurons. PGC-1α is another crucial regulator of COX in neurons as stimulates 
induction of transcription factors NRF1 and NRF2. They have been shown to regulate all subunits 
of COX complexes as well as the expression of several genes crucial for neurons such as NMDA 
receptors (Priya et al., 2012). Thus, there is a tight coupling of neuronal activity, energy 
generation, and energy consumption at a molecular level. It is known that during neuronal 
differentiation and maturation, the number of mitochondria per cell increases because of the 
energy demand of neurons increases as they become excitable and form synapses. Addition to 
its role increasing cellular energy, it has also been shown to be involved in the formation, 
maintenance, and reorganization of synapses via increasing dendritic spines (Sheng, 2014). The 
idea that increasing the amount/or function of mitochondria could be beneficial in 
mitochondrial disease, Bezafibrate, a PPAR pan-agonist, was first tested in fibroblasts of patients 
with mitochondrial diseases and it increased enzyme activities of complexes I, III, and IV (Bastin 
et al., 2008). However, bezafibrate was not effective in Cox deficiency Surf1 knockout (Viscomi 
et al., 2011) or deleted mice (Yastuga et al., 2012).   
 During this study, bezafibrate was administered to patient S1A by Prof Dr. Schülke, and 
he reported that the patient did not go through a metabolic crisis during the administration 
period, and it was beneficial. Also, transcriptomic gathered from iPSC-derived patient 2D, and 
3D models showed significant downregulation of PGC-1α. Therefore, bezafibrate was tested in 
the patient-derived NPC models, and the results showed that bezafibrate rescued the 
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bioenergetics defects and also it improved neuronal complexity in a dose-dependent manner. 
Considering that in vivo models were not recapitulating the disease mechanism seen in patients, 
it was worth to try this FDA approved the drug on human neuronal cells. These are the first 
findings showing bezafibrate´s therapeutical potential in human-derived neuronal cells of COX 
deficiency. Detailed analysis is needed to understand the mechanism. 
 
4.3.3.  SB-43152:  Inhibition of TGF-β1 receptor  
 Proper functioning of the nervous system depends on how accurate the neurons wired 
and specifically in the neuronal circuits. Extracellular signals are essential to make a permissive 
environment that supports neurons to develop and extend. Morphogens are secreted proteins 
expressed in a restricted region of a tissue that instructs cells about their fate and cells 
differentiate in response to morphogen signaling depending on their position within the 
gradient and thus their distance from the morphogen source (Teleman et al., 2001). Classical 
and relevant morphogens have been reported to be Shh, Wnt, and TGFβ/Bmp signaling 
(Sánchez‐Camacho & Bovolenta, 2009).  Transcriptomic data of the patient-derived 2D and 3D 
models showed deregulation of these three crucial signaling pathways and also some of the 
morphogens such as NTN1, SLIT, Semaphorins (Figure 3.6.) which are known to play an essential 
role in guiding axons.  
 In this study, neuronal induction from NPCs to DA-enriched composite cultures was 
initiated by inhibition of both BMP and TGFβ signaling by delivering small molecules 
dorsomorphin (DM) and SB43152 (SB). Specifically, transcriptomics data revealed the 
upregulation of TGFβ1R; and the different concentrations of SB was tested on NPC cultures. The 
results showed that SB partially rescued bioenergetics in terms of decreasing ECAR levels, 
whereas the most striking effect was that it improved neuronal complexity in a dose-dependent 
manner significantly. Canonical TGFβ signaling has a variety of cellular processes, including cell 
differentiation, proliferation, and specification of developmental fate (Shi and Massague, 2003). 
TGFβ family contains two subfamilies, the TGFβ/Activin/Nodal subfamily and the BMP/GDF/MIS 
subfamily. In the dataset, most of those pathways seem to be also dysregulated, whereas further 
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5. Conclusions and future perspectives 
 Overall, the first human mechanistic neuronal 2D and 3D models of SURF1 mutations 
have been generated, and novel insights into the understanding of the disease mechanisms have 
been investigated. Most of the neuropathology seen in patients has been recapitulated in these 
models as SURF1 mutations caused aberrant bioenergetics profile, as well as they, prevented 
neuronal generation and maturation. Plus, the phenotypic experiments and transcriptomics 
results showed that defects start at NPC level and leading to prematurely cell types, which major 
the primary neuropathology saw in patients. Ultimately, data suggested LS be considered and 
approached as a neurodevelopmental disorder rather than neurodegenerative disease, and 
most of the deregulated genes also indicate defects to be happening during the migration phase 
where immature neurons go from their birthplaces to their final positions, outgrowth of axons 
and dendrites from neurons, guidance of the motile growth cone, and generation of synapses. 
The transcriptomic data gathered from neuronal models were analyzed, and some of the targets 
were tested on NPC function to check if they improve the well-defined phenotypes. Two 
candidate therapeutic targets have been suggested.  
 In this study, the activation of the master metabolic regulator PGC1α with Bezafibrate 
restored bioenergetics defects, and inhibition of the TGF-β1 receptor with SB-431542 
ameliorated neural progenitor function and early neuronal branching. Impaired neuronal 
morphogenesis in 2D and 3D models of the pediatric mitochondrial disease might be 
ameliorated via both PGC1α and TGFβ combo modulation. Similar interventions may represent 
potential therapeutic strategies for LS, which is currently incurable. Our data also underlies the 
importance of mitochondrial homeostasis for neural progenitor function in healthy and diseased 
states. Moreover, it would be fascinating to test these suggested therapeutical approaches in 
the iPSC-derived 3D model of LSSURF1.  
 Several open questions remain, more detailed explanation of the disease mechanism 
is still needed. Mass spectrometry-based metabolomics and proteomics would allow 
quantifying significantly altered metabolites and relative proteins abundance, which would 
deepen the insight into the underlying mechanism of this neurometabolic disorder.  
Therefore, the collected pellets and supernatants from DA composite cultures derived from 
isogenic line SVS1C and SVS1C.C were sent for proteomics and metabolomics. Currently, our lab 
has established a collaboration which is working on the integration of multi-omics data implying 
the integration of transcriptomics, proteomics, and metabolomics data. Each type of omics data 
provides a list of differences associated with the disease and integration of different omics data 
types would then elucidate potential causative changes leading to disease. A fundamental 
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expectation from these analyses is predicting the phenotypic traits, elucidating essential 
biomarkers, and ultimately generating insights into the genetic underpinnings of the heritability 
of complex traits. However, there have been challenges to find compelling and advanced 
analysis strategies to harness the utility of these enormous high-throughput data fully.  
 Furthermore, elaborating on the first findings of cerebral organoids would be 
necessary, so more detail immunohistochemical analyses have to be performed with more 
protein markers specific to different neuronal or progenitor types. Thus, it can be better 
understood if these structural defects are exclusive to migration, differentiation, or maturation 
processes. High-density micro-electrode arrays (MEAs) recordings could be performed to 
understand the functionality of neuronal connectivity in cerebral organoids. Also, single-cell 
genomic methods could be applied to characterize these organoid models with more resolution 
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6. Material 
6.1.  Biological material and experimental models 
6.1.1.  Cells 
 Different cell lines were used in this study. The skin fibroblasts were obtained from 
three LSSURF1 patients from two distinct consanguineous families: SURF1 A (S1A) line carries the 
homozygous mutation c.530T>G (p.V177G), and SURF1 B (S1B) and SURF1 C (S1C) lines which 
were taken from siblings carry the same homozygous mutation c.769>A (p.G257R). All of the 
mutations are missense mutations which lead to a change in one amino acid in a protein. Prof. 
Schülke has the written consent of the parents of the patients´, and they are according to the 
Declaration of Helsinki to all aspects of the study. The study was approved by the ethics 
committee of the Charité (EA2/131/13 and EA2/107/14). The healthy control fibroblasts BJ and 
CON1 were previously characterized in our lab, and also established in our study (Lorenz et al., 
2017). The fibroblast cell lines used in this study are summarized in Table 6.1.1.A. with the 
background information. 
 
 Table 6.1.1.A.: Background information of the fibroblasts  
 
 ESCs and iPSC lines used and generated in this study were explained in section 3.2. and 
specified in Table 6.1.1.A. hESC line H1 was purchased from WiCell and was used by the German 
license of Alessandro Prigione issued by the Robert Koch Institute (AZ: 3.04.02/0077-E01). 
Ethical approval was obtained by local authorities to use patient fibroblasts for iPSC derivation. 
The healthy control lines used in this study were previously characterized. TFBJ (BJ derived 
episomal plasmid transfected iPSCs) (Yu et al., 2011) was already characterized in our lab and 
used in a study (Lorenz et al., 2017). The other healthy control iPSC line XM001 (episomal 
plasmid transfected) was characterized in another lab and was published in a study as well 
(Wang et al., 2018). Additionally, human embryonic stem cell lines (hESC) H1 and H9 were 
purchased from WiCell and used according to the German law (personal license to A.P., #AZ: 
3.04.02/0077-E01). The background information of the ESCs and iPSCs used in this study are 
summarized in Table 6.1.1.B. 
 
Fibroblasts
Name Disease Age Gender Gene Mutation Source
BJ Control 0 M - - ATCC
CON1 Control 32 M - - Dr. Doss
S1A LS 9 M SURF1 p.Val177Gly Prof. Schülke
S1B LS 8 F SURF1 p.Gly257Arg Prof. Schülke
S1C LS 1,7 M SURF1 p.Gly257Arg Prof. Schülke
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 Table 6.1.1.B.: Background information of the ESCs and iPSCs 
 
 After generation of clinically feasible SVS1C iPSCs; the aim was to employ Clustered 
regularly interspaced short palindromic repeats (CRISPR)/Cas9 system for precise correction of 
769G>A on SURF1 gene in SVS1C iPSCs. The information about biallelic correction and resulted 
in SVS1C.C iPSC lines were given in section 3.3.2. and specified in Table 6.1.1.C.  
 
 
Table 6.1.1.C.: Background information of gene-edited iPSCs 
 
 
6.1.2.  iPSC-derived models 
 2D and 3D iPSC-derived models were used in this study to model LS. iPSC-derived NPC 
and DA enriched composite cultures are 2D modeling system. They were explained in detail in 
section 3.4. and summarized in Table 6.1.1.D. and 6.1.1.E., respectively.  
 
Table 6.1.1.D.: Background information on iPSC-derived NPC cultures (2D) 
 
Gene edited iPSCs
Name Disease Gender Gene Mutation Source
SVS1C.C 3p Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
SVS1C.C 3bb Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
SVS1C.C 3c Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
smNPCs
Name Disease Gender Gene Mutation Source
H1 Control M - - Gizem Inak
TFBJ Control M - - Gizem Inak
XM001 Control F SURF1 - Gizem Inak
SVS1A LS  M SURF1 p.Val177Gly Gizem Inak
SVS1C LS  M SURF1 p.Gly257Arg Gizem Inak
SVS1C.C 3p Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
SVS1C.C 3bb Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
SVS1C.C 3c Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
ESCs and iPSCs
Name Disease Age Gender Gene Mutation Source
H1 Control - M - - WiCell Research Institute
H9 Control - F - - WiCell Research Institute
TFBJ Control 0 M - - ATCC
XM001 Control 47 F SURF1 - Heiko Lickert
SVS1A LS 9  M SURF1 p.Val177Gly Gizem Inak
SVS1C LS 1,8  M SURF1 p.Gly257Arg Gizem Inak
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Table 6.1.1.E.: Background information on iPSC-derived DA enriched composite cultures (2D) 
 
 The information about iPSC-derived 3D cerebral organoids can be found in section 3.7. 
and specified in Table 6.1.1.F. Additionally, iPSC-derived cerebral organoids experiments were 
done in close collaboration with Dr. Agnieszka Rybak-Wolf, and the protocol was adopted from  
(Lancaster et al., 2013) to make cerebral organoids (section 5.3.).  
 
Table 6.1.1.F: Background information on iPSC-derived cerebral organoids (3D) 
 
 
6.2. Laboratory equipment 
 Relevant technical appliances used to prepare this study are listed. 
Devices   
Item Product name Supplier 
  Universal 32 R Hettich 
Centrifuge 5810R Eppendorf 
  Heraeus Pico Microcentrifuge 
Thermo Fischer 
Scientific 
Cell culture Bench UVF 
BDK Luft und 
Reinraum  
  BDK-S Technik GmbH 
  Maxisafe 2020 TF 
Thermo Fischer 
Scientific 
Cell sorter BD FACSAria TM III BD Biosciences 
  Gentle MACS Dissociater Miltenyi Bioscie3nce 
  OctoMACS Seperator Miltenyi Bioscie3nce 
HCA Cellomics microscope CX7  
Thermo Fisher 
Scientific 
Columns LS Columns  Miltenyi Biotec 
  MS Columns   
DA enriched
composite cultures
Name Disease Gender Gene Mutation Source
H1 Control M - - Gizem Inak
TFBJ Control M - - Gizem Inak
XM001 Control F SURF1 - Gizem Inak
SVS1A LS  M SURF1 p.Val177Gly Gizem Inak
SVS1C LS  M SURF1 p.Gly257Arg Gizem Inak
SVS1C.C 3p Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
SVS1C.C 3bb Isogenic control M SURF1 Corrected p.Gly257Arg Gizem Inak
Cerebral organoids
Name Disease Gender Gene Mutation Source
XM001 Control F SURF1 - Dr. Agnieszka Rybak-Wolf
SVS1C LS  M SURF1 p.Gly257Arg Dr. Agnieszka Rybak-Wolf
SVS1C.C 3p Isogenic control M SURF1 Corrected p.Gly257Arg Dr. Agnieszka Rybak-Wolf
SVS1C.C 3bb Isogenic control M SURF1 Corrected p.Gly257Arg Dr. Agnieszka Rybak-Wolf
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Concentrator  10K centrifugal filter Amicon® Ultra-15 
Electrochemiluminescence (ECL) MESO QuickPlex SQ 120 MSD 
  EPS 301  
Amersham 
Biosciences 
  Transilluminator TM-36 UVP Inc. 
Electrophereseses  GeneGenius Gel Imaging System Syngene 
  Microwave Privileg 
  Electrophoresis chamber   
Fluorescent microscope Imager Z1 Carl  Zeiss GmbH 
Filter Pre-seperation filters Miltenyi Bioscie3nce 
Freezing container Mr. Frosty  Nalgene 
Freezer, -20 Comfort  Liebherr 
Freezer, -80 Innova4725  New Brunswick  
Fridge UP3021  Scientific Liebherr  
Hemocytometer Neubauer Plus  
ThermoFisher 
Scientific  
High Content Analysis Platform 
Incubator 
CellInsight CX7  
ThermoFisher 
Scientific  
Incubator Heraeus BBD 6220 
ThermoFisher 
Scientific 
  Binder BD 6220   
  Binder BCB 160 Binder GmbH 
  Binder CB 160   
Liquid Nitrogen device   
Thermo Fisher 
Scientific  
Luminescent Image analyser LAS‐3000  Fujifilm  
Microcentrifuge  Biofuge pico  Heraeus  
  Leica m80 Leica Microsystems 
  Eclipse Ni-E Ts2 Nikon 
Microscope x710 microscope Keyence 
  P902 electron microscope Zeiss 
  Upright microscope  (Axioskop, Zeiss)  
  Spinning disk microscope CSU-W  Andor/Nikon 
Patch-clamp amplifier  EPC-9 HEKA Elektronik 
Pipettes (2-1000ul) Pipetman Classic  Gilson 
Pipetaid PIPETBOY acu 2  Integra Biosciences  
Plate reader Tecan Infinite M200  Tecan  
Process BeadChip iScan system   Illumina 
qPCR machine ViiA TM 7 
Thermo Fischer 
Scientific TM 
Seahorse XF Analyser Seahorse Xfe96 Analyser  Agilent Technologies 
Serological pipettor Pipetboy acu INTEGRA Biosciences 
Shaker Rocky LTF Labortechnik  
Single Channel Electronic 
Pipette 0.5- 10μl, 5-100μl, 20-
300μl, 50-1000μl  Research Pro Eppendorf 
 





  MJ Research PTC 200  MJ Research 
Thermal Cyclers Simpli Amp Thermal cycler  Life Technologies 
  Mastercycler X50s Eppendorf 
Thermomixer Thermomixer comfort Eppendorf 
Vortexer Vortex Genie 2 Scientific industries 
Water Bath Isotemp 220  
Thermo Fisher 
Scientific  
  TW8 Water Bath Julabo 
 
6.2.1. Chemicals and consumables 
6.2.1.1. General consumables 
General consumables and respective producers are listed in this section. 
Items Supplier 
Cell spatula  TPP 
Coverslips Greiner Bio 
Cell culture plates, 6-well, 24-well  Greiner Bio 
Conical tubes (15 ml, 50 ml) Greiner Bio One 
Cryovials Corning 
DNA Gel Loading Dye (6X)  Thermo Fisher Scientific  
dNTP Set  Thermo Fisher Scientific  
Falcon tubes, 15 mL and 50 mL Falcon 
Falcon polystyrene test tubes  Corning 
Glas pipettes Sarstedt 
KnockOut DMEM  Thermo Fisher Scientific  
Matrigel Matrix  Corning 
Multi-well plates (6-well, 12-well, 24-well) Greiner Bio-One 
NuPAGE™ Novex® Bis-Tris gel system  Invitrogen  
Opti-MEM  Thermo Fisher Scientific  
orbital shaker (80 rpm)  IKA 
Pipette tips, 2 μL, 10 μL, 200 μL, 1000 μL Greiner Bio 
Pasteur pipettes, glass, 150mm Applied Biosystems  
Plastic flasks (T-25, T-50, T-150) Greiner Bio-One 
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Pipette tips, 2 mL, 5 mL, 10 mL, 25 mL  Sarstedt AG & Co. KG 
PCR SingleCap 8er-SoftStrips 0.1ml  Biozym  
QUICKPLEX assay plate MSD 
Reaction tubes, 500 μL, 1.5 mL, 2 mL Sarstedt AG & Co. KG 
RNase H Hybridase Thermostable RNase H Epicentre 
Seahorse 96 well plate 
Seahorse Bioscience 
Seahorse cartridge  Seahorse Bioscience 
Shandon Immuno-Mount  Thermo Fisher Scientific  
slides   Thermo Fisher Scientific 
Tissue-Tek®  O.C.T.™  
Ultra-low attachment culture dish Corning 
Vacuum filtration 250 mL, 500 mL, 0.22 μm  Applied Biosystems  
96 well black, clear bottom cell culture microplates Falcon 
96-well Seahorse XFe96 cell culture microplate Agilent 
100 bp DNA Ladder  Thermo Fisher Scientific  
384-well black, clear bottom microplate  Falcon 
13 mm Ø Coverslips   Thermo Fischer Scientific 
384-well plates for qPCR Thermo Fisher Scientific  
 
 
6.2.1.2.  Cellular consumables 
Item Supplier 
a-Tocotrienol Cayman Chemicals 
Accutase  ThermoFisher 
Antimycin A Sigma Aldrich 
Amino acids  Gibco 
Ascorbic acid Sigma Aldrich 
Avanafil  Selleckchem 
BDNF  MACS Miltenyi 
Bezafibrate Selleckchem 
B-27 supplement (10x)  Gibco 
CHIR-99021, GSK-3 inhibitor  Cayman Chemical 
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Compound E  Merck Millipore 
db-cAMP sigma Aldrich 
Disinfection solution  Gigasept Schuelke 
Dihydrolipoicacid Santacruz Biotech 
Dimethyl sulfoxide (DMSO), sterile-filtered  Sigma Aldrich 
DMEM, 4.5g/l glucose, 500ml Gibco 
DMEM/F12, 500ml  Gibco 
Donkey normal serum  Gibco 
DNase/RNase-free distilled water  Gibco 
FBS, fetal bovine serum  Gibco 
FCCP, 25mM  Sigma Aldrich 
FGF2 PeproTech 
FGF8 MACS Miltenyi 
Glucose  Sigma Aldrich 
GDNF MACS Miltenyi 
hLIF  Merck Millipore 
Hoechst 33342  Life Technologies 
KO-DMEM ThermoFisher Scientific 
KO-SR Gibco 
L-Glutamine  Lonza 
Mitomycin C  Sigma-Aldrich 
MitoTrackerRed CMXRos  Thermo Fischer Scientific 
Matrigel matrix, growth factor reduced  BD Biosciences 
Immu-Mount Media Thermo Fisher Scientific 
MycoZap Plus-CL Lonza 
N-2 supplement (10x)  Gibco 
N-acetly cysteine Sigma Aldrich 
Neurobasal medium  Gibco 
Pen/Strep Lonza 
PBS Sigma Aldrich 
Phenol Red Sigma Aldrich 
Purmorphamine Millipore 
Pyruvate  Gibco 
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Retinoic acid  Sigma Aldrich 
ROCK inhibitor (Y-27632)  Enzo Life Sciences 
Rotenone Sigma Aldrich 
SAG, SHH agonist Enzo Life Science 
SB-431542, TGFB1R inhibitor  Selleckchem 
StemMACS iPS-Brew XF, human  Miltenyi Biotech 
TGF-B3 MACS Miltenyi 
Triton X-100  Sigma Aldrich 
Tween-20  Sigma Aldrich 
 
 
6.2.1.3.  Molecular and chemical consumables 
Item Supplier 
Acrylamide, 30%  Sigma Aldrich 
APS Sigma Aldrich 
AscI NEBR0558S 
Ava II  NEB #R01535 
Bbs1  NEB #R3189 
BsaJI NEB #R0536S 
BsiWI NEB #R3553S 
DNA Extension Ladder 1kb Life Technologies 
DNA Extension Ladder 100bp Life Technologies 
DNA Gel Loading Dye (6X) Life Technologies 
DNA Kit FlexiGene  Qiagen 
DNase I  Invitrogen 
dNTP 25 mM USB 
EDTA  Carl Roth 
Ethanol 70 % Carl Roth 
Ethidium bromide  Carl Roth 
Glycerol, 85%  Carl Roth 
GoTaq Flexi buffer  Promega 
GoTaq DNA Polymerase  Promega 
Isopropanol, 100%  Carl Roth 
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MgCl2, 25mM  Carl Roth 
Not I NEB #R3189S 
Nsil NEB #R0127S 
oligo-dT, 1ug/ul  Invitrogen 
Phusion Hot StartII DNA Polymerase  Thermo Fisher Scientific.  
5X Phusion GC Buffer  Thermo Fisher Scientific 
Protease  Qiagen 
Reverse transcriptase Affymetrix 
Reverse transcriptase Buffer Affymetrix 
RNeasy Mini Kit  Qiagen 
RNase-free distilled water  Gibco 
SYBR green PCR mix  Applied Biosystems 
TEMED  Sigma Aldrich 
Tween-20  Sigma Aldrich 
TrisBase  Sigma Aldrich 
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6.2.2. Media 
 All media were sterile-filtered and pre-warmed to 37 °C before usage. Maintenance and 
freezing media are listed below with their components and suppliers.    
Embryoid Body     
  
Volume Stock conc. Final conc. 
  
KO-DMEM 40 ml 1x 1x 
  
  KO-SR 10 ml 1x 5x 
EB Pen/Strep 500 µl 0.1 mg/ml 10 mg/ml 
  Glutamine 500 µl 2 mM 200 mM 
  NEAA 500 µl 1x 100x 
  Pyruvate 500 µl 1 mM 100 mM 
 
ESC/iPSC     
 
  Volume Stock conc. Final conc. 
  
KO-DMEM 450 ml 1x 1x 
  
  KO-SR 100 ml 1x 50x 
  Amino acids 5 ml 1x 100x 
ES Pyruvate 5 ml 1 mM 100 mM 
  bFGF (FGF2) 650 µl 9 ng/ml 8 µg/ml 
  Pen/Strep 5 ml 0.1 mg/ml 10 mg/ml 
  MycoZap 1 ml 1x 500x 





   
  
Volume Stock conc. Final conc. 
  
iPS Brew 
Supplement 10 ml 50x 1x 
iPS Brew MycoZap 1 ml 500x 1x 
  Pen/Strep 5 ml 10 mg/ml 0.1 mg/ml 
     
  




medium 400 ml 1x 1x 
mTeSR 
mTeSR1 5x 
Supplement 100 ml 5x 1x 
  MycoZap 1 ml 500x 1x 
  Pen/Strep 5 ml 10 mg/ml 0.1 mg/ml 
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NPC culture     
  
Volume Stock conc. Final conc. 
  Ham's F-12 240 ml 1x 0.5 x 
  Neurobasal 240 ml 1x 0.5 x 
  N2 2.5 ml 100x 0.5x 
SM- B27  5 ml 50x 0.5x 
  Pen/Strep 5 ml 10 mg/ml 0.1 mg/ml 
  Glutamine 5 ml 200 mM 2 mM 
  MycoZap 1ml 500 x 1x 








  SM- 10 ml 1x 1x 
SM+ Pu 7.69 µl 0.65 mM 0.5 µM 
  CHIR 5 µl 6 mM 3 µM 
  Vit. C 10 µl 0.2 M 200 µM 
 
 
DA enriched     
composite culture     
  
Volume Stock conc. Final conc. 
  SM- 10 ml 1x 1x 
DSM+ FGF8 2 µl 500 µg/ml 100 ng/ml 
  Pu 15.38 0.65 mM 1 µM 




   
    Volume Stock conc. Final conc. 
  SM - 10 ml 1x 1x 
  BDNF 10 µl 10 µg/ml 10 ng/ml 
DSM2+ GDNF 10 µl 10 µg/ml 10 ng/ml 
  TGF-B3 10 µl   1µg/ml  1 ng/ml 
  Vit.C 10 µl 0.2 M 200 µM 
  db c-AMP 50 µl 100 mM 500 µM 
  Pu 7.69µl 0.65mM 0.5µM 
 
    
    Volume Stock conc. Final conc. 
  SM- 10 ml 1x 1x 
  BDNF 10 µl 10 µg/ml 10 ng/ml 
  GDNF 10 µl 10 µg/ml 10 ng/ml 
DMSM+ TGF-b3  10 µl   1µg/ml  1 ng/ml 
  Vit.C 10 µl 0.2 M 200 µM 
  db c-AMP 50 µl 100 mM 500 µM 
 
  101 
 
 
CRISPR/Cas9 FACS media 
    
  
 Volume  Stock conc. Final conc. 
   PBS  9,2 ml  1x 1x 
   FBS  500 µl  1x 1 to 20 
Pre-FACS media  Pen/Strep  100 µl  10 mg/ml 1 to 100 
   Gentamycin  100 µl  10 mg/ml 1 to 100 
   EDTA  100 µl  2 mM 1 to 100 
     
  
 Volume  Stock conc. Final conc. 
Post-FACS media  mTESR1  1 ml  1x 1x 
   ROCK inhibitor  1 µl  3,2 mg/ml 3,2 µl/ml 
 
 




ddH2O 1 L 
DMEM base 8.3 g 
NaCl 1.85 g 
Phenol red 15 mg 
Glutamine 10 mL 
 
 
6.2.3. Buffers and solutions     
4 % PFA  4 g PFA dissolved in 100 ml, pH 7.4  
  
 
  200 mM Tris pH 6.8 
  400 mM DTT 
4x SDS loading buffer  8% SDS 
  40% glycerol 
  bromophenol blue  
  
Blocking buffer (IHC) 5 % DNS in PBS-T 
  
Blocking buffer  (WB) 3 % milk powder in PBS-T  
  
  50 mM HEPES pH 7.4 
  150 mM NaCl 
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  1.5 mM MgCl2 
Cell lysis buffer  0.1% NP 40 
  1 mM EDTA 
  1x Complete™ protease inhibitors 
  2u/ml benzonase  
  
  30 % ethanol  
Coomassie staining solution  10 % acetic acid 
  




6.2.4. Oligonucleotides and sequences 
qRT-PCR 
Gene Forward Reverse 
NANOG CCTGTGATTTGTGGGCCTG GACAGTCTCCGTGTGAGGCAT 
SOX2 GTATCAGGAGTTGTCAAGGCAGAG TCCTAGTCTTAAAGAGGCAGCAAAC 
GDF3 TTGGCACAAGTGGATCATTGC TTGGCACAAGTGGATCATTGC 
DPPA4 TGGTGTCAGGTGGTGTGTGG CCAGGCTTGACCAGCATGAA 
DNMT3B GCTCACAGGGCCCGATACT GCAGTCCTGCAGCTCGAGTTTA 
OCT4 GTGGAGGAAGCTGACAACAA ATTCTCCAGGTTGCCTCTCA 
DCX GAAGCCATCAAACTGGAGAC GAAATCATGGAGACAAGTTACCTG 
NKX2.2 CCTTCAGTACTCCCTGCAC TGTCATTGTCCGGTGACTC 
LHX2 GAAGGGGCGGCCGAGGAAAC GCTGGTCACGGTCCAGGTGC 
SCN7A CTTTGTGGCAACAGGACAGA AATAAGGCCCAGCCAAAACT 
KCNQ2 GGCTTCAGCATCTCCCAGT GACTCTCCCTCCGCAATGTA 
SYP ATTGTGCCAACAAGACCGAGAGT AGGAAGATGTAGGTGGCCAGAG 
SYT13 TGGGTTCCTCCCTCTTTCTT GAAAATGTGTGCTGGTGGT 
ARX CTGCTGAAACGCAAACAGAGGC CTCGGTCAAGTCCAGCCTCATG 
SPON1 CTCTTCCTGCAGAGGAGTAGTGTCA CTGGGACTCAGGC ATAGTCACTTC 
NTN1 TGCAAGAAGGACTATGCCGTC GCTC GTGCCCTGCTTATACAC 
GATA3 TGTCTGCAGCCAGGAGAGC ATG CATCAAACAACTGTGGCCA 
PPARGC1A GCTTTCTGGGTGGACTCAAGT TCTAGTGTCTCTGTGAGGACTG 
PDK3 CGCTCTCCATCAAACAATTCCT CCACTGAAGGGCGGTTAAGTA 
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MYC CCAGCAGCGACTCTGAGGA GAGCCTGCCTCTTTTCCACAG 
LDHA TATGGAGTGGAATGAATGTTGC CCCTTAATCATGGTGGAAACTC 
ACTB TCAAGATCATTGCTCCTCCTGAG ACATCTGCTGGAAGGTGGACA 
GAPDH CTGGTAAAGTGGATATTGTTGCCAT TGGAATCATATTGGAACATGTAAACC 
 
Mutation analysis 
S1A TGATGGCAAGCTATGAGGGG CCGCCATATACACATGTGAGAAC 
S1C ACTTCCGTACGTTGTGGACC GCAGCTGATCTGTCACACAC 
Primer induced restriction analysis (PIRA) 
S1A CATTACCCTAGAGTCACCATCCCG G GGAGCCTGGTGGACTCCC 




  Forward Reverse 




TALEN Library design 
  
TAL 1 - (5´-3´) TAL 2 – (5´-3´)  
I-GAGC   :    2 / D / 6 IV-AGC    :  9 / A / 10 
II-CAGC  :    4 / D / 6 III-CTAG  :  7 / E / 3 
III-CCTG :    7 / C / 7 II-ACAA   :  3 / G / 9 
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(Red letters indicate where the mutation reside and correction is aimed. Red highlighted area 
indicates TTAA box, TAL1 is highlighted in pink. TAL2 is highlighted in light blue. ) 
 
 








     
Primer U6 (for 
sequencing) 










(Underlined letters indicate mismatch and small case letters indicate silent mutations.) 
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Myco 1 CGCCTGAGTAGTACGTTCGC   
Myco 2 CGCCTGAGTAGTACGTACGC   
Myco3 TGCCTGAGTAGTCACTTCGC   
Myco 4 CGCCTGGGTAGTACATTCGC   
Myco 5 CGCCTGAGTAGTAGTCTCGC   
Myco 6 TGCCTGGGTAGTACATTCGC   
Myco r1   GCGGTGTGTACAAGACCCGA 
Myco r2   GCGGTGTGTACAAAACCCGA 
Myco r3   GCGGTGTGTACAAACCCCGA 
 
6.2.5. Antibodies 
Primary Antibody     
IHC analysis       
Target protein    Used dilution  Provider  species  
TUJ1   1 to 3000 Sigma-Aldrich mouse 
FOXA2 1 to 100 Seven hills rabbit 
SYP 1 to 500 Sigma-Aldrich mouse 
GFAP 1 to 500 Synaptic systems guinea pig 
OCT4 1 to 300 Biotechnology mouse 
NANOG 1 to 300 R & D Systems goat 
SOX2 1 to 100 Sigma-Aldrich mouse 
TRA-1-60 1 to 200 Sigma-Aldrich mouse 
S100ß 1 to 600 abcam mouse 
HES5 1 to 50 Biotechnology Rabbit 
TH 1 to 500 Biotechnology rabbit 
NURR1 1 to 500 Sigma-Aldrich rabbit 
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VAMP2 1 to 500 Synaptic systems rabbit 
SMA 1 to 200 Dako Cytomation mouse 
PAX6 1 to 200 Covance rabbit 
SOX2 1 to 100 Santa Cruz goat 
SOX17 1 to 50 R & D Systems goat 
LIN28 
 
Protein Tech Europe Rabbit 
MAP2 1 to 100 Synaptic systems guinea pig 






MT-CO2 1 to 1,500 abcam Mouse 
Tubulin 1 to 4,000 Sigma-Aldrich mouse 
 
Secondary Antibody       
 
Used dilution Provider  Against species 
Alexa Fluor 488 1 to 300 Invitrogen donkey anti-mouse 
Cy2 1 to 300 Sigma-Aldrich goat anti-mouse 
  1 to 300 Sigma-Aldrich donkey anti-rabbit 
Cy3 1 to 300 Merck Millipore donkey anti-mouse 
  1 to 300 Merck Millipore donkey anti-goat 
  1 to 300 Sigma-Aldrich donkey anti-guinea pig 
Cy5 1 to 300 Sigma-Aldrich donkey anti-mouse 
  1 to 300 Sigma-Aldrich donkey anti-goat 
 
MACS Quant Analysis     
Target protein    Used dilution  Provider  
A2B5-APC 1 to 11 Miltenyi Biotec 
GLAST (ACSA-1)-APC 1 to 11 Miltenyi Biotec 
PSA-NCAM-PE 1 to 11 Miltenyi Biotec 
CD11B-Vioblue 1 to 50 Miltenyi Biotec 
O4-APC 1 to 11 Miltenyi Biotec 
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6.2.6. Kits  
Kit Suplier 
AmpliTaq Gold™ 360 Master Mix  Thermo Fisher Scientific  
BCA Protein assay   Pierce  
Clone Jet PCR Cloning  Thermo Fisher Scientific  
CytoTune-iPS 2.0  Thermo Fisher Scientific 
CyQUANT  Molecular Probes 
DNeasy blood and tissue kitx QIAGEN  
FlexiGene DNA Kit 250 QIAGEN  
High Output TG NextSeq® 500/550 
Infinium OmniExpressExome-8  Illumina 
Lactate Fluorometric Assay Kit  BioVision 
Lipofectamine 3000    Thermo Fisher Scientific 
Lipofectamine 2000   Thermo Fisher Scientific  
MSB Spin PCRapace  Stratec Biomedical  
NativePAGE™ Novex® Bis-Tris gel system  Invitrogen  
NucleoBond Xtra Maxi Plus  MACHEREY-NAGEL GmbH & Co. KG  
PCR Clean-Up System  Promega 
Pure Yield Plasmid Miniprep System  Promega Corporation  
Phire Animal Tissue Direct PCR  Thermo Fisher Scientific  
Pro-inflammatory Panel I  MSD 
QIAprep Spin Miniprep  QIAGEN  
Qiagen RNeasy Mini  QIAGEN  
TruSeq Stranded Total LT Sample Prep Illumina 
Wizard SV Gel and PCR Clean-Up System   Promega Corporation  
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6.2.7. Plasmids  
Purpose Identifier  Provider  
TALEN PB-MV-Puro-TK Addgene 
CRISPR/Cas9 pU6(BbsI)-CAG-Cas9-venus-bpA (#1) Dr. Pawel Lisowski 
  
614.CAG-hRad52-EF1BFP (#2) Dr. Bruna Paulsen 
  
602.pCAG-i53-EF1BFP (#3) Dr. Bruna Paulsen 
SURF1 gene 
pLenti PGK Neo DEST  Addgene 
augmentation 
pLenti_PGK_SURF1 Dr. Chris Secker 





Adobe illustrator  Adobe Inc. 
AxioVision  v46-3-0 Zeiss 
BD FACSDiva Software v8.0.2  BD Biosciences 
Cellomics Neuronal Profiling v3.5  Thermo Fisher Scientific 
CLC Genomics Workbench v11  QIAGEN Bioinformatics  
DESeq2 v1.20.00 R package Biocondoctor 
FiJi verison v1.52h ImageJ 
FlowLogic v7.2.1. Inivai 
GraphPad Prism v5 GraphPad Software 
HCS Studio Cell Analysis Software v6.6.1.  Thermo Fisher Scientific  
Image J NIH 
KaryoStudio v1.4  Illumina 
Serial Cloner v2.1 Serial Basics 
STAR Aligner  v2.6.0c GitHub 
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7. Methods 2 
7.1. Cell biology 
7.1.1. Cell culture 
 For different kinds of experiments, different cell types and models were used: skin 
fibroblasts, induced pluripotent stem cells (iPSCs), and iPSC-derived NPCs, NPC-derived composite 
cultures (neurons and glial cells). Lastly, iPSC-derived cerebral organoids used in this study. I have 
cultivated and maintained the first four cell types for this study. Cerebral organoids were managed 
by Dr. Agnieszka Rybak-Wolf. Each cell type needs a specific condition for optimal growth and 
maintenance of cell specific properties. T75 cell culturing flasks, different format of well plates (6, 
12, 24 and 96), mini or 150mm, low attachment Petri dishes were used depending on the designed 
experiment. Cells were maintained in standard cell culture media supplemented with appropriate 
compositions of small molecules and additional supplements supporting the survival of the specific 
cell tape. All media were sterile-filtered and pre-warmed to 37°C before usage. Media composition 
and can be found in section 6.2.2. 
 
7.1.1.1. Cultivating conditions 
 Different cell types require different culturing conditions. Skin fibroblasts do not need 
coating on the plates, whereas iPSCs, NPCs, and composite cultures needed matrigel coating to 
attach and survive. Matrigel (the membrane-like matrix) was used in a concentration of 5 mg/ml. 
Knock Out DMEM (Dulbecco’s Modified Eagle Medium) was used to dilute the gel stock solution. 
Plates are coated one day before use and stored overnight in +4°C.  
 Skin fibroblasts were cultured in DMEM media, and the media was changed once in three 
days. They were split with Trypsin at 1:8 ratio. iPSCs were cultured in three different media types: 
ES ´lab made´, mTeSR1 provided by "Stem Cell Technologies” or iPSBrew provide by “Miltenyi 
Biotec". Under normal conditions, cells were cultured feeder-free and in mTeSR1 or iPS Brew. 
Media was changed daily. Cells were split regularly once a week in a split ratio of 1:4, mechanically. 
For transfection purposes, iPSCs were split with Accutase in a ratio of 1:1. Under stressful conditions 
such as post-FACS transfection phase, iPSCs were plated on feeders (MEFs) to provide support and 
promote survival and were given either ES, iPS Brew or mTesR1. Neuronal progenitor cells were 
cultured in SM+ media. Media was changed once in three days. Cells were split regularly once a 
                                                          
2  Methods have partially been reused with modifications from the published version: Inak, G., Rybak-Wolf, A., Lisowski, 
P., Juettner, R., Zink, A., Mlody, B., … Prigione, A. (2019). SURF1 mutations causative of Leigh syndrome impair human 
neurogenesis. BioRxiv. https://doi.org/10.1101/551390 
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week in a split ratio of 1:8 by Accutase. If NPCs were directed to differentiate further to DA-enriched 
composite cultures, they were split by Accutase and DSM+ media was given when the good 
confluency was around 70%. After they were kept in culture for 8 days, they were given DSM2+ 
media. On the 10th day, the cells were split with Accutase, and they were plated on matrigel plates 
and were given DMSM+ ROCK inhibitor. DMSM+ media was changed every 4 days, and the cells 
were maintained for 4, 6, or 8 weeks, depending on the maturation stage aimed for the specific 
experiment. Because neurons do not proliferate anymore, regular splitting is not necessary.  
 
7.1.1.2. Splitting cells 
 Fibroblasts were split when they were at 80-90 % conﬂuency. Cells were incubated with 
0,05 % Trypsin-EDTA for 5 minutes at 37 °C until the cells were detached. Afterward, they were 
collected into DMEM media and centrifuged at 120 rcf for 5 minutes. The cell pellet was 
resuspended in DMEM medium, and cells were plated according to splitting ratio.  
   iPSCs were split mechanically, and they were picked as single clones. The aim of picking 
single colonies is to get rid of the differentiated cell types.  A special laminar hood “BDK-S” is used 
for working with uncovered cells directly under the “Leica M80” microscope. Picked cells were 
transferred into new wells containing fresh media and ROCK Y-27632 inhibitor.   
 NPCs were split with the enzyme Accutase for single cell splitting. Cultivation media was 
sucked up, and Accutase was given. After 3 mins of incubation at 37 °C, cells were collected by 
pipetting up and down and transferred into a new Falcone tube. To stop the Accutase activity, the 
cells were washed one time in Dulbecco’s Phosphate Buffered Saline (DPBS) or the required media 
and centrifuged with 120 rcf for 4 mins. To seed the cells, the pellet was resolved in the acquired 
amount of the cell type-specific media and transferred in wanted split ration into a new well, 
containing fresh media and, in the case of composite cultures, ROCK Y-27632 inhibitor to prevent 
apoptosis on the fragile cell types as neurons. Neurons were split with gently as they were 
centrifuged at a low speed and for fewer minutes (40 RCF, 2 minutes). Cells of composite cultures 
tend to sink to the bottom by gravity. They survive better when they were plated as single cells, so 
Accutase splitting is important.  
 
7.1.1.3. Cryopreservation and Thawing  
 In order to ensure different reproducibility passages of all cell lines were frequently 
frozen. Therefore, harvested cells in 0.5-1 ml culture medium together with an equal volume of 2 x 
freezing medium were transferred into 2 ml low temperature freezing vials. Within a freezing 
container allowing slow freezing at a rate of −1 °C/min (‘Mr. Frosty,’ Thermo Fisher Scientific) the 
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vials were placed at −80 °C overnight before liquid nitrogen storage. Frozen cells have been thawed 
rapidly in 37 °C water bath and centrifuged at 120 rcf for 4 min. Subsequently, the cell pellet was 
resuspended in the required growth medium (Table 6.2.2.) with ROCK Y-27632 inhibitor and seeded 
on appropriately prepared culture plates.  
 
7.1.2. iPSC generation 
 Patient fibroblasts were reprogrammed using Sendai viruses (CytoTune-iPS 2.0 from 
Thermo Fisher Scientific). All pluripotent stem cells (PSCs) were cultivated on Matrigel (BD 
Bioscience)-coated plates using StemMACS iPS-Brew XF medium (Miltenyi Biotec GmbH, #130-
104-368), supplemented with Pen/Strep (Thermo Fisher Scientific) and 1ml Mycozap. We 
routinely monitored against mycoplasma contamination using PCR. 10 µM Rock inhibitor (Enzo, 
ALX-270-333-M005) was added after splitting to promote survival. PSC cultures were kept in a 
humidified atmosphere of 5% CO2 at 37 °C and 5% oxygen. All other cultures were kept under 
atmospheric oxygen condition. Karyotype analysis was performed by MDC Stem Cell Core 
Facility. Briefly, DNA was isolated using the DNeasy blood and tissue kit (Qiagen, Valencia, CA). 
SNP karyotyping was assessed using the Infinium OmniExpressExome-8 Kit and the iScan system 
from Illumina. CNV and SNP visualization was performed using KaryoStudio v1.4 (Illumina). 
 
 
7.1.3. FACS Sorting 
 CRISPR/Cas9 transfected cells were sorted by flow cytometer BD FACS Aria. By using the 
unedited CH4 line, cells were sorted in the first step in order of granularity/surface by the side 
scatter (SSC-A), and size by forward scatter (FSC-A). To eliminate doublets during sorting, the 
resulting population from analyses were gated and first adjusted in FSC-W against FSC-H and second 
in SSC-W against SSC-H. This led to the exclusion of cell droplets with incorrect cell size and cell 
signal ratio. After adjusting the morphology properties, the cell population was screened for cells 
containing pU6(Bbsl)-CAG-eCas9-venus-bpA(#1) by using the GFP channel for Venus-positive cells 
and cells containing pCAG-i53-EF1BFP and CAG-hBRCA1-EF1BFP by using BFP channel for BFP 
positive cell. Only double positive cells were used for further cultivation and analyses of edited 
events. Cells were kept in Pre-FACS media before and during sorting, then they were transferred 
into a prepared tube with post-FACS medium and then plated onto MEFs 6 well plates. Around 500 
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7.1.3.1. Generation of feeder cells  
 Mouse embryonic fibroblasts (MEFs, feeders) served as feeder cells during PSC-
culturing. Those cells were obtained from 2-week-old mouse embryos (strain CF1) and plated 
on Petri dishes maintained in DMEM. The medium was changed every 2-5 days, and at 80-90 % 
confluence cells were passaged. After sufficient expansion, the MEFs were mitotically 
inactivated by incubating them with Mitomycin C (Sigma-Aldrich) for two h at 37 °C. Finally, cells 
were counted with a Neubauer hemocytometer and frozen as aliquots of 1.3 x106 cells/vial for 
one 6-well-plate. MEFs were used as a support for the survival of FACS-sorted cells. MEFs plates 
were prepared one day before as they need almost one day to attach. Therefore DMEM-medium 
had to be warmed, and Matrigel plates had to be incubated in the binder incubator at 37°C for 
20 min. The frozen MEFs had to be thawed and filled into a 15 ml falcon. Some ml of DMEM 
were added. The mixture was centrifuged for 4 min at 120 rcf. The supernatant was discarded, 
and the pellet was solved in 9 ml of DMEM and resuspended 15 times. For a six well-plate 1.5 
ml DMEM was added to each well before adding 500 µl cell suspension to each well. Afterward, 
the cells were checked under a microscope.  
 
7.1.4. Differentiation of NPCs and DA neuronal cultures 
 NPCs and dopaminergic (DA) neurons were obtained using a previously published 
protocol (Reinhardt et al., 2013). Briefly, PSCs were detached from Matrigel-coated plates using 
Accutase (1 mg/mL), and the collected cells were transferred into low-attachment Petri dishes 
and kept for two days in SM- media. From day 2 to day 6, SM+ media was added to have 1:1 
ratio. On day 6, the suspended cells were transferred onto Matrigel-coated well plates using 
SM+ media. NPCs were maintained on this media without rock inhibitor and used for 
experiments between passage 7 and 20. For DA differentiation, I used NPCs between passage 7 
and 13. To initiate the differentiation, the media was changed to DSM+ media. After seven days, 
the media condition was replaced with DSM2+ media.  On day 9, cells were split with Accutase 
gently and seeded on Matrigel-coated plates in DMSM+ media. Media composition can be found 
in section 6.2.2. The scheme of the differentiation protocol used in this study is summarized in 
Figure 7.1.4. (Reinhardt et al., 2013). After neurospheres were plated on Matrigel-coated plates 
on day 4, the small molecules (DM, SB) were added to basal media to inhibit both bone 
morphogenetic proteins (BMP) and transforming growth factor (TGFß) signaling pathways. 
Purmorphamine was added to stimulate sonic hedgehog (SHH) pathway, and in order to 
stimulate the canonical WNT pathway, glycogen synthase kinase-3 (GSK3) is inhibited by CHIR. 
At day 10, NPCs were formed, and they were maintained until they reach passage 6 to have a 
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homogenous population. If the passage number of NPCs were between 6 and 13, they were 
further differentiated into dopaminergic neuron-enriched cultures (DA). The cells were then 
treated with the developmental patterning factors such as SHH and fibroblast growth factor 8 
(FGF8), which specify the formation of ventral midbrain dopaminergic neural cells. The neural-
like cells were kept in culture for further maturation stages for 4 weeks (28 days) or 8 weeks (56 
days). They were treated with ascorbic acid (vitamin C), brain-derived neurotrophic factor 
(BDNF), glial cell line-derived neurotrophic factor (GDNF), transforming growth factor beta 1 
(TGFß), and cyclic adenosine monophosphate (cAMP) which are known to promote neuronal 









   




Figure 7.1.4.: Scheme of the differentiation protocol from iPSCs to fully differentiated NPC-derived 
neurons  
d 0-10, Embryoid bodies (EBs) derived from iPSCs were directed towards to neural lineage through the 
small molecules dorsomorphin (DM) and SB43152 (SB), and CHIR99021 (CHIR). The SHH pathway was 
stimulated using the small molecule purmorphamine (PMA). Epithelium cells were formed and expanded. 
d 10-22, PMA and FGF8 were given to NPCs for eight days, which helps the specification of ventral midbrain 
cells, including midbrain dopaminergic neurons. Then only PMA and ascorbic acid were given for two days. 
d 22-56, Neurons were given cAMP, BDNF, GDNF, and TGF-b3 for maturation for 28 days or 56 days. 
 
7.1.5. Electrophysiology 
  To analyze passive and active membrane properties, spiking and synaptic activity in DA 
neuronal cultures, whole-cell patch clamp recordings were carried out on week 4, 6, and 8 weeks 
of differentiation. DA neurons were visualized under phase contrast optics on an upright 
microscope (Axioskop, Zeiss) by using a 63x/0.95 water immersion objective. Recordings were 
performed using a patch-clamp amplifier (EPC-9, HEKA Elektronik). Recording pipettes were 
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filled with an intracellular solution containing (in mM): 4 NaCl, 120 KCl, 5 EGTA, 10 HEPES, 5 
glucose, 4 MgCl2, 0.5 CaCl2 (pH 7.3, 270 mOsmol/kg). The pipette to bath resistance ranged 
from 5 to 7 MOhm. Series resistance compensation was applied as much as possible (50– 70%). 
The effective series resistance was in the range of 20–40 MOhm and was checked throughout 
the whole experiment by using a short depolarizing pulse (10 mV, 20 ms). Recordings were 
accepted only if the series resistance was less than 40 MOhm. Bath solution contained (in mM): 
136 NaCl, 2.5 KCl, 20 glucose, 20 HEPES, 2 CaCl2, 1 MgCl2 (pH 7.3, 305 mOsmol/kg). Whole cell 
input resistance (RIN) was estimated based on passive current responses to moderate 
depolarizing voltage pulses of short duration (±10 mV for 20 ms). Whole-cell membrane 
capacitance (CN) was estimated by integration of the capacitive current transient and division 
by the respective stimulation voltage. Voltage-gated Na+- and K+-currents were elicited by a 
series of 200 ms depolarizing pulses applied from the holding potential of -70 mV, in 10 mV 
increments between -70 and +70 mV. Passive responses were subtracted by using a 
hyperpolarizing pulse of -20 mV. Spontaneous synaptic currents were recorded in voltage-clamp 
mode at a holding potential of -70 mV without specific blockers. To evaluate action potential 
generation and discharge properties, cells were adjusted to -90 mV by steady current injection 
and depolarized by injection of positive current pulses (5 – 50 pA) of 1-sec duration under 
current clamp conditions. Signals were acquired at a rate of 10 kHz and analyzed off-line using 
WinTida 5.0 (HEKA Electronics). All patch clamp experiments were performed at room 
temperature (20–25 °C). 
 
7.1.6.  Generation of iPSC-derived cerebral organoids 
 Cerebral organoids were generated according to the protocol described by Lancaster et 
al., 2014 with some modifications. Shortly, after dissociation into single-cell suspension with 
accutase, 10,000 cells were seeded per one well of 96 well-plate in 100 µl of EB (medium 
supplemented with bFGF and 50 µM ROCK inhibitor). After 4 days, the medium was replaced with 
EB medium without bFGF and ROCK inhibitor and at day 6 with neural induction medium (NIM). At 
day 11, organoids were embedded in Matrigel (Corning, 356234) and kept in NIM for two days, and 
in organoid differentiation medium without retinoic acid (RA) for another four days. Next, 
organoids were transferred to ultra-low attachment 6-well plates and culture on an orbital shaker 
(80 rpm) in organoid maturation medium. The composition of the original organoids maturation 
medium was changed by adding: chemically defined lipid concentrate (1x), ascorbic acid (0.4mM), 
BDNF (20ng/ml), HEPES. The organoid size was analyzed by measuring the area using ImageJ 
software. Each human cerebral organoid was fixed in 4% paraformaldehyde overnight at 4°C, 
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dehydrated by 40% sucrose in PBS and embedded in Tissue-Tek® O.C.T.™ Compound. 12 µm 
sections were cut and mounted onto slides (Thermo Fisher Scientific). Mounted sections were 
incubated for 1 h at room temperature with blocking solution (5% normal goat serum+0.3% Triton 
X-100 in PBS) and incubated with primary antibodies diluted in blocking solution overnight at 4°C. 
After three washes with PBST (0.1% TritonX100), corresponding fluorophore-conjugated secondary 
antibodies diluted in the blocking solution were added and incubated for 2 h at room temperature 
and followed by DAPI staining. Finally, stained slides were washed with PBST three times, mounted, 
and analyzed using a Keyence bz-x710 microscope.  
 
7.1.7. Immunostaining 
 Cells grown on Matrigel-coated coverslips were fixed with 4% paraformaldehyde (PFA, 
Science Services) for 20 min at RT and washed two times with PBS. For permeabilization, cells 
were incubated with blocking solution containing 10% normal donkey serum (DNS) and 1% 
Triton X-100 (Sigma-Aldrich) in PBS with 0.05% Tween 20 (Sigma-Aldrich) (PBS-T) for 1 h at RT. 
Primary antibodies were diluted in blocking solution and incubated overnight at 4oC on a shaker. 
Primary antibodies used were as follows: PAX6 (Covance, 1:200), SOX2 (Santa Cruz, 1:100), TUJ-
1 (Sigma-Aldrich, 1:3000), OCT4 (Santa Cruz, 1:300),  LIN28 (ProteinTech Europe, 1:300), TRA-1-
60 (Millipore, 1:200), MAP2 (Synaptic System, 1:100), GFAP (Synaptic Systems, 1:500), NANOG 
(R&D Systems, 1:200),  (SMA) (DakoCytomation, 1:200), SOX17 (R&D Systems, 1:50), TH 
(Millipore, 1:300), FOXA2 (Sevenhills, 1:100), S100ß (Abcam, 1:500), SYP (Sigma-Alrich, 1:500); 
VAMP2 (Synaptic Systems, 1:500), NURR1 (Sigma-Aldrich, 1:500). Corresponding secondary 
antibody (Alexa Fluor, 1:2000, Life Technologies) were diluted in blocking solution for with h at 
RT on a shaker. Counterstaining of nuclei was carried out using 1:10,000 Hoechst 
(ThermoFisher). All images were acquired using the confocal microscope LSM510 Meta (Zeiss) 
in combination with the Axiovision V46-3-0- software (Zeiss) and further processed with 
AxioVision software and ImageJ. 
 
7.1.8. Bioenergetic profiling 
 Live-cell assessment of cellular bioenergetics was performed using Seahorse XF96 
extracellular flux analyzer (Seahorse Bioscience), as described previously 51. Briefly, 20,000 cells 
were plated into each Matrigel-coated well of the XF96 well plates. NPCs were maintained in 
the plates for two days, while DA cultures were maintained in the plates for 4 weeks or 8 weeks.  
On the assay day, the cells were incubated at 37 °C 5% CO2 for 60 min to allow media 
temperature and pH to reach equilibrium before starting the simultaneous measurement of 
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mitochondrial respiration (oxygen consumption rate, OCR) and anaerobic glycolysis 
(extracellular acidification rate, ECAR) using the sequential introduction of oligomycin, FCCP, and 
then rotenone plus antimycin A (all products at 1 µM and from Sigma). Normalization to DNA 
content in each well of the plate was performed using the CyQUANT Kit (Molecular Probes). The 
supernatants were stored before and after the seahorse assay and used for lactate 
measurement using a Lactate Fluorometric Assay Kit (BioVision).  
 With this device, it was possible to measure simultaneously oxygen consumption rates 
(OCR), indicating the mitochondrial respiration (OXPHOS), and extracellular acidification rates 
(ECAR) indicating glycolytic activity. The ratio between those parameters allowed assessing a 
cellular preference for OXPHOS or glycolysis. Furthermore, cells were metabolically perturbed 
by the addition of four different compounds which shifted the bioenergetic profile. The first 
injection after basal measurements of OCR and ECAR was Oligomycin, which blocks Complex V 
of the electron transport chain (ETC). This prevention of ATP synthesis led to an increase of the 
proton gradient across the mitochondrial inner membrane while the consumption of oxygen 
decreased. The mobile ion carrier FCCP served as an uncoupler of the mitochondrial membrane. 
Upon this second injection, the proton flux re-established nonspecifically, and mitochondrial 
membrane potential collapses, leading to a fast consumption of energy and oxygen. In this case, 
also ECAR increased because the disruption of OXPHOS leads the cells to attempt to generate 
their ATP by using glycolysis. An additional injection of FCCP was performed to determine the 
continuous mitochondrial uncoupling. Finally, the last injection was a combination of the ETC 
inhibitors Rotenone (Complex I blocker) and Antimycin A (Complex III blocker) (Figure 7.1.8.) 
This simultaneous addition completely inhibited mitochondrial respiration and shut down OCR 
but pushed ECAR as the cells shifted to a more glycolytic state to produce ATP. The monitoring 
of OCR and ECAR values upon these treatments enables calculations of several bioenergetic 
parameters (Table 7.1.8.). 
 
 Parameter   Calculation  
  
OCR Basal Respiration Ø Basal – Ø (Antimycin A + Rotenone)    
Maximal Respiration  Ø FCCP1 – Ø (Antimycin A + Rotenone)    
Spare Respiratory Capacity  Ø FCCP1 – Ø Basal  
  
ECAR  Basal Glycolysis Ø Basal  
Glycolytic Reserve Ø Oligomycin – Ø Basal    
OCR/ECAR   rate 3 OCR / rate 3 ECAR  
 
Table 7.1.8  Calculation of bioenergetics parameters from Seahorse data 
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7.1.9. CyQUANT Cell Proliferation Assay 
 The fluorescence-based method CyQUANT was used for quantifying cells and for 
setting a normalization count on the XF96 Seahorse data. As the Seahorse assay finished, the 
cell plate was washed twice with PBS and dried by blotting the plate on a clean paper tissue. For 
a freezing step, which was important for efficient cell lysis, the plate was stored at -20 °C 
overnight or -60 °C for 5 minutes. For the CyQUANT assay component B (20 x cell lysis buffer) 
was diluted 1:20 in ddH2O and component A (GR dye stock) was diluted 1:200 in 1 x component 
B for a detection range up to 100000 cells. Then 50 μl of the component A/B mixture was added 
per well of the thawed XF96 plate. After 5 min dark adaption, the fluorescence was measured 
at 480 nm excitation and 520 nm emission in a Tecan reader. Data analysis was performed using 
Microsoft Excel. 
 
7.1.10.  Cell proliferation assay 
 For cell proliferation assay, NPCs were seeded with a concentration of 5,000 cells per well 
on Matrigel-coated black-wall clear-bottom 96 well-plates containing 100 μl SM+ medium. Each 
plate was marked as either Day 0, Day 2, Day 4, or Day 7 plate. After 4 hours, the cells in Day 0 plate 
were washed 2x with PBS - 0.05% Tween, and then fixed with 4% Paraformaldehyde (PFA, Thermo 
Fischer) for 15 min, followed by 2x washings with PBS. The other plates were fixed on day 2, 4, and 
7 post-seeding with the same procedure. The fixed plates were kept at 4oC until all plates were 
ready for quantification. Quantification of cells was done through Hoechst (8.1 μM) staining. TECAN 
plate-reader (Infinite M200, Thermo Fischer Scientific) was used to quantify Hoechst fluorescence 
in the wells, and the data were analyzed in relation to the value of Day 0 plate.  
 
7.1.11. Mycoplasma test 
 For the PCR based test of mycoplasma, 9 primers (6 forward, 3 reverse) are used to 
amplify the 6 most common mycoplasma strains. Supernatant directly taken from the well is 
used as PCR template, without further isolation of mycoplasma DNA. Supernatant from a 
contaminated cell line is used as a positive control (provided by AG Kühn). Table 7.1.10 shows 
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Mycoplasma-PCR          
 
Reagent   Volume [µl]    Temperature [°C]  Time [sec]   
 
Supernatant, media  2   95 180 
 
10x dream tag buffer 2,5   95 20   
5mM dNTPs 0,5   65 30 x29 times 
Primer mix  0,5   72 60   
Dream Taq DNA polymerase 0,25   72 240 
 
Nuclease-free water  19,25   16 pause 
 
Table 7.1.10. The PCR protocol for mycoplasma test 
 
7.2. Molecular biology 
7.2.1. TALEN vector construction 
 First desired constructs are HR+TALE1+TALE2 to correct the mutation, and the second 
vector is HR+TALE1+TALE3 to introduce the mutation. The sequence of the strings and the vector 
are listed in supplementary data. Strings and the vectors were digested at specific restrictions 



















Figure 7.2.1.: The scheme of TALEN constructs for SVS1A  
a, The HR vector diagram showing where the restriction sites are. d-e, Diagrammatic summary how to 
clone homologous arms into the HR-vector for introducing TALEN mediated genome 
corrections/mutations with the restriction sites Not I, BsiWI, AscI, and Nsil. 
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 The first step was the ligation of string TALE1 into the HR vector and to do minipreps. 
Picked clones were subjected to test digestion with NotI and BsiWI to understand if the ligation 
was correct. The expected band size for TALE1 string is around 500 bp, and the HR vector is 
around 5800 bp. Clone 4 has the right expected band sizes after the digestion with respective 
enzymes, whereas other clones seem to have mismatched bands (Suppl. Figure 7.2.1. a).  Non-
digested HR vector was loaded as a control.  
 Once HR vector+TALE1, TALE2, and TALE3 were digested with Ascl and Nsil enzymes 
and followed by ligation steps. E.coli were transfected with ligated vectors, and the mini-preps 
were prepared. The clones were picked the next day. The test digestion was done to check if HR 
vector + TALE 1 + TALE2 and HR vector + TALE 1 + TALE 3 have the expected band sizes (Suppl. 
Figure 7.2.1. b). TALE2 and TALE3 have lower band sizes because they do not have TALE 1 string 
integrated. After the test digestion, the bands were extracted from the gels and sent for Sanger 
sequencing with M13 reverse primer, which is listed in supplementary data. The HR Vector + 
TALE 1 + TALE 2 and HR Vector + TALE 1 + TALE 3 were confirmed to have the right sequences.  
 
7.2.2. CRISPR/Cas9 genome editing 
 We prepared CRISPR/eSpCas9 sgRNA plasmid for SVS1C following a published 
protocol. We first designed a sgRNA sequence (within 10 nucleotides from the target site 
corresponding to A>G mutation using CRISPR (http://crispor.tefor.net/). We annealed the 
oligomer pairs and cloned them into pU6(BbsI)-CAG-Cas9-venus-bpA(#1) plasmid (Addgene ID 
86986) carrying eSpCas9 variant from eSpCas9(1.1) plasmid (Addgene ID 71814) with reduced 
off-target effects and improved on-target cleavage (Sabir, et al., 2016). The PCR product of the 
eSpCas9 variant was sub-cloned into a CAG expression plasmid (Addgene ID 86986). DNA was 
submitted for Sanger sequencing to conﬁrm correct sgRNA sequence. We designed 149 nt 
single-strand oligo-deoxynucleotide (ssODN) HDR template to convert G>A (mutation 
correction) with two silent mutations within sgRNA sequence in the proximity to the protospacer 
adjacent motif (PAM) site (3 and 6 nt downstream) to prevent recurrent Cas9 cutting in edited 
cells. To improve the recombination of ssODN with eCas9-induced double-strand break via 
single-stranded template repair (SSTR) and ssODN, we applied ectopic expression of RAD52 and 
of a dominant-negative subfragment of 53BP1 (dn53BP1), which may counteract the 
endogenous 53BP1 (Paulsen et al., 2017). Plasmids encoding components of the DNA repair 
pathways (human RAD52, and mouse dn53BP1) were kindly obtained from Bruna Paulsen. For 
the generation of dn53BP1, a fragment containing the Tudor domain (residues 1,221 to 1,718 of 
mouse 53BP1) was sub-cloned, and the PCR products of the genes were then sub-cloned into a 
 
  120 
 
CAG expression plasmid and sequenced. Transient transfection of plasmids was carried out in 
SVS1C grown in feeder-free conditions in StemMACS™ iPS-Brew XF culture media (MACS 
Miltenyi Biotec) in a 6-cell culture plate. One day before transfection, we dissociated the cells 
using Accutase and seeded ~ 1 x 105 cells per well of a pre-coated 6-well plate as single cells or 
small clumps. Cell was cultivated in fresh medium containing 10 mM Y-27632 overnight. 
Lipofection was performed using Lipofectamine 3000 Kit (Thermo Fisher Scientific) according to 
the manufacturer’s protocol. The plasmids were diluted up to 2 mg DNA in 125 ml of Opti-MEM 
reduced serum medium and added as the DNA-lipid complex to one well of a 6-well plate in a 
dropwise manner with the addition of 5 mM Y-27632 to the culture medium for 24 h. The 
medium was changed on the following da, and the cells were kept 48h in culture until 
fluorescence-activated cell sorting (FACS). Dissociated cells using Accutase for 5 min were 
washed and resuspended with DPBS. Then, cells were ﬁltered using Falcon polystyrene test 
tubes (#352235, Corning) and transferred to Falcon polypropylene test tubes (#352063, 
Corning). Sorting was performed using BD FACSAria III at the MDC FACS Facility. Sorted cells 
were suspended in recovery mTeSR™ medium (STEMCELL Technologies) with 1X Penicillin-
Streptomycin (P/S) (Gemini Bio-products) and ROCK inhibitor and plated onto 6-well plates (5K 
cells/well). Growing single-cell-derived colonies were transferred from 6-well plates to one well 
each of 24-well plate and maintained until the colony grew big enough to be partially harvested 
for DNA isolation using Phire Animal Tissue Direct PCR Kit (Thermo Fisher Scientific) according 
to manufacturer’s protocol. PCR reaction was carried out using 100 ng gDNA in 50 ml with 
Phusion High-Fidelity DNA Taq polymerase (Thermo Fisher Scientific) according to 
manufacturer’s instructions and annealing temperature 61˚C. For Sanger sequencing or 
fragment analysis, the PCR products were gel puriﬁed using, e.g. the Wizard SV Gel and PCR 
Clean-Up System (Promega). SURF1 gene product was amplified with SVS1C primers (product 
length 550 nt). For primer induced restriction analysis (PIRA) the PCR product of 550 nt was cut 
by Bbs1 (NEB #R3539) into 221+324 nt fragments only in the presence of the mutation c.769G>A. 
PCR products were submitted to LGC https://www.lgcgroup.com) for Sanger sequencing. Primer 
sequences, gRNA sequences, and HDR sequence are reported in section 6.2.4. Samples sent for 
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Samples   1 2 3 4 5 
  Stock 
Concentration 
sgRNA sgRNA sgRNA sgRNA sgRNA 
+HDR +HDR +HDR +HDR +HDR 
Confluency  
per well (6wp) 
 - 90%  90% 90% 90% 90% 
OptiMEM A [µl] -  125 125 125 125 125 
HDR ssODN [µl] 1.5 µg/µl 3 3 3 3 3 
Plasmid #1 [µl] 1.3 µg/µl 2 2 2 2 2 
Plasmid #2 [µl] 0.9 µg/µl 1.5 1.5 1.5 1.5 1.5 
Plasmid #3 [µl] 1.5 µg/µl 1 1 1 1 1 
p 3000 [µl]  - 3.75 3.75 3.75  3.75  3.75  
OptiMEM B [µl]  - 125 125 125 125 125 
Lipofect3000 [µl]  - 5 5 5 5 5 
Table 7.2.1.: The transfection amounts for CRISPR/Cas9 
 
7.2.3. RNA-sequencing 
 PolyA mRNA-seq was carried out for the samples: DA 4w of H1, XM001, SVS1A, SVS1C 
and DA 8w of H1, XM001, SVS1A, SVS1C (each done in biological triplicate). Total RNA was 
isolated using the Qiagen RNeasy Mini Kit (#74106, Qiagen) and quality-checked by Nanodrop 
analysis (Nanodrop Technologies). mRNA-seq was performed by BGI using an oligo dT selection 
(mRNA enrichment) strategy with oligo dT beads to select mRNA with poly A tail using BGISEQ-
500 with DNB seq technology. Ribo-zero total RNA-seq was carried out for the samples: DA 4w 
of SVS1C and SVS1C.C and DA 8w of SVS1C and SVS1C.C (each done in biological triplicate). 500 
ng of total RNA were rRNA depleted using RNase H-based protocol. Briefly, total RNA was mixed 
with 1 μg of a DNA oligonucleotide pool comprising 50-nt long oligonucleotide mix covering the 
reverse complement of the entire length of each mouse rRNA (28S rRNA, 18S rRNA, 16S rRNA, 
5.8S rRNA, 5S rRNA, 12S rRNA), incubated with 1U of RNase H (Hybridase Thermostable RNase 
H, Epicentre), purified using RNA Cleanup XP beads (Agencourt), DNase treated using TURBO 
DNase rigorous treatment protocol (Thermo Fisher Scientific) and purified again with RNA 
Cleanup XP beads. rRNA-depleted RNA samples were further fragmented and processed into 
strand-specific cDNA libraries using TruSeq Stranded Total LT Sample Prep Kit (Illumina) and 
sequenced on NextSeq 500, High Output Kit, 1x 150 cycles. Raw sequencing reads were mapped 
to the human genome (GRCh38 assembly) using STAR (version 2.6.0c) aligner (Dobin et al., 
2013). We used the default settings, except --outFilterMismatchNoverLmax, which was set to 
0.05. Reads were counted using the htseq-count tool, version 0.9.1 (Anders et al., 2015), with 
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gene annotation from GENCODE release 27 (Frankish et al., 2019). Differential gene expression 
analysis was performed using the DESeq2 (version 1.20.00) R package (Love et al., 2014). For 
mRNA-seq, read counts for genes expressed in H1, XM001, SVS1A, and SVS1C were summed up 
across the triplicates. SVS1A and SVS1C were treated as disease replicates, and compared to H1 
and XM001. For ribozero sequencing, SVS1C was compared to the SVS1C.C. All genes with the 
adjusted P-value lower than 0.05 were considered differentially expressed. Functional 
enrichment analysis was done using the gProfileR R package (Reimand et al., 2016), version 
0.6.6, with default settings. All expressed genes were used as background. All R scripts are 
available on request. All RNA-seq data have been deposited in the GEO database (Accession 
number GSEEI26360). 
 
7.2.4. qRT-PCR analyses 
 Cells were harvested, washed with PBS and pelletized by centrifugation. Total RNA was 
extracted using the RNeasy Mini Kit (Qiagen) according to the protocol “RNA-isolation from 
Animal Cells.” The RNA concentration was measured by NanoDrop (Thermo Scientific). Isolated 
RNA was used for qRT-PCR. For quantitative gene expression analysis cDNA was generated from 
isolated RNA using the reverse transcriptase M-MLV (Affymetrix/USB). For each sample, 1 μg 
RNA was diluted in 9 μl with RNase/DNase-free distilled water (Gibco) and 1 μl oligo-dT (0.5 
μg/μl, 15mer) was added (final volume 10 μl). The mixture was incubated at 72 °C for 5 min and 
cooled down on the ice. Meanwhile, a master mix for the reverse transcription according to the 
manufacturer´s guideline. Subsequently, 15 μl of this master mix was added to 10 μl RNA/oligo-
dT sample and incubated at 42 °C for 1 h, followed by inactivation of the enzyme at 65 °C for 10 
min. The resulting cDNA was diluted 1:10 in nuclease-free water and stored at −20 °C. Gene 
expression analysis was performed by quantitative real-time RT-PCR (qPCR) using SYBR Green 
PCR Master Mix and the ViiA™ 7 Real-Time PCR System (Applied Biosystems). For each target 
gene, cDNA samples and negative controls were measured in triplicates using 384-Well Optical 
Reaction Plates (Applied Biosystems). Relative transcript levels of each gene were calculated 
based on the 2− ΔΔCT methods. Data were normalized to the housekeeping gene ACTB and are 
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Master mix for RT   
Reagent Volume [µl] 
dNTP, 25mM 0,5 
M-MLV RT 0,1 
M-MLV Rxn Buffer 5 
distilled water 9,4 
  
Master mix for Rxn   
Reagent Volume [µl] 
1,8 ul Fwd primer (0,3uM) 1,8 
1,8 ul Rev primer (0,3uM) 1,8 
6,0 ul SYBR Green PCR mix 6 
0,4 ul distilled water 0,4 
 Table 7.2.4.: Master mixes for the reverse transcription 
 
7.2.5. Primer induced restriction analysis  
 For primer induced restriction analysis (PIRA) of S1A, the PCR product of 141 bp was 
cut by SmaI (NEB #R0141S) into 23+118 bp in the presence of c.530T>G mutation. For PIRA of 
S1C, the PCR product of 437 bp was cut by Ava II (NEB #R0153S) into 292+145 bp fragments only 
in the presence of the mutation c.769G>A. For PIRA of SVS1C, the PCR product of 550 bp was 
cut by Bbs1 (NEB #R3539) into 221+324 bp fragments only in the presence of the mutation 
c.769G>A. Primer sequences are reported in Table 6.2.4.   
 
Protocol calculation for one reaction         
Components Volume   Protocol for 35 cycles     





Nr of cycles 
dNTPs (10 µM) 1 µl   98°C 30 1x 
Primer Fwd (10 µM) 2,5 µl   98°C 10 35x 
Primer Rev (10 µM) 2,5 µl   61°C 30  
DNA Template 400 ng   72°C 30  
DMSO 1,5 µl   72°C 600 1x 
Phusion Taq 0,25 µl   4°C hold 1x 
MgCl2 0,5 µl         
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Autoclaved water 30,75 µl         
 Table 7.2.5.: The protocols  for the PCR & PIRA PCR 
 
7.2.6.  SURF1 overexpression 
 SURF1 (amino acid sequence NP_003163.1) (the amino acid sequences is provided in 
section 6.2.4.) and mCitrine expressing lentiviral plasmids were generated using the Gateway™ 
cloning system (Katzen, 2007). Open reading frames from entry vectors encoding the GFP 
derivative mCitrine or the SURF1 protein (entry clone id: RZPDo839E0486) were shuttled into a 
lentiviral destination vector harboring a phosphoglycerate kinase (PGK) promoter (pLenti PGK 
Neo DEST (w531-1) was a gift from Eric Campeau & Paul Kaufman (Addgene plasmid # 19067; 
http://n2t.net/addgene: 19067; RRID: Addgene_19067) (Campeau et al., 2009). Lentivirus 
preparation was performed by the Viral Core Facility of the Charité Berlin as previously described 
(Lois et al., 2002). In brief, HEK293T cells were co-transfected with 10 µg of shuttle vector, 5 µg 
of helper plasmids pCMV-dR8.9, and 5 µg of pCMV-VCV-G using X-tremeGENE 9 DNA 
transfection reagent (Roche Diagnostics). Cell culture supernatant containing the virus was 
collected after 72 h and filtered for purification. Virus aliquots were flash-frozen in liquid 
nitrogen and stored at -80°C. NPCs were seeded on 6 well plates at a concentration of 
approximately 500,000 cells per well. The next day, cells were transduced with mCitrine viruses 
(GFP) or wild-type SURF1 (SURF1-OE) with a titer of 1,85E+08 and 1,32E+08 particles per ml, 
respectively. One day later, the medium was changed, and NPCs were kept in the incubator for 
two days to recover. Antibiotic selection was carried out using 500 µg per ml of gentamycin 
(G418) for 5 days according to killing curves previously performed on NPCs. 
 
Transduction Titration Virus concentration   
 (particle per cell) (particle/cell) 
Volume 
[µl] Cell number 
smS1C no     500*10^3 
smS1C + mCitrine 1,85E+08 5 13,51  500*10^3 
smS1C + SURF1 1,32E+08 5 18,94  500*10^3 
 Table Figure 7.2.6.: The transduction amounts for lentivirus 
 
7.3. Protein biochemistry 
7.3.1. Western blotting 
 NPCs were lysed in Lysis Buffer (200mM NaCl, 50mM Tris-HCl pH 8.0, 0.05% SDS, 2mM 
EDTA, 1% NP40, 0.5% sodium deoxycholate supplemented with (100mM NaF, 10µM PMSF, 1:25 
EDTA-free protease inhibitor cocktail (Merck), 1:1000 Benzonase (Roche)) for 1 h at 4°C. Protein 
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concentration was determined using the Pierce™ BCA assay (Thermo Fisher Scientific). 120 µg 
proteins for each sample were loaded on NuPAGE Novex 4-12% Bis-Tris precast SDS-PAGE gels 
(ThermoFisher Scientific) and transferred onto Immobilin-FL PVDF membranes (Merck Millipore) 
by semi-dry transfer. The primary antibodies used were as follows: MT-CO2 (ab110258 Abcam, 
1:1,500) and anti‐tubulin (Sigma, 1:4,000). Chemiluminescence was measured in a Fujifilm LAS‐
3000 after the addition of Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). 
 
7.3.2. COX enzyme activity and histochemistry 
 The activities of cytochrome c oxidase (COX) for complex IV and of succinate 
dehydrogenase (SDH) for complex II were assessed using a colorimetric assay on iPSC-derived 
NPCs. Enzyme histochemical stains of cytochrome C oxidase and succinate dehydrogenase were 
performed using standard procedures (Dubowitz et al., 2013). After gentle centrifugation, NPCs 
from SVS1C and genetically corrected SVS1C.C (clones 3p and 3bb) were carefully transferred on 
tissue tek on a cork plate and shock frozen in isopentane pre-cooled in liquid nitrogen. 10 µm 
thick cryosections of these cells were stained by SDH, COX, and combined COX-SDH. 
 
7.3.3. Magnetic-Activated Cell sorting  
 We performed magnetic-activated cell sorting (MACs) in order to quantify A2B5-
positive cells, NCAM-positive cells, GLAST-positive cells, CD11b-positive cells, and O4-positive 
cells from 4w and 8w DA neuronal cultures. We used A2B5-APC antibody (130-093-582; Miltenyi 
Biotec), GLAST (ACSA-1)-APC antibody (130-095-814; Miltenyi Biotec), PSA-NCAM-PE antibody 
(130–093-274; Miltenyi Biotec), CD11b-VioBlue antibody (130–095-822; Miltenyi Biotec), and 
O4-APC antibody (130–109-153; Miltenyi Biotec), according to the manufacturer's instructions. 
 
7.3.4. Cytokine secretion analysis 
 The supernatant of the samples used for RNA-Seq (DA 4w of H1, XM001, SVS1A, SVS1C, 
and DA 8w of H1, XM001, SVS1A, SVS1C) was collected and concentrated with Amicon 10K. The 
samples were assayed in triplicates using the Pro-inflammatory Panel I (MesoScale Discovery, 
Gaithersburg, MD, USA) for quantitative measurement of 10 cytokines from a single sample 
volume of 25 μL using an electrochemiluminescent detection method. The cytokines measured 
were: interferon (IFN)-γ, interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor 
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7.4. Microscopic investigation 
7.4.1. Transmission electron microscopy  
 Skeletal muscle and mitochondria biopsy was carried out for patient S1C. 
Ultrastructural analysis was performed after fixation of the cells in 2.5% glutaraldehyde for 48 
hours at 4°C, postfixation in 1% osmium tetroxide, and sample embedding in. Semi-thin sections 
were used to identify viable and characteristic cells, and respective ultrathin sections were 
stained with uranyl acetate and lead citrate. A P902 electron microscope (Zeiss, Oberkochem, 
Germany) was used to analyze the specimens. 
 
7.4.2. High-content analysis  
HCA-based quantification of neuronal cells and branch complexity was assessed using the CX7 
microscope (Thermo Fisher Scientific). Briefly, NPCs or neurons (at 4 weeks or 8 weeks of 
differentiation) were split using Accutase and seeded at a density of 10,000 cells/ on Matrigel-
coated 96 well plates with black-wall and clear-bottom (Corning).  The cells were stained with 
TUJ1 antibody and counter-stained with Hoechst (see below for details on staining method). The 
morphological changes of TUJ1-positive cells were quantified using the “Cellomics Neuronal 
Profiling v3.5 BioApplication” (XTI Infinity High Content Platform, Thermo Fisher Scientific). 
Hypoxia and drug treatments were conducted O.N. one day before the assay day. 
 
7.4.3. Mitochondrial movement 
 DA cultures were grown on 35 mm dishes with coated bottom and 1.5 coverslips.  25 
nM MitoTrackerRed CMXRos (Thermo Fischer Scientific) was added for 10 min and then replaced 
with DA culture media. Live-cell imaging recordings were conducted using a spinning disk 
microscope (CSU-W, Andor/Nikon) which incubating conditions of 37°C with 5% CO2. We used 
a 40x oil objective, and we imaged the cells every 2 sec. The raw image files were stored as 16-
bit in “.nd2” format at 337x337 µm (1024x1024 pixel) at an interval of 2 sec and a total of 200 
images per series (total time per series: 6:40 min). The image pre-processing was carried out 
with Fiji (ImageJ 1.52h) adapted from a previous report (Iaenetti et al., 2016). To compensate 
for photo-bleaching during the time series, we applied the “Bleach Correction” tool, followed by 
a top-hat spatial filter to increase gray values of mitochondrial objects. The total mitochondria 
count was calculated by creating a binary image where the minimum gray value (min) was set 
to min=Mean+StdDev, and the maximum gray value (max) was set to max= Mean+StdDev+1, 
where “Mean,” and “StdDev” were obtained by using the “Measure” tool. Next, the “watershed” 
tool was applied to break up large mitochondria networks. A total number of mitochondria was 
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quantified using the “Analyze Particles” tool with standard setting and a size preference for 8-
200 pixel. The moving mitochondria were defined by a particle size of at least 6 pixels that 
changed location over the time course of 4 frames (=8 seconds). This was accomplished by 
subtracting the following 4th frame for each frame in the time series (on the top-hat filtered 
image). Afterward, the subtracted image series was converted into a binary image series. The 
number of moving mitochondria was similarly counted using the “Analyze Particles” tool with 
standard setting and a size preference for 6-200 pixel. Finally, the percentage of moving 
mitochondria per sample was calculated by dividing the average number of moving 
mitochondria by the average number of total mitochondria, multiplied with 100. The percentage 
of stationary mitochondria was obtained by the subtraction of moving mitochondria from 100.  
  
 
7.5. Statistical analysis 
Data were analyzed using GraphPad-Prism software (Prism 4.0, GraphPad Software, Inc.) ad R 
package. Data presentation and respective statistical analysis of each graph are described in the 
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8. Supplementary Information 








Suppl. Figure 3.1.3: EM images of muscles from S1C patients 
Transmission electron microscopy (TEM) image are showing normal mitochondria in muscle biopsy from 






Suppl. Figure 3.2.2.1.: Molecular characterization of iPSCs from LSSURF1 patients 
PCR products were separated on a 1.5% agarose gel. The expected band sizes for the SVS1C and SVS1A 







Suppl. Figure 3.4.1.4..: Cellular proliferation assay in NPC cultures of SVS1C isogenic line  
Cellular proliferation assay in NPC cultures from isogenic lines SVS1C and SVS1C.C (mean +/- s.e.m.; n=4 



























Suppl. Figure 3.3.2.2.: The workflow and screening strategy for CRISPR/ Cas9 corrected clones 
a, The scheme shows the workflow of the CRISPR/Cas9 correction strategy on iPSCs and the microscopic 
images of single cell-derived iPSC clones. Scale bar: 10 µm. b-c, The dot plots show the FACS sorted cells in 
two different channels: Venus and BFP. Q1 shows BFP- positive cells, Q2 shows BFP/Venus-positive cells, 
Q3 shows Venus-positive cells, and Q4 shows BFP/Venus-negative cells. Each dot represents a cell. 
Representative transfected double positive single cell images. Scale bar: 10 µm. (Contributions are 






Suppl. Table 3.4.2.2.2.: Summary of the values for cytokine profiling in composite cultures of all lines 
Table showing how much non-stimulated human astrocytes in culture expressed IFN-y, IL-10, IL-12p70, IL-
13, IL-1ß, IL-2, IL-4, IL-6, IL-8,  (n=2 independent experiments). Highlighted in red are the cytokines that are 
significantly detected in non-stimulated DA cultures. Only DA cultures derived from hESC line H1 also show 
the presence of TNF-alpha. The cytokines IL-13, IL-6, and IL-8 were present in all the samples but were not 
significantly altered in LSSURF1 cultures.  
 











 Suppl. Figure 3.4.2.3.3: FCCP treatment decreases the number of motile mitochondria in DA-enriched 
composite cultures  
Quantification of moving mitochondria in 4w and 8w DA cultures from SVS1C and genetically corrected 
SVS1C.C. The cells were treated with an uncoupler FCCP (10 um) to induce a decrease in motility of 
mitochondria (median +/- 95% confidence interval; * p<0.05,  *** p<0.001, one way ANOVA followed by 

















Suppl. Figure 3.4.2.5.: Passive membrane properties of neurons in DA-enriched composite cultures of all 
lines 
Comparison of passive membrane properties. a, Cell capacitance (in picofarad, pF) in iPS-derived 4w, 6w 
and 8w DA neuronal cultures from CTRL ES (H1), CTRL iPS (XM001) and  SURF1 patients (SVS1A and SVS1C) 
and c, in DA neuronal cultures from SVS1C and SVS1C.C (mean +/- s.e.m.; at least n=2 independent 
experiments). b, Input resistance (in MilliOhm, Mohm) in iPSC-derived 4w, 6w, and 8w DA cultures from 
CTRL ES (H1), CTRL iPS (XM001) and SURF1 patients (SVS1A and SVS1C) and d, in DA neuronal cultures 
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from SVS1C and SVS1C.C (mean +/- s.e.m.; at least n=2 independent experiments). (Contributions are 









Suppl. Figure 3.5.A.: Derivation of cerebral organoids from iPSCs  
a, Schematic of the generation of cerebral organoids from iPSCs with days information. b, Representative 
bright field images are showing the transition of the cells undergoing differentiation to three-
dimensional structures. (Contributions are indicated in section 8.3.). 
 
 
Additional Suppl. Figure 3.5.1.A. 
 Classically, neurogenesis starts with precursor cell proliferation in 
neurodevelopmental biology and continues as their capacity to generate new cell types, and if 
they survive, they will get functionally integrated. Radial glia cell types have different fate 
choices as they can differentiate into neurons, or they could also give rise to glial cells (Suppl. 
Figure 3.5.1.A a). This balance is tightly maintained, regulating the neurogenic capacity of the 
stem cell pool.  
    In the mammalian system, the first divisions of neural stem cells (NSCs) (NESTIN, SOX2, 
KI67) are exclusively neurogenic, either giving rise to neural-restricted intermediate progenitors 
(TBR2, and NCAM) or immature neuron (CALRETININ/CALB) or to mature neurons (NEUN/FOX3). 
Once the bulk of neurogenesis has occurred, NSCs then become primarily gliogenic at the end 
of the differentiation phase.  Patient-derived organoids show upregulation in genes for 
proliferating responsible for precursor cell types (Suppl. Figure 3.5.1.A b). Then there is a 
downregulation of genes responsible for neurogenesis and postmitotic maturation cell types.  
Interestingly, Calretinin (CALb2) is significantly upregulated, which is a marker of maturing 
new neuron types. As the neurons get mature enough, they switch the expression of calcium-
binding protein calretinin to calbindin (Brandt et al. 2003). This could suggest the presence of 
pre-mature neuronal types as it has been discussed in the outcome of 2D neuronal experiments. 
Previous studies done on cell fate specification comes from miR-124, which is a crucial regulator 
of cell fate determination, stimulating neuronal lineages by suppressing glial lineage-specific 
genes such as SOX9 and STAT3. STAT3 activity especially is crucial for astrogenesis as it is a direct 
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transcriptional activator of the astrocytic genes GFAP and S100B. Patient-derived cerebral 
organoids showed repression of astrogenesis genes compared to the edited line as all of the 
genes are downregulated (Supp. Figure 3.5.1.A.). (Sloan et al., 201). Overall, patient-derived 




















Suppl. Figure 3.5.1.A.: Differentially regulated cell specification genes in cerebral organoids of LSSURF1 
a, Summary of the developmental process of neurogenesis and its relevant markers. Radial ganglion cells 
(RGL) are either giving rise to intermediate progenitors (IPCs) to neuronal types (right) or giving rise to 
glial cells (left).  b, Log fold changes (LFC) of genes regulating neurogenesis in iPSC-derived cerebral 
organoid cultures from SVS1C compared to genetically edited line SVS1C.C (´´ p<0.01, • p<0.0001).  
  
 
Additional Suppl. Figure 3.5.1.B. 
 Two main signaling pathways Wnt/ß-Catenin and SHH-Smoothened regulate the 
dopaminergic neurogenic niche in the ventral midbrain. Several members of the Wnt family have 
been shown to regulate distinct aspects of the development of ventral midbrain DA neurons. 
For instance, Wnt5a regulates the differentiation of DA neurons while WNT1, WNT2, and WNT3 
are in favor of generating initial DA progenitors in the ventral midbrain (Andersson et al., 2013).  
Patient-derived cerebral organoids showed downregulation in WNT5 and no difference in other 
WNTs, which suggests a defect in the differentiation stage of DA neurons (Figure 3.5.1.B.). 
Moreover, patient-derived cerebral organoids displayed significant downregulation of mDA 
progenitors OTX1 and OTX2.  FOXA2 and OTX2 regulate the expression of two LIM homeobox 
transcription factors. LMX1A is required for the specification of mDA neurons. Normally, LMX1A 
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orchestrates the induction of MSX1, which induces the proneuronal protein expression NGN2 as 
well as the suppression of NKX6-1 (LMX1A+/MSX1+/NKX6-1-) (Andersson et al., 2006). This 
network is essential not only for the specification of the DA progenitors but also for the 
suppression of alternative neural fates in which patient-derived cerebral organoids fail to 
implement this by looking at the expression profile of the genes. LMX1B, on the other hand, is 
necessary for the differentiation of mDA progenitors and involved in the maturation of 
postmitotic DA neurons along with NURR1 (NR4A2), and patient-derived organoids showed 
significantly different expression profile of LMX1B and NURR1 suggesting differentiation defects 
as well.  Additionally, the expression of the GIRK2 protein is used broadly to identify the A9 
midbrain dopamine populations, which was also significantly downregulated. Overall, 
transcriptomics data suggest SURF1 mutations cause defects in the specification, differentiation 











Suppl. Figure 3.5.1.B..: Differentially regulated midbrain dopaminergic genes in cerebral organoids of 
LSSURF1 
Log fold changes (LFC) of genes regulating midbrain dopaminergic (mDA) neuronal development-related 
genes in iPSC-derived cerebral organoid cultures from SVS1C compared to genetically edited line SVS1C.C 






























Suppl. Figure 3.7.1: Bioenergetic and neuronal profiling of 8w DA composite cultures of SVS1C upon 
stably expressing wild-type SURF1 
a-e, Oxygen consumption rate (OCR), extracellular acidification rate (ECAR) and extracellular lactate in 8w 
DA composite cultures of SVS1C lines stably expressing GFP derivative mCitrine (GFP) or wild-type SURF1 
(SURF1-OE). d-f, High content analysis (HCA)-based quantification of neuronal profiling such as neurite 
length per neuron (left) and branch point total count (right) based on TUJ1-expressing neurons in NPC 
cultures of SVS1C upon stably expressing wild-type SURF1. Yellow line is the value for genetically corrected 
SVS1C.C line (mean +/- s.e.m.; n=2 independent experiments; * p<0.05, ** p<0.01, *** p<0.001; Mann-













Supp. Figure 7.2.1.: Screening for the right TALEN constructs 
a, TALE 1 and the HR vector were digested at specific restrictions sites and were ligated into amplified and 
purified HR vectors. Red underlined clone number 4 has the right size band after subjected to test digestion 
with NotI and BsiWI. b, Clone 4 is then used to ligate TALE 2 and TALE 3, respectively. The expected band 
size for TALE2  or TALE 3 strings are around 500 bp, and the HR vector is 5800 bp and TALE1 is 550 bp. 
 











Supp. Figure 3.7.4.: Restored bioenergetic profile in NPC cultures of SVS1C upon Bezafibrate treatment 
a-b, Maximal respiration, and ATP production in NPC cultures upon different concentrations of Bezafibrate. 
Yellow line is the value for genetically corrected SVS1C.C line (mean +/- s.e.m.; n=2 independent 




8.3. Contributions  
 * Figure 3.1.2. The pedigree of patients´ families and the PCR images were provided by 
Prof. Markus Schülke (Charité Universitätsmedizin). 
 * Figure 3.1.3. The MRI images of the patients were taken by Prof. Markus Schülke 
(Charité Universitätsmedizin). 
 * Figure 3.2.2.3. / Figure 3.3.3.3.2.  The virtual karyotyping of the generated iPSCs was 
performed by Stem Cell Core facility, (MDC and BIH, 2017-2018). Dr. Barbara Mlody did the 
bioinformatics analyses (MDC, 2017-2018). 
 * Figure 3.3. DNA cleavage binding domain was engineered to design TALs by BIH stem 
cell core facility, (MDC, 2016).  
 * Figure 3.3.2.1. Dr. Pawel Lisowski planned the strategy of the CRISPR/Cas9 (MDC, 2017-
2018). 
 * Figure 3.3.2.2. / Suppl. Figure 3.3.2.2. Elisa Massow helped to screen the transfected 
clones via PIRA PCR, and FACS for the CRISPR/Cas9 experiments during her bachelor thesis (TU 
Berlin, 2018) under my and Dr. Pawel Lisowski´s supervision. Master student Tobias Hahn helped 
to find the corrected clones during his master thesis (Hochschule Albstadt-Sigmaringen, 2018).  
 * Figure 3.4.1.2. Celina Kassner gave technical support for Western Blot experiments. 
 * Figure 3.4.1.2. / Suppl. Figure 3.1.3. The TEM images of mitochondria and the 
assessment of mitochondria enzyme activity were taken/performed by Prof. Werner Stenzel 
(Charité  Universitätsmedizin, 2018-2019).  
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 * Figure 3.4.1.2.c The mitochondrial enzyme activity experiments were performed by 
Prof. Werner Stenzel (Charité  Universitätsmedizin, 2018-2019).  
 * Figure 3.4.1.1. / Figure 3.6. The transcriptome analyses of iPSC-derived 2D and 3D 
cultures were done by Peter Glazar (BIMSB and MDC, 2018-2019). 
 * Figure 3.4.2.3.3. The analyses of stationary and moving mitochondria in iPSC-derived 2D 
cultures were done by Dr. Barbara Mlody (MDC, 2018). I did the recordings at Advanced Light 
Microscopy, MDC and Dr. Anje Sporbert helped me to set it up. 
 * Figure of 3.4.2.5.C. The patch clamp recordings of the iPSC-derived neurons were 
performed by Dr. Rene Jüttner (MDC, 2015-2018).  
 * Figures of 3.5.B. The derivation of the iPSC-derived 3D cultures was conducted by the 
collaboration partner Dr. Agnieszka Rybak-Wolf (BIMSB and MDC, 2018-2019). Dr. Agnieszka Rybak-
Wolf did the RNA-Seq and the RT-PCR experiments of the iPSC-derived cerebral organoids.  
 * Figures in section 3.7. / Suppl. Figure 3.4.1.4. The experiments of the investigation of 
treatment strategies and cell proliferation assay were completed by Ummi Ciptasari during her 
master thesis (Charité Universitätsmedizin, 2019) under my supervision. 
 * Figure 7.2.6. Thanks to Dr. Christopher Secker and to the Viral Core Facility (Charité, 
2018) for generating lentiviral particles. 
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